US20210123909A1 - Nanodiamond particles and related devices and methods - Google Patents
Nanodiamond particles and related devices and methods Download PDFInfo
- Publication number
- US20210123909A1 US20210123909A1 US16/987,351 US202016987351A US2021123909A1 US 20210123909 A1 US20210123909 A1 US 20210123909A1 US 202016987351 A US202016987351 A US 202016987351A US 2021123909 A1 US2021123909 A1 US 2021123909A1
- Authority
- US
- United States
- Prior art keywords
- ndp
- fluorescence
- particles
- emission
- species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002245 particle Substances 0.000 title claims abstract description 226
- 239000002113 nanodiamond Substances 0.000 title claims abstract description 148
- 238000000034 method Methods 0.000 title abstract description 73
- 238000001514 detection method Methods 0.000 claims abstract description 79
- 208000007536 Thrombosis Diseases 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 27
- 239000000032 diagnostic agent Substances 0.000 claims description 25
- 229940039227 diagnostic agent Drugs 0.000 claims description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 101800001224 Disintegrin Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 101710113844 Disintegrin bitistatin Proteins 0.000 claims description 3
- 241000894007 species Species 0.000 abstract description 102
- 239000012491 analyte Substances 0.000 abstract description 87
- 238000011002 quantification Methods 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 241000700605 Viruses Species 0.000 abstract description 9
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract description 5
- 239000000523 sample Substances 0.000 description 79
- 238000003384 imaging method Methods 0.000 description 59
- 230000005284 excitation Effects 0.000 description 53
- 210000001715 carotid artery Anatomy 0.000 description 52
- 241000700159 Rattus Species 0.000 description 47
- 241001465754 Metazoa Species 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 27
- CEPSBUIWVLQEKQ-UHFFFAOYSA-N n-(3,3-diphenylpropyl)-6-fluoropyridine-3-carboxamide Chemical compound C1=NC(F)=CC=C1C(=O)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 CEPSBUIWVLQEKQ-UHFFFAOYSA-N 0.000 description 26
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 23
- 229940098773 bovine serum albumin Drugs 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 230000008878 coupling Effects 0.000 description 19
- 238000010168 coupling process Methods 0.000 description 19
- 238000005859 coupling reaction Methods 0.000 description 19
- 238000001802 infusion Methods 0.000 description 19
- 210000000269 carotid artery external Anatomy 0.000 description 18
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 238000004891 communication Methods 0.000 description 16
- 239000006166 lysate Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 208000005189 Embolism Diseases 0.000 description 15
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- 239000012216 imaging agent Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 238000011065 in-situ storage Methods 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 13
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 13
- 210000001367 artery Anatomy 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 11
- 230000035602 clotting Effects 0.000 description 11
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 108010044426 integrins Proteins 0.000 description 9
- 102000006495 integrins Human genes 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- 239000002250 absorbent Substances 0.000 description 8
- 230000002745 absorbent Effects 0.000 description 8
- 210000000709 aorta Anatomy 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000003191 femoral vein Anatomy 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- -1 FIG. 19B) Chemical compound 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000005670 electromagnetic radiation Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 210000002048 axillary vein Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 239000003431 cross linking reagent Substances 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 238000003260 vortexing Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 102100023710 Proteinase-activated receptor 4 Human genes 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000003998 snake venom Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 239000002435 venom Substances 0.000 description 4
- 210000001048 venom Anatomy 0.000 description 4
- 231100000611 venom Toxicity 0.000 description 4
- PYZOVVQJTLOHDG-FQEVSTJZSA-N 2-[(2s)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1h-1,4-benzodiazepin-2-yl]acetic acid Chemical compound O=C([C@H](CC(O)=O)NC1=CC=2)N(C)CC1=CC=2C(=O)N(CC1)CCC1C1CCNCC1 PYZOVVQJTLOHDG-FQEVSTJZSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000271935 Bitis Species 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 3
- 108700021041 Disintegrin Proteins 0.000 description 3
- 241000662429 Fenerbahce Species 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000010226 confocal imaging Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 229940075894 denatured ethanol Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000003314 quadriceps muscle Anatomy 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 description 2
- 101001113471 Homo sapiens Proteinase-activated receptor 4 Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 150000007930 O-acyl isoureas Chemical class 0.000 description 2
- 101710121439 Proteinase-activated receptor 4 Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000942 confocal micrograph Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 108010059557 kistrin Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229950010501 lotrafiban Drugs 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000006439 vascular pathology Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101000666940 Agkistrodon piscivorus piscivorus Disintegrin applaggin Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100293868 Bos taurus NDP gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 241000122860 Echis carinatus Species 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000634679 Homo sapiens Nucleolar complex protein 2 homolog Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010057175 Mass conditions Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- YUWBVKYVJWNVLE-UHFFFAOYSA-N [N].[P] Chemical compound [N].[P] YUWBVKYVJWNVLE-UHFFFAOYSA-N 0.000 description 1
- OBNDGIHQAIXEAO-UHFFFAOYSA-N [O].[Si] Chemical compound [O].[Si] OBNDGIHQAIXEAO-UHFFFAOYSA-N 0.000 description 1
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical compound [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010036006 albolabrin Proteins 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- TTZWEOINXHJHCY-UHFFFAOYSA-N carapanaubine Natural products O=C1NC(C(=C(OC)C=C2)OC)=C2C11CCN2CC3C(C)OC=C(C(=O)OC)C3CC21 TTZWEOINXHJHCY-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 108010025752 echistatin Proteins 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 108010070423 elegantin Proteins 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000045046 human NOC2L Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XXWNADNJWWLFFP-UHFFFAOYSA-N obtustatin Chemical compound C=1C=C(O)C=CC=1CC(C(=O)N1C(CCC1)C(=O)NCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C1CCCN1C(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CSSCC(NC1=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)N2)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)O)NC3=O)CSSCC(C(NC(CC=4C5=CC=CC=C5NC=4)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CO)C(=O)NC(CC=4N=CNC=4)C(=O)N4)C(C)O)C(C)O)=O)NC(=O)C(C(C)O)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(C)NC(=O)C5CCCN5C(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C2CSSCC(N)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)N2CCCC2C(=O)NC1CSSCC3NC(=O)C4CC1=CC=C(O)C=C1 XXWNADNJWWLFFP-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108700021367 rat Prl7d1 Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 108010039519 triflavin Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000001604 vasa vasorum Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
- G01N21/6458—Fluorescence microscopy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6489—Photoluminescence of semiconductors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/02—Mechanical
- G01N2201/022—Casings
- G01N2201/0221—Portable; cableless; compact; hand-held
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
Definitions
- Nanodiamond particles and related devices and methods such as nanodiamond particles for the detection and/or quantification of analytes, are generally described.
- the present invention relates to the field of medical and veterinary diagnostics and treatment. More specifically, the invention relates to a diagnostic reagent, tool, and system that are specific for detection of platelets and blood clots. In addition, the invention relates to detection of internal body bleeding sites in a variety of diseases and trauma conditions.
- Cardiovascular diseases such as stroke and heart attack, are the leading cause of mortality in developed countries. Deaths from strokes and heart attacks are predominantly the consequence of blood clots (thrombi) formed in the cerebral and cardiac vessels or thrombo-embolic events (TEE) associated with blood clots formed in remote vessels (e.g., peripheral venous system, cardiac atria appendixes).
- thrombi blood clots
- TEE thrombo-embolic events
- TEE fatal atherosclerosis vascular disease
- risk factors e.g., atherosclerotic vascular disease
- clinical presentation of consequences of blood flow occlusion by thrombi leading to stroke or heart attack command prompt medical investigations in search for the TEE culprits.
- Such investigations are mostly hospital-based imaging tests, such as angiography, CAT scans, MRI, and ultrasound.
- the current technologies are important for timely and successful management of strokes and heart attacks, yet several important limiting factors must be addressed.
- immunochromographic assays such as lateral flow assays
- lateral flow assays are generally used to detect the presence or absence of an analyte such as an antigen in a sample.
- analyte such as an antigen in a sample.
- assays generally lack automated processing, accurate quantification methods, and may, in some cases, require subjective interpretation, leading to false positives and/or false negatives.
- Nanodiamond particles and related devices and methods such as nanodiamond particles (e.g., fluorescent nanodiamond particles) for the detection and/or quantification of analytes, are generally described.
- the subject matter of the present invention involves, in some cases, interrelated products, alternative solutions to a particular problem, and/or a plurality of different uses of one or more systems and/or articles.
- diagnostic agents are provided.
- the diagnostic agents comprise a fluorescent nanodiamond particle chemically bonded to a polypeptide and/or polynucleotide.
- the fluidic device comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region, and a control region in fluidic communication with the detection region, the control region comprising a plurality of a third species bound to the control region.
- the system comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region and a detector configured to quantify a fluorescent emission at the detection region.
- the system comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region and a detector configured to quantify an infrared signal at the detection region.
- the method comprises introducing, into a fluidic channel of a fluidic device, a sample suspected of containing an analyte, exposing the sample to a species bound to a plurality of fluorescent nanodiamond particles such that the analyte, if present, binds to at least a portion of the species bound to the plurality of fluorescent nanodiamond particles, removing any fluorescent nanodiamond particles and species not bound to the analyte, and quantifying a fluorescence emission of the plurality of fluorescent nanodiamond particles bound to the analyte.
- the method comprises administering, to a subject (e.g., a human, a mammal) suspected of having a particular analyte, a plurality of fluorescent nanodiamond particles bound to a species such that the species may bind to the analyte, if present, and detecting a fluorescent emission of the plurality of fluorescent nanodiamond particles comprising the species bound to, if present, the analyte.
- a subject e.g., a human, a mammal
- FIG. 1A is a schematic illustration of a system including fluorescent nanodiamond particles, according to one set of embodiments
- FIG. 1B is a schematic illustration of a system including fluorescent nanodiamond particles, according to one set of embodiments.
- FIG. 2A is a schematic illustration of a system including fluorescent nanodiamond particles for detection of an analyte, according to one set of embodiments.
- FIG. 2B is a schematic illustration of a system including fluorescent nanodiamond particles for detection of an analyte upon introduction of a sample suspected of containing the analyte, according to one set of embodiments.
- FIG. 2C is a schematic illustration of a system including fluorescent nanodiamond particles for detection of an analyte after introduction of a sample suspected of containing the analyte, according to one set of embodiments.
- FIG. 3 is a schematic illustration of an exemplary fluorescent nanodiamond particle functionalized with a species such as human IgG, according to one set of embodiments.
- FIG. 4 is a photograph of an exemplary system including a reservoir comprising a plurality of fluorescent nanodiamond particles, according to one set of embodiments.
- FIG. 5 is a plot of semi-ELISA for detection of human IgG bound to fluorescent nanodiamond particles at various concentrations versus control (bovine serum albumin (BSA)), according to one set of embodiments.
- BSA bovine serum albumin
- FIG. 6 is a plot of the quantification of fluorescent nanodiamond particles functionalized with bitistatin in a carotid artery clot versus control vessels in rats, according to one set of embodiments.
- FIG. 7A shows scanning confocal microscopy images of carotid arteries from rats with generated clots with fluorescent nanodiamond particles introduced, according to one set of embodiments.
- FIG. 7B shows a scanning confocal microscopy image of a carotid artery from a rat with a generated clot with fluorescent nanodiamond particles introduced, according to one set of embodiments.
- FIG. 8 shows images of tissue suspensions of clots treated or not with fluorescent nanodiamond particles, injected systematically to the femoral vein close to a clot generated in carotid artery, according to one set of embodiments;
- FIG. 9 is a fluorescence scan result showing two dimensional screening of excitation vs. emission wavelengths to optimize fluorescence of NDP-Fs used in the exemplary embodiment.
- the figure shows optimization of the maximal fluorescence for NDP-Fs.
- the heat map represents the results of fluorescence screening in the entire spectrum of excitation vs. emission wavelengths.
- the experiment was performed using a Tecan plate reader. NDP-Fs were applied on a 96-well plate (0.3 mg/0.1 ml) as a suspension in PBS. The blank, or negative control, was established using PBS alone.
- FIG. 10 presents a line graph indicating detection of Bt on NDP-Fs in a “semi-ELISA” assay.
- NDPs were coupled to Bt or BSA, which were used in concentrations as indicated on the X-axis, per 1 mg of NDP-Fs. 0.2 mg of each NDP sample was used for semi-ELISA in three replicates. The experiment was performed on a 96-well plate (U-shape bottom) with gentle rotation during incubations. NDPs were blocked with 10% goat serum before primary antibody against Bt was added. NDP samples were incubated with anti-Bt antibody for one hour at 37° C., and the plate was washed three times with PBST by centrifugation (1,000 ⁇ g) at room temperature.
- Goat anti-rabbit IgG AP conjugated (Sigma Inc.), diluted 1:2000, was added and incubated for one hour as above. Final washing was performed as above and substrate (pNPP) was added to AP. Color was developed for 30 minutes, and NDP samples were centrifuged. The supernatant was transferred to a 96-well plate and read using an ELISA plate reader under 405 nm wavelength. Error bars represent standard deviation (SD) from three independent samples applied for the semi-ELISA procedure.
- SD standard deviation
- FIG. 11 is a line graph showing interaction of purified integrin with NDPs in semi-ELISA.
- the experiment was performed using a U-shape bottom 96-well plate. The plate was blocked overnight with 5% BSA, whereas NDPs were blocked with 3% BSA by incubation for 1 hour at 37° C. before application on the plate. Blocked NDPs were added to the wells (0.2 mg per well) and the plate was centrifuged (10,000 ⁇ g) at room temperature.
- Platelet Fibrinogen Receptor at the indicated concentrations was added in 0.1 ml of Hanks' Balanced Salt Solution (HBSS) containing Ca 2+ (as CaCl 2 ) and Mg 2+ (as MgCl 2 ) at physiological concentrations to each well and incubated for 1 hour at 37° C. NDPs were washed three times by centrifugation of the plate (1,000 ⁇ g) at room temperature and primary polyclonal antibody against the fibrinogen receptor was added (2 ⁇ g/ml). Incubation was performed for one hour at 37° C., and samples were washed three times, as described above.
- HBSS Hanks' Balanced Salt Solution
- Goat anti-rabbit IgG AP conjugated (Sigma Inc.), diluted 1:3000, was added and incubated for one hour as above. Final washing was performed as above and substrate (pNPP) was added to AP. Color was developed for 30 minutes, and NDP samples on the plate were centrifuged at 10,000 ⁇ g at room temperature to collect the NDP as a pellet. Supernatant was transferred to flat bottom 96-well (0.1 ml) plates and read using an ELISA plate reader at 405 nm wavelength.
- FIG. 12 presents a line graph showing adhesion of NDP-F-Bt and NDP-BSA to immobilized PFR.
- PFR was immobilized on a 96-well plate by overnight incubation at 4° C. in PBS. The plate and NDPs were blocked with 3% BSA. NDPs coupled to 1 mg protein (Bt or BSA) were used in the experiment. NDPs (300 mg) were added to the wells. Incubation was performed for one hour at 37° C. in HBSS buffer containing calcium and magnesium at physiological concentrations. Unbound NDPs were intensively washed out six times using the same buffer with vacuum aspiration. Finally, HBSS (100 ⁇ l) was added to the wells and fluorescence was read using a fluorescence plate reader with 485 nm (excitation) and 530 (emission) wavelengths.
- FIG. 13 presents a line graph showing quantitation of adhesion of NDP-F-Bt and NDP-BSA to immobilized fibrinogen receptor.
- Fibrinogen receptor was immobilized on 8-well glass chamber slides by overnight incubation at 4° C. The wells were blocked with 3% BSA, and NDPs previously also blocked by 3% BSA were added (50 mg per well per 200 ml) in HBSS containing calcium and magnesium at physiological concentrations. The adhesion procedure was performed as per FIG. 12 . In the final step, the slide was prepared with mounting buffer (Vector Lab). Images were analyzed under fluorescence microscope (400 ⁇ ) using an oil objective. The numbers of NDPs were calculated using ImageJ software. Error bars represent SD for three independent pictures taken for each concentration of fibrinogen receptor.
- FIG. 14 depicts representative images of adhered NDP-F-Bt to immobilized PFR.
- PFR concentration indicated
- FIG. 13 the bars represent 20 ⁇ m.
- FIG. 15 shows pictures of fluorescent images taken by IVIS and confocal microscopy of carotid artery clots after treatment with FNDP via an external carotid artery infusion.
- FIG. 15A shows an in situ carotid bifurcation region image indicating fluorescence of a carotid arterial clot after treatment visible via IVIS imaging after exposure of the carotid bifurcation zone.
- FIGS. 15B and 15C are high magnification images of fluorescence emanating from the carotid bifurcation in vivo suggesting accumulation of FNDP in the clot.
- FIG. 15A shows an in situ carotid bifurcation region image indicating fluorescence of a carotid arterial clot after treatment visible via IVIS imaging after exposure of the carotid bifurcation zone.
- FIGS. 15B and 15C are high magnification images of fluorescence emanating from the carotid bifurcation in vivo suggesting accumulation of FNDP in
- FIGS. 15D and 15F show confocal images taken on an Olympus IX83, showing that FNDP fluorescence is detected at an excitation of 543 nm and an emission of 655-755 nm.
- FIG. 16 shows fluorescent images taken by IVIS and confocal microscopy of carotid artery clots after intravenous treatment with FNDP.
- FIG. 16A shows an ex vivo fluorescent image of a carotid artery from saline-treated control.
- FIG. 16B shows an ex vivo fluorescent image of a carotid artery from an IV FNDP-treated animal showing fluorescence localized to the branch with clot.
- FIGS. 16C-F show confocal images taken on an Olympus IX83.
- FIG. 16G is a graph showing the number of FNDPs present in carotid clot lysates from animals treated locally via the external carotid artery or intravenously as compared with saline treated controls.
- FIGS. 17A-17B show fluorescent microscopy of the specificity of the interaction of F-NDP-Bt for clot generation from rat blood plasma by thrombin (1 U/ml).
- FIG. 17A shows images of plasma clots obtained from fluorescence microscope Olympus IX81 analysis, under 100 ⁇ magnification.
- FIG. 17B shows images of plasma clots obtained in an IVIS 50 imaging system. Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). Exposure time: 1 minute. Arrows point the localization of the clot.
- FIGS. 18A-18B show images of vessels filled with F-NDP-Bt implanted subcutaneously in a rat (post-mortem).
- FIG. 18A shows an image of the implanted glass capillaries filled with F-NDP-Bt (4 mg/ml) or PBS (control). Exposure time was 5 seconds.
- FIG. 18B shows an image of a rat aorta filled with F-NDP-Bt. The rat aorta was dissected from a euthanized female rat, washed with PBS to remove residues of coagulated blood, and filled with 300 ⁇ l of F-NDP-Bt suspension (2 mg/ml) in PBS.
- FIG. 18C shows plots of average fluorescence intensity for F-NDP-Bt, F-NDP-Bt+lotrafiban (lt), and F-NDP-BSA in thrombin-induced PRP clots.
- FIG. 18D shows representative images of the clots in FIG. 18C from IVIS.
- FIGS. 19A-19C show dose response curves with and without 700 nm diameter fluorescent nanodiamond particles functionalized with bitistatin (i.e. probe) for mean maximum platelet aggregation +/ ⁇ standard deviation linear regression lines for proteinase-activated receptor 4 (PAR4 AP, FIG. 19A ), adenosine diphosphate (ADP, FIG. 19B ), and arachidonic acid (AA, FIG. 19C ).
- PAR4 AP proteinase-activated receptor 4
- ADP adenosine diphosphate
- AA arachidonic acid
- FIGS. 20A-20C show box plots of 700 nm and 200 nm diameter probes binding to platelet populations at various concentrations.
- FIG. 20A shows the percentage of all platelets
- FIG. 20B shows the percentage of CD62+ve platelets
- FIG. 20C shows the percentage of GPIIb/IIIa+ve platelets bound to the 700 nm and 200 nm probes at various concentrations.
- Data shown are the mean (+), the line within the box represents the median, upper and lower edges of the box represents 75 th and 25 th percentiles, and upper and lower whiskers represent the 95 th and 5 th percentiles.
- FIG. 21 shows a plot of percentage of platelets bound to 700 nm diameter probes for stimulated versus unstimulated platelet populations. Data shown are mean percentage (+/ ⁇ standard deviation) of all platelets bound to the probe in simulated versus unsimulated platelets at a concentration of 350 mcg/mL of probe.
- FIG. 22 shows a plot of percentage of platelets bound to 200 nm diameter probes for stimulated versus unstimulated platelet populations. Data shown are mean percentage (+/ ⁇ standard deviation) of all platelets bound to the probe in simulated versus unsimulated platelets at a concentration of 350 mcg/mL of probe.
- FIGS. 23A-23D show flow cytometry dotplots for unsimulated and simulated populations of cells and platelets.
- FIGS. 24A-24D show flow cytometry dotplots for unsimulated and simulated populations of cells and platelets.
- FIGS. 25A-25B show plots of volume versus size ( FIG. 25A ) and fluorescence intensity versus size ( FIG. 25B ) for F-NDPs before and after sterilization.
- FIGS. 26A-26C show a comparison of NIR fluorescence intensity of F-NDP(NV) and F-NDP(NVN) in suspensions.
- FIG. 26A F-NDP suspensions were scanned for fluorescence in a fluorescence plate reader for a range of excitation and emissions. The fluorescence is normalized by subtracting a blank well and log 10 processed.
- FIG. 26B Capillaries were filled with indicated density of F-NDP in PBS and analyzed by IVIS imaging using 5 seconds exposure. Insert indicates representative images of capillaries. Average fluorescence is presented in the plot.
- FIG. 26C Comparison of fluorescence intensity for different concentrations of F-NDP(NV) as function of exposure time. Error bars represent SD for three to five independent experiments. *Difference between F-NDP(NV) and F-NDP(NVN) (P ⁇ 0.01)
- FIGS. 27A-27D show a comparison of intensity of fluorescence of different sizes of F-NDP(NV) under different exposure times in IVIS.
- Left panes shows representative images of F-NDP(NV), presented in concentrations as pointed on the plot. Sizes of particles are (from the top): 100, 700, and 10,000 nm, respectively. Error bars represent SD for three independent experiments.
- FIGS. 28A-28H show a comparison of the ability to detect F-NDP NIR fluorescence through different biological barriers using IVIS.
- FIG. 28A Capillaries filled with F-NDP(NV) (4 mg/ml), F-NDP(NVN) (4 mg/ml), or PBS were positioned under abdominal skin patch of euthanized rat. Positions of capillaries are indicated by arrows.
- FIG. 28B Capillary filled with F-NDP(NV) (4 mg/ml) covered by rat quadriceps muscles ranged from 2 mm (flanking) to 5.9 mm (in the center).
- FIG. 28A Capillaries filled with F-NDP(NV) (4 mg/ml), F-NDP(NVN) (4 mg/ml), or PBS were positioned under abdominal skin patch of euthanized rat. Positions of capillaries are indicated by arrows.
- FIG. 28B Capillary filled with F-NDP(NV) (4 mg/ml) covered by
- FIG. 28C Capillaries filled with F-NDP (4 mg/ml) or PBS were inserted into porcine axillary vein.
- FIG. 28D Capillaries filled with F-NDP (4 mg/ml) or PBS were covered with porcine skin (2.5 mm) free of subdermis
- FIG. 28E Intensity of fluorescence for different concentrations of F-NDP(NV) through 2.5 mm porcine skin free of subdermis.
- FIG. 28F Porcine axillary veins filled with F-NDP(NV) (2 mg/ml) or PBS and covered with 8 mm porcine skin including dermis and subdermis.
- FIG. 28G Representative ultrasound of human carotid artery showing the artery 11.89 mm below the surface.
- FIGS. 29A-29N show F-NDP(NV)-Bit infusion via external carotid artery. Carotid arteries clots are imaged in situ and removed from the animal for further direct imaging and analysis.
- FIGS. 29A-29F Images of fluorescence recorded by an IVIS scanner designed for whole animal imaging using a 580-610 nm excitation and a 695-770 nm emission passband with 2 second exposure. Auto-fluorescence was subtracted based on excitation at 445-490 nm
- FIG. 29G Fluorescence of carotid artery after F-NDP(NV)-Bit treatment
- FIG. 29H Fluorescence of carotid artery after F-NDP(NV)-Bit treatment
- FIG. 29I Fluorescence of carotid artery after F-NDP(NV)-Bit treatment
- FIG. 29J saline treatment
- FIG. 29K In situ images of a FeCl3-generated clot carotid artery compared with untreated contralateral artery.
- FIG. 29K Large numbers of F-NDP(NV)-Bit are visible.
- FIG. 29L After IV treatment at low dose (1 mg), F-NDP(NV)-Bit are found in the lysate at the site of clot formation.
- FIG. 29N Almost no fluorescent particles are detected in saline control.
- FIGS. 30A-30S shows F-NDP(NV)-Bit intravenous infusion.
- FIGS. 30A-30J images of fluorescence are performed on an IVIS scanner designed whole animal imaging using a 580-610 nm excitation and a 695-770 nm emission passband with 2 second exposure. Autofluorsesence was subtracted based on excitation at 445-490 nm.
- FIG. 30Q Total number of F-NDP(NV)-Bit detected per carotid bifurcation in the clotted side compared with the contralateral control as counted by hemocytometer.
- Nanodiamond particles and related devices and methods such as nanodiamond particles for the detection and/or quantification of analytes, are generally described.
- the present invention provides diagnostic agents and methods for risk assessment of subjects, including both humans and non-human animals at risk of thrombo-embolic events (TEE), which are the main cause of cardiovascular death from strokes and heart attacks.
- TEE thrombo-embolic events
- the diagnostic agents and methods of the invention enable assessment of the total body burden of intravascular clots and detection of nascent thrombi at common predilection sites for clot formation using non-radiation (e.g., X-ray), non-MRI, and non-ultrasound techniques.
- the technology generally comprises a non-invasive, telemetry-based fluorescent recording system suitable for use in a fast and affordable ambulatory setting.
- the invention includes multiple innovative scientific and engineering breakthroughs.
- the invention is based, at least in part, on the recognition that fluorescent nano-diamond particles (NDP-F) functionalized with a species (e.g., a polypeptide such as the disintegrin Bitistatin (Bt), immunoglobulins such as IgG, and/or bovine serum albumin (BSA)) may have the innate ability to bind e.g., avidly to activated platelet fibrinogen receptors (PFR).
- a species e.g., a polypeptide such as the disintegrin Bitistatin (Bt), immunoglobulins such as IgG, and/or bovine serum albumin (BSA)
- BSA bovine serum albumin
- data presented herein demonstrate successful coupling of Bt to NDP-F and retention of Bt bioactivity.
- the methods, reagents, and de novo protocols used to accomplish the invention are not known to the inventors as having been reported by others before.
- the device comprises a plurality of nanodiamond particles and a species (e.g., a polypeptide, a polynucleotide) bound to the nanodiamond particles.
- a species e.g., a polypeptide, a polynucleotide bound to the nanodiamond particles.
- the plurality of nanodiamond particles may be exposed to a sample suspected of containing an analyte.
- the analyte may bind to the species such that the presence of the analyte in the sample may be detected.
- the devices, systems, and methods described herein are useful for the detection of an analyte in a sample obtained from a subject for, for example, diagnostic purposes.
- the systems, devices, and methods described herein may be useful for diagnosing, prevent, treating, and/or managing a disease or bodily condition.
- such systems, devices, and methods described herein may be useful for detecting and/or quantifying the presence of a virus (e.g., ebola) in a subject and/or a sample obtained from the subject.
- a virus e.g., ebola
- the systems and methods described herein may comprise quantification of the amount of analyte present in the sample.
- the present invention may also enable broad scale survey of TEE risks that may be applicable in many medical emergency and life-threatening conditions beyond strokes and heart attacks.
- the technology not only can be used for individuals suspected to be at risk for TEE but also can be periodically deployed as part of primary health care office assessments, no different than annual mammography, lipids tests, or physical examinations.
- the present invention monitors fluorescent light emittance and is expected to be highly affordable, minimally invasive (requiring only a single injection of a safe dose of nanoparticles), and can be conducted and interpreted in an ambulatory setting by a trained emergency medical technician or a primary care physician, similar to ECG monitoring.
- One general aspect of the invention is an imaging agent for detection of a thrombus in a subject.
- the agent is composed, in an exemplary embodiment, of three elements, as follows: i) a fluorescent nano-diamond particle (NDP-F); ii) a ligand that functionalizes the NDP-F, such as a —COOH, —OH, —NH 2 , or —C ⁇ O moiety; and iii) a protein attached to the ligand.
- the three can be bonded together in any order and by any type of chemical bonds, but are typically covalently bonded in the order described.
- the objective of the imaging agent is to specifically bind the agent to a discrete biological target in a human or non-human animal body.
- Yet another aspect of the invention is a diagnostic method for detection of activated platelets.
- the diagnostic method is based in large part on the ability of a species such as a polypeptide (e.g., bitistatin, BSA, human IgG) to bind to a specific antigen (e.g., PFR) with high affinity and/or avidity.
- a species such as a polypeptide (e.g., bitistatin, BSA, human IgG) to bind to a specific antigen (e.g., PFR) with high affinity and/or avidity.
- the polypeptide e.g., bitistatin
- the fluorescence of the NDP-F allows non-invasive and relatively harmless imaging of the location and size of the thrombus, or multiple thrombi.
- the diagnostic method is qualitative, and in other embodiments it is semi-quantitative or quantitative.
- the method comprises: i) administering to a subject suspected of having, or potentially having, one or more sites of thrombus, a detectable amount of the diagnostic agent of the invention, ii) allowing sufficient time for the diagnostic agent to localize to the site(s) of thrombus, and iii) detecting the diagnostic agent by detecting fluorescence emission after excitation with a suitable electromagnetic stimulus (e.g., excitation light, such as emission from a hand held device).
- a suitable electromagnetic stimulus e.g., excitation light, such as emission from a hand held device.
- step iii) the act of excitation can be omitted if the fluorescent tag is intrinsically fluorescent in the subject's body.
- the step of administering can be any action that results in introduction of the imaging agent into the systemic blood stream of the subject. It thus may be, for example and without limitation, via intravenous injection or infusion.
- the invention includes a method of detecting clots or clot formation in subjects.
- this method can be considered a method of detecting or imaging clots, clot formation, platelet activation, or pathological zones that form a risk for clot formation, such as an atherosclerotic vascular plaque or inflammation.
- the method steps are those described above.
- a clot in a subject may be detected by administering a plurality of nanodiamond particles functionalized with a species (e.g., a polypeptide such as bitistatin) which may bind to at least a portion of a clot.
- a species e.g., a polypeptide such as bitistatin
- the diagnostic and imaging methods of the present invention by virtue of introduction of a non-natural bio-active substance into a subject's body, do not relate solely to collection of data regarding a biological event, but instead relate to physical and physiological changes to the subject's body.
- introduction of the non-naturally occurring imaging agent into the blood stream of a subject physically alters the make-up of the blood stream.
- binding of the imaging agent to activated platelets alters the body's natural ability to interact with the activated platelets, and thus the clotting cascade.
- Other physical and physiological changes upon administration of the imaging agent of the invention will be apparent to the skilled artisan.
- kits for practicing the methods of the invention include the imaging agent of the invention in packaged form suitable for distribution, delivery, and/or storage for use in a method of the invention.
- the package is made of a suitable material, such as, but not limited to, a cardboard or plastic box and the like, a metal container and the like, or a foil pouch or the like.
- the kit includes sufficient imaging agent in a container for a single administration, whereas in other embodiments, the kit includes sufficient imaging agent for two or more administrations.
- the imaging agent can be supplied in a single container for multiple uses or in two or more containers, each containing sufficient imaging agent for a single use.
- a combination of single-use and multiple-use containers can be included in a kit.
- the kit (regardless of how many containers of imaging agent are provided in the kit) can be provided in packaged combination with one or more reagents or devices for administration of the imaging agent to a subject.
- a kit of the invention can include, in packaged combination, the imaging agent with an antiseptic (e.g., ethanol swabs or pads or iodine swabs or pads), one or more syringes, one or more needles adapted to connect with a syringe, and/or one or more pieces of gauze and/or adhesive to facilitate closure and healing of the site of administration.
- an antiseptic e.g., ethanol swabs or pads or iodine swabs or pads
- a plurality of nanodiamond particles (e.g., NDP-F) bound to a species such as a polypeptide or polynucleotide may be introduced into a sample suspected of containing an analyte.
- the polypeptide and/or polynucleotide may be selected such that, if present, the polypeptide and/or polynucleotide binds to the analyte.
- the analyte, the species, and/or the nanodiamond particle may bind such that the presence of the analyte may be detected.
- the detection of the analyte comprises quantification of an emission (e.g., a fluorescent emission, a near infrared emission) by the nanodiamond particle.
- quantification of the emission comprises quantification of a relative intensity and/or quantification of a wavelength of the emission.
- the intensity of the emission may be proportional (e.g., directly proportional, exponentially proportional, logarithmically proportional) to the amount of analyte present in the sample.
- the plurality of (fluorescent) nanodiamond particles are administered to a subject.
- the plurality of nanodiamond particles may be administered orally, rectally, vaginally, nasally, or uretherally to the subject.
- the plurality of nanodiamond particles are administered surgically (e.g., implanted) and/or injected (e.g., into the systemic circulation, intraoccularly, into the spinal system, e.g., via syringe).
- the plurality of nanodiamond particles may be administered to a subject (e.g., for the detection of an analyte suspected of being present in the subject).
- a subject e.g., for the detection of an analyte suspected of being present in the subject.
- the plurality of nanodiamond particles comprising the species may be administered to the subject and, upon detection of an emission (e.g., fluorescent emission, near infrared emission) of the nanodiamond particles, demonstrate the presence of an analyte in the subject.
- the analyte may be at least a portion of a (blood) clot capable of binding to the nanodiamond particles.
- a detection device configured to measure and/or detect a fluorescent emission and/or a near infrared emission may be applied to the subject (e.g., on or near the skin, at a location internal of the subject) such that, if the analyte is present, the emission is detected and/or quantified.
- the methods, devices, and systems described herein may be useful for determining and/or quantifying the amount of analyte present in a sample.
- the sample is a fluid.
- the sample is whole blood.
- the sample is obtained from a subject such as whole blood, plasma, urine, sputum, sweat, and/or other biological fluids. Methods for collecting such samples are known in the art.
- the sample is introduced into a fluidic device (e.g., a fluidic device comprising a reservoir comprising a plurality of nanodiamond particles).
- the sample may be diluted (e.g., prior to determining and/or quantifying the amount of analyte present in the sample).
- a buffer solution may be added to the fluidic device comprising the plurality of nanodiamond particles before, during, and/or after introducing the sample to the fluidic device such that the sample is diluted.
- the buffer solution is contained within a reservoir in fluidic communication with one or more components of the fluidic device.
- the sample may be diluted in a buffer solution prior to, or during, the introduction of the plurality of nanodiamond particles to the sample.
- an analyte in a sample is readily determinable without any subsequent process steps.
- the analyte is present in a subject and the nanodiamond particles may be administered to the subject, as described above.
- nanometer generally refers to a diamond particle having an average cross-sectional dimension of less than 1 micrometer (e.g., less than or equal to 900 nanometers, less than or equal to 800 nanometers, less than or equal to 700 nanometers, less than or equal to 600 nanometers, less than or equal to 500 nanometers, less than or equal to 400 nanometers, less than or equal to 300 nanometers, less than or equal to 200 nanometers, less than or equal to 100 nanometers, less than or equal to 90 nanometers, less than or equal to 80 nanometers, less than or equal to 70 nanometers, less than or equal to 60 nanometers, less than or equal to 50 nanometers, less than or equal to 40 nanometers, less than or equal to 30 nanometers, less than or equal to 20 nanometers, or less than or equal to 10 nanometers).
- 1 micrometer e.g., less than or equal to 900 nanometers, less than or equal to 800 nanometers, less than or equal to 700 nanometers,
- the nanodiamond particle may have an average cross-sectional dimension of greater than or equal to 5 nanometers, greater than or equal to 10 nanometers, greater than or equal to 20 nanometers, greater than or equal to 30 nanometers, greater than or equal to 40 nanometers, greater than or equal to 50 nanometers, greater than or equal to 60 nanometers, greater than or equal to 70 nanometers, greater than or equal to 80 nanometers, greater than or equal to 90 nanometers, greater than or equal to 100 nanometers, greater than or equal to 200 nanometers, greater than or equal to 300 nanometers, greater than or equal to 400 nanometers, greater than or equal to 500 nanometers, greater than or equal to 600 nanometers, greater than or equal to 700 nanometers, greater than or equal to 800 nanometers, or greater than or equal to 900 nanometers.
- the nanodiamond particles described herein may be auto-fluorescent (e.g., the nanodiamond particles emit fluorescent light e.g., after absorption of electromagnetic radiation).
- the nanodiamond particles may comprise one or more atomistic-type defects (e.g., a point defect such as a nitrogen-vacancy (NV) center, a point defect such as a nitrogen-vacancy-nitrogen (NVN) defect, combinations thereof) which result in near-infrared fluorescence and/or photoluminescence that may be detected and/or quantified.
- Other defects are also possible (e.g., Si-vacancy defects).
- the nanodiamond particles fluoresce in response to an applied electromagnetic radiation.
- the nanodiamond particle may be excited (e.g., by applying electromagnetic radiation having a first wavelength) such that the nanodiamond particle emits a detectable emission (e.g., an electromagnetic radiation having a second wavelength, different than the first wavelength).
- a detectable emission e.g., an electromagnetic radiation having a second wavelength, different than the first wavelength.
- the analyte binds to the nanodiamond particle (e.g., binds to a species bound to the nanodiamond particle) such that an emission from the nanodiamond particle may be detected and/or quantified.
- detection of an emission of nanodiamond particles in a subject may indicate that the nanodiamond particles are bound to the suspected analyte.
- the emission may be quantified (e.g., to determine the relative amount of analyte present in the subject).
- the sample suspected of containing the analyte may be added to a fluidic device such that, if present, the analyte binds to the nanodiamond particles (e.g., to the species bound to the nanodiamond particles) and to a detection region in the fluidic device.
- the presence of an emission indicates the presence of the analyte in the sample.
- the intensity and/or wavelength of the emission may be quantified.
- the systems, devices, and methods comprise a plurality of nanodiamond particles and a species bound to the plurality of nanodiamond particles.
- the devices and methods described herein may, in some embodiments, permit the analysis of analytes from whole blood without additional filtering or separation steps and/or have relatively high sensitivity as compared to certain existing analyte quantification methods.
- device 100 comprises a plurality of nanodiamond particles 110 associated with a species 120 (e.g., a species which may bind to an analyte, if present).
- the nanodiamond particles are associated with (e.g., bound to) the species via functionalization of the nanodiamond particle.
- a nanodiamond particle is associated with a species via formation of a bond, such as an ionic bond, a covalent bond, a hydrogen bond, Van der Waals interactions, and the like.
- the covalent bond may be, for example, a carbon-carbon, carbon-oxygen, oxygen-silicon, sulfur-sulfur, phosphorus-nitrogen, carbon-nitrogen, metal-oxygen, or other covalent bond.
- the hydrogen bond may be, for example, between hydroxyl, amine, carboxyl, thiol, and/or similar functional groups.
- the species may include a functional group, such as a thiol, aldehyde, ester, carboxylic acid, hydroxyl, and the like, wherein the functional group forms a bond with the nanodiamond particle.
- the species may be an electron-rich or electron-poor moiety wherein interaction between the nanodiamond particle and the species comprises an electrostatic interaction.
- the species may be associated with a functionalized nanodiamond particle comprising a —COOH, —OH, —NH 2 , —SH, or —C ⁇ O functional group by reacting the functionalized nanodiamond particle and the species in the presence of a cross-linking agent.
- Non-limiting examples of suitable cross-linking agents include carbodiimides such as 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC); amine-reactive compounds such as N-Hydroxysuccinimide ester, imidoester, and hydromethylphosphine; sulfhydryl-reactive compounds such as maleimide, pyridyl disulfides, and iodoacetyl; aldehyde-reactive compounds such as hydrazide and alkoxyamine; and photoreactive cross-linking agents such as aryl azides and diazirine. Other cross-linking agents are also possible. Those of ordinary skill in the art would be capable of selecting suitable cross-linking agents based upon the type of species selected and the teachings of this specification.
- EDC 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
- the species may bind with a target analyte.
- the species may comprise a biological or a non-biological (chemical) group capable of binding another biological or chemical molecule in a sample (e.g., a biological or chemical molecule present on an analyte).
- the species may include a functional group, such as a thiol, aldehyde, ester, carboxylic acid, hydroxyl, amine, polyethelene glycol and the like, wherein the functional group forms a bond with the analyte.
- the species may be an electron-rich or electron-poor moiety wherein interaction between the analyte and the species comprises an electrostatic interaction.
- the species and analyte interact via a binding event between pairs of biological molecules including proteins, nucleic acids, glycoproteins, carbohydrates, hormones, and the like.
- specific examples include an antibody/peptide pair, an antibody/antigen pair, an antibody fragment/antigen pair, an antibody/antigen fragment pair, an antibody fragment/antigen fragment pair, an antibody/hapten pair, an enzyme/substrate pair, an enzyme/inhibitor pair, an enzyme/cofactor pair, a protein/substrate pair, a nucleic acid/nucleic acid pair, a protein/nucleic acid pair, a peptide/peptide pair, a protein/protein pair, a protein/receptor pair, a small molecule/protein pair, a glutathione/GST pair, an anti-GFP/GFP fusion protein pair, a Myc/Max pair, a maltose/maltose binding protein pair, a carbohydrate/protein pair, a carbohydrate derivative/protein pair,
- the species and analyte interact via an antibody/antigen pair binding event.
- the species and analyte interact via a protein/receptor pair binding event.
- the species may comprise a protein such as disintegrin (e.g., Bitistatin) and the analyte may comprise a receptor molecule such as a fibrinogen receptor.
- the species and the analyte interact via a binding event between pairs of biological molecules including proteins, nucleic acids, glycoproteins, carbohydrates, hormones, or the like.
- the species is selected from the group consisting of (poly)peptides, (poly)nucleotides, and ligands.
- the species is a polypeptide, such as a protein, an antibody, and/or an antigen.
- the antibody is an immunoglobulin such as IgA, IgG, IgM, IgE, or the like.
- the species is a (poly)nucleotide (e.g., an oligonucleotide), such as DNA or RNA.
- the species is a disintegrin such as albolabrin, applagin, barbourin, batroxostatin, bitistatin, obtustatin, schistatin, echistatin, elegantin, eristicophin, flavoridin, halysin, kistrin, mojastin, rubistatin, tergeminin, salmosin or triflavin.
- the species may comprise a protein such as serum albumin (e.g., bovine serum albumin).
- Nanodiamond particles functionalized with a species e.g., Bitistatin
- a species e.g., Bitistatin
- NDP-F Fluorescent Nanodiamond Particles
- Non-limiting examples of analytes that may be detected and/or quantified include a biological compound, a drug, a macromolecule, a salt, an electrolyte, an enzyme, a nucleic acid (e.g., a (poly)nucleotide), a carbohydrate, a (poly)peptide, a protein, a lipid, a phosphate, a sulfonate, a virus, a pathogen, a bacterium, a fungus, an oxidant, a reductant, a toxin, a surfactant, and combinations thereof.
- a nucleic acid e.g., a (poly)nucleotide
- a carbohydrate e.g., a (poly)peptide
- a protein e.g., a (poly)nucleotide
- a lipid e.g., a lipid, a phosphate, a s
- the analyte is a virus (e.g., ebola, Marburg, Bundibugyo, sudan, junin, lassa, MERS, small pox, Zika, pertussis, rubella, rubeola).
- the analyte is a bacterial toxin (e.g., anthrax).
- the analyte is a biological entity associated with a particular parasite and/or fungus.
- the systems and methods described herein may be useful for the detection and/or quantification of viruses such as ebola.
- the analyte is a receptor molecule (e.g., a fibrinogen receptor).
- a receptor molecule e.g., a fibrinogen receptor.
- the systems and methods described herein may be useful for the detection of blood clots.
- the analyte may comprise a marker/antigen for a particular disease or condition.
- the analyte may be a marker/antigen associated with blood clots, traumatic brain injury, bone diseases (e.g., osteroporosis, osteoarthrosis), inflammation and/or (auto)immune diseases (e.g., Crohn, psoriasis) ulcers, cardiac ischemia and stroke, atherosclerosis, muscle diseases, Alzheimer's/Parkinson's, tumors and tumor metastasis, or others.
- the systems and methods described herein may be useful for the detection and/or diagnosis in a subject of blood clots, traumatic brain injury, inflammation and/or (auto)immune diseases (e.g., Crohn's, psoriasis), ulcers, cardiac ischemia and stroke, atherosclerosis, muscle diseases, Alzheimer's/Parkinson's, tumors and tumor metastasis, or others.
- autoimmune diseases e.g., Crohn's, psoriasis
- ulcers e.g., Crohn's, psoriasis
- cardiac ischemia and stroke e.g., atherosclerosis
- muscle diseases e.g., Alzheimer's/Parkinson's, tumors and tumor metastasis, or others.
- the plurality of nanodiamond particles and the species associated with the nanodiamond particles are present (e.g., in a reservoir) and/or introduced into a fluidic device.
- fluidic device 102 comprises a sample inlet 130 and a reservoir 140 in fluidic communication with sample inlet 130 .
- reservoir 140 comprises a plurality of (fluorescent) nanodiamond particles 110 (and species 120 associated with nanodiamond particle 110 ).
- a sample may be introduced to the sample inlet such that the sample flows into the reservoir and the sample interacts with the plurality of nanodiamond particles and species.
- an analyte if present in the sample, binds to the species.
- detection region 150 may be positioned downstream of, and/or in fluidic communication with, reservoir 140 .
- a detector 160 may be positioned proximate detection region 150 .
- the detector in some cases, may be configured to quantify an emission (e.g., an intensity of the emission, a wavelength of the emission) at the detection region.
- the emission may be fluorescent and/or near-infrared.
- the analyte if present, may bind to the species.
- the analyte may bind to a second species (e.g., an antibody) associated with (e.g., bound to) the detection region.
- the analyte bound to the second species and the first species (associated with the nanodiamond particles) may be detected and/or quantified by measuring (e.g., via the detector) the emission of the nanodiamond particles.
- a detector may be positioned proximate a region of a subject suspected of containing an analyte and/or a clot.
- the plurality of (fluorescent) nanodiamond particles functionalized with a species may be administered to a subject, and the detector may be positioned proximate the subject such that any nanodiamond particles bound to the analyte and/or clot may be detected (e.g., via an emission of the nanodiamond particles).
- the detector may be an optical detector (e.g., fluorescence detectors, visible light and/or UV detectors, near infrared detectors, microscopes).
- optical detector e.g., fluorescence detectors, visible light and/or UV detectors, near infrared detectors, microscopes.
- the emission is a fluorescent emission.
- the wavelength of the emission is greater than or equal to 250 nm, greater than or equal to 300 nm, greater than or equal to 350 nm, greater than or equal to 400 nm, greater than or equal to 450 nm, greater than or equal to 500 nm, greater than or equal to 550 nm, greater than or equal to 600 nm, or greater than or equal to 650 nm.
- the wavelength of the emission is less than or equal to 700 nm, less than or equal to 650 nm, less than or equal to 600 nm, less than or equal to 550 nm, less than or equal to 500 nm, less than or equal to 450 nm, less than or equal to 400 nm, less than or equal to 350 nm, or less than or equal to 300 nm. Combinations of the above-referenced ranges are also possible (e.g., greater than or equal to 250 nm and less than or equal to 700 nm). Other ranges are also possible.
- the emission is a near infrared emission.
- the wavelength of the emission is greater than 700 nm, greater than or equal to 750 nm, greater than or equal to 800nm, greater than or equal to 850 nm, greater than or equal to 900 nm, or greater than or equal to 950 nm.
- the wavelength of the emission is less than or equal to 1000 nm, less than or equal to 950 nm, less than or equal to 900 nm, less than or equal to 850 nm, less than or equal to 800 nm, or less than or equal to 750 nm. Combinations of the above-referenced ranges are also possible (e.g., greater than 700 nm and less than or equal to 1000 nm). Other ranges are also possible.
- the nanodiamond particle may emit a fluorescent and/or near infrared emission upon excitation by electromagnetic radiation having a particular wavelength.
- the nanodiamond particle may be exposed to electromagnetic radiation having a wavelength of greater than or equal to 250 nm, greater than or equal to 300 nm, greater than or equal to 350 nm, greater than or equal to 400 nm, greater than or equal to 450nm, greater than or equal to 500 nm, greater than or equal to 550 nm, greater than or equal to 600 nm, greater than or equal to 650 nm, greater than or equal to 700 nm, greater than or equal to 750 nm, greater than or equal to 800 nm, greater than or equal to 850 nm, greater than or equal to 900 nm, or greater than or equal to 950 nm (e.g., such that the nanodiamond particle emits a fluorescent emission and/or near infrared emission in one of the above
- the nanodiamond particle may be exposed to electromagnetic radiation having a wavelength of less than or equal to 1000 nm, less than or equal to 950 nm, less than or equal to 900 nm, less than or equal to 850 nm, less than or equal to 800 nm, or less than or equal to 750 nm, less than or equal to 700 nm, less than or equal to 650 nm, less than or equal to 600 nm, less than or equal to 550 nm, less than or equal to 500 nm, less than or equal to 450 nm, less than or equal to 400 nm, less than or equal to 350 nm, or less than or equal to 300 nm.
- the device may comprise a particle such as a nanoparticle (e.g., a silica nanoparticle, a sapphire nanoparticle, a garnet nanoparticle, a ruby nanoparticle) having an emission in one of the above referenced ranges associated with a species (e.g., a species capable of binding to one or more target analytes).
- a nanoparticle e.g., a silica nanoparticle, a sapphire nanoparticle, a garnet nanoparticle, a ruby nanoparticle
- the particle may be autofluorescent.
- the particle may be functionalized with (e.g., associated with) a fluorescent molecule.
- the fluidic device (e.g., comprising a sample inlet and a reservoir comprising a plurality of nanodiamond particles and a species associated with the nanodiamond particles) comprises a lateral flow assay configuration (e.g., in a lateral flow device).
- a lateral flow assay configuration e.g., in a lateral flow device.
- system 200 comprises a lateral flow assay format.
- system 200 comprises reservoir 210 comprising a plurality of fluorescent nanodiamond particles 220 bound to a first species. Downstream of reservoir 210 , in certain embodiments, is a second reservoir 230 comprising a second species (e.g., a first antibody to a target analyte) and a third reservoir 240 comprising a third species (e.g., a second antibody capable of binding to the antibody to the target analyte). In certain embodiments, the first species and the second species are the same.
- a second species e.g., a first antibody to a target analyte
- third reservoir 240 comprising a third species (e.g., a second antibody capable of binding to the antibody to the target analyte).
- the first species and the second species are the same.
- a sample suspected of containing an analyte 250 may be introduced into system 200 (e.g., such that the sample flows and interacts with reservoir 210 ).
- at least a portion of analyte 250 binds to the species on plurality of fluorescent nanodiamond particles 220 .
- FIG. 2C as the sample suspected of containing analyte 250 flows along the system, at least a portion of the analytes 250 (e.g., now bound to the species and/or plurality of fluorescent nanodiamond particles 220 ) bind to the second species in reservoir 230 .
- at least a portion of plurality of fluorescent nanodiamond particles 220 not bound to the analyte may be captured in reservoir 240 (e.g., where the third species is capable of binding to the first species).
- the devices and systems herein may be multiplexed. That is to say, in some embodiments, the devices may comprise two or more, three or more, four or more, or five or more fluidic components and/or reservoirs comprising a plurality of nanodiamond particles. In some such embodiments, more than one analyte may be detected, if present in the sample, in a single device. In certain embodiments, one or more analytes may be detected in a device comprising a plurality of fluidic components and/or reservoirs comprising a plurality of nanodiamond particles.
- a sample suspected of containing an analyte may be introduced into a fluidic channel of a fluidic device, exposing the sample to a species bound to a plurality of fluorescent nanodiamond particles such that the analyte, if present, binds to at least a portion of the species bound to the plurality of fluorescent nanodiamond particles.
- any fluorescent nanodiamond particles and species not bound to the analyte may be removed and a fluorescence emission of the plurality of fluorescent nanodiamond particles bound to the analyte may be quantified.
- the amount of analyte present in the sample may be correlated with the intensity of the fluorescence emission.
- a system comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, and a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region.
- the detector may be configured to quantify a fluorescent emission at the detection region and/or configured to quantify an infrared signal at the detection region.
- a fluidic device comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, and a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region.
- the fluidic device may further comprise a control region in fluidic communication with the detection region, the control region comprising a plurality of a third species bound to the control region.
- the third species may be the same or different as the first species and/or the second species.
- the first species bound to the plurality of fluorescent nanodiamond particles may be a first antibody (e.g., capable of binding selectively to the target analyte)
- the second species may be the first antibody or may be a second antibody different than the first antibody (e.g., capable of binding selectively to the target analyte)
- the third species may be an anti-antibody to the first antibody.
- the control region may provide an indication, if an emission is present, that the system is working properly (e.g., the plurality of nanodiamond particles were properly featured and introduced into the sample).
- the fluidic device comprises an absorbent material.
- an absorbent region comprising the absorbent material is positioned downstream of, and in fluidic communication with, the detection region and/or the control region.
- the absorbent material is associated with one or more components (e.g., the reservoir, the detection region) of the fluidic device.
- the absorbent material may at least partially drive the flow of the sample in the fluidic device (e.g., wicking).
- capillary action may at least partially drive the flow of the sample in the fluidic device.
- suitable absorbent materials include solid materials, porous materials, particles, powders, and gels.
- the absorbent material may comprise fabric, cellulose, cotton, and/or a polymer. Those of ordinary skill in the art would be capable of selecting suitable absorbent materials based upon the teachings of this specification.
- the methods described herein comprise administering, to a subject suspected of having a particular analyte (e.g., present in the bloodstream), a plurality of fluorescent nanodiamond particles bound to a species such that the species may bind to the analyte, if present, and detecting a fluorescent and/or near infrared emission of the plurality of fluorescent nanodiamond particles comprising the species bound to, if present, the analyte.
- detecting a fluorescent emission indicates the presence of a blood clot in the subject.
- detecting a fluorescent emission indicates the presence of a virus (e.g., ebola, Marburg, Bundibugyo, sudan, junin, lassa, MERS, etc.) in the subject.
- the present invention also provides a diagnostic agent for detection or imaging of thrombotic events in a human or non-human animal, where the agent comprises a fluorescent nanodiamond particle chemically bonded to disintegrin Bitistatin (Bt).
- the fluorescent nanodiamond particle and the Bt are covalently bonded.
- the diagnostic agent may be fluorescent as a result of an intrinsic property of the nanodiamond particle.
- the diagnostic agent emits a detectable electromagnetic signal when excited by an electromagnetic source.
- Additional exemplary embodiments relate to a method for diagnosis or prognosis of a thrombo-embolic event.
- the method comprises: administering to a subject suspected of having suffered from or suspected of being at risk of, a thrombo-embolic event, a diagnostically effective amount of the diagnostic agent of the invention; allowing sufficient time for the diagnostic agent to localize to the site(s) of thrombus; and detecting the diagnostic agent by detecting fluorescence emission of the diagnostic agent.
- the method can be practiced as a method of detection of activated platelets and/or a method of detecting clots or clot formation in subjects.
- kits may include the diagnostic agent of the invention in packaged form suitable for distribution, delivery, and/or storage for use in a diagnostic method (e.g., a diagnostic method for detection of a thrombus).
- the packaged form may include a suitable material for distribution, delivery, and/or storage of the diagnostic agent.
- the kit further comprises, in packaged combination, one or more reagents or devices for administration of the diagnostic agent of the invention to a subject.
- the kit can also include a device that emits excitation energy for the diagnostic agent, and preferably further includes a detector for detection of emission response from the diagnostic agent.
- the device e.g., a device that emits excitation energy, a detector for detection of emission response
- the device is a hand-held device.
- a “subject” or a “patient” refers to any mammal (e.g., a human), for example, a mammal that may be susceptible to a disease or bodily condition.
- subjects or patients include a human, a non-human primate, a cow, a horse, a pig, a sheep, a goat, a dog, a cat or a rodent such as a mouse, a rat, a hamster, or a guinea pig.
- the invention is directed toward use with humans.
- a patient may be a subject diagnosed with a certain disease or bodily condition or otherwise known to have a disease or bodily condition.
- a patient may be diagnosed as, or known to be, at risk of developing a disease or bodily condition.
- a patient may be suspected of having or developing a disease or bodily condition, e.g., based on various clinical factors and/or other data.
- the patient may be diagnosed with having or developing a particular disease or bodily condition after the detection and/or quantification of an analyte (e.g., a virus, an antigen, an antibody) in a sample obtained from the patient.
- an analyte e.g., a virus, an antigen, an antibody
- a subject may demonstrate health benefits, e.g., upon administration of the fluorescent nanodiamond particles.
- a “fluid” is given its ordinary meaning, i.e., a liquid or a gas.
- a fluid cannot maintain a defined shape and will flow during an observable time frame to fill the container in which it is put.
- the fluid may have any suitable viscosity that permits flow. If two or more fluids are present, each fluid may be independently selected among essentially any fluids (liquids, gases, and the like) by those of ordinary skill in the art.
- the following example demonstrates an exemplary functionalized fluorescent nanodiamond particle with a species (e.g., for binding to anti-human IgG-AP).
- FIG. 3 illustrates the conjugation of a fluorescent nanodiamond particle (F-NDP), functionalized with a carboxylic acid group, and bound to a species (e.g., Bitistatin).
- F-NDP fluorescent nanodiamond particle
- Such functionalized F-NDPs can be used, for example, to image and detect the presence of blood clots using external scanners (e.g., detectors for UV and/or NIR emissions).
- the following example demonstrates the incorporation of fluorescent nanodiamond particles into an exemplary system such as a lateral flow assay format.
- FIG. 4 shows the loading of three exemplary systems (system 400 , system 410 , and system 420 ), each with a reservoir of fluorescent nanodiamond particles (shown as the dot in each system) placed on a nitrocellulose substrate.
- system 400 water with 1% Tween 20 to system 410 , and 10 mM sodium phosphate with 1% Tween 20 to system 420 , flow of the fluorescent nanodiamond particles along the substrate of each device was observed (system 402 , system 412 , and system 422 respectively).
- F-NDP fluorescent nanodiamond particles conjugated with a species (e.g., human IgG) for the detection of an analyte (e.g., anti-human IgG).
- a species e.g., human IgG
- an analyte e.g., anti-human IgG
- FIG. 5 shows a plot of semi-ELISA for detection of human IgG coupled to the F-NDP NV (700 nm).
- F-NDP were coupled to human IgG, or BSA (control), which were used in concentrations as indicated, per 1 mg of F-NDP.
- 0.2 mg of each F-NDP-IgG or F-NDP-BSA sample were used for semi-ELISA, which was performed on a U-shape bottom 96-well plate. The plate was blocked overnight with 3% BSA in PBST. F-NDP-IgG were blocked with 3% BSA in PBST by incubation for 1 hour at 37° C.
- Blocking agent was removed by centrifugation (1,000 g) at room temperature and washed 2 ⁇ with PBST.
- Goat anti-human IgG AP-conjugated (Sigma Inc.), diluted 1:5000, was added and incubated for 1 hr. as above. Final washing was performed as above, and p-nitrophenyl phosphate substrate (pNPP) to alkaline phosphatase (AP) was added. Color was developed for 30 min, and NDP samples on plate were centrifuged. Supernatant was transferred to a flat bottom 96-well plate and read using an ELISA plate reader under 405 nm wave length. Error bars represent four repeats in semi-ELISA from the same samples.
- FIG. 6 shows the accumulation number of F-NDP-Bt in carotid arteries in rats with generated clots.
- Carotid arteries with generated clots or not (control) were dissected from rats at the end of the experiments.
- Vessels were solubilized with 12 N HCl by overnight incubation at 60° C. in a ratio of 100 mg per ml.
- the resulting solution was diluted 10 ⁇ with water and centrifuged using 14,000 rpm at room temperature and re-suspended in the same volume of water.
- FIG. 7A is a scanning confocal microscope (SCM) image of carotid arteries from rats with a generated clot. Generation of a clot was performed using ferric chloride. F-NDP-Bt suspension was injected locally, close to the clot. Rats were euthanized, and carotid arteries with clots were dissected. Imaging was performed using SCM. Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). NIR detection of F-NDP-Bit is indicated by the white arrows.
- SCM scanning confocal microscope
- FIG. 7B shows a scanning confocal microscope image of carotid arteries from rats with generated clot.
- Generation of a clot was performed using ferric chloride.
- F-NDP-Bt suspension was systemically injected to the animal tail.
- the rat was euthanized, and the carotid artery with clots was dissected. Imaging was performed using SCM. Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). NIR detection is indicated by white arrows.
- FIG. 8 shows images of tissue suspensions of clots treated or not with F-NDP-Bt, injected systematically to the femoral vein close (locally) to the clot generated in carotid artery.
- Tissues of the clot were manually homogenized in the presence of RIPA buffer (Triton X-100 based) in ratio one vein for 100 ml. Suspension of the lysate was applied on glass slide and immediately analyzed under the microscope. Magnification 100 ⁇ .
- F-NDP i.e., NDP-F
- a polypeptide e.g., Bitistatin (Bt)
- Bt Bitistatin
- a major innovation of the present invention is the demonstration of a concentration-dependent association of the engineered NDP-F-Bt agent to purified PFR.
- the selection of Bt was based on the high selectivity/specificity of Bt to the PFR, concomitant with negligible interactions with other RGD-dependent integrins, such as receptors for vitronectin (avb3) and fibronectin (a5b1).
- the present strategy to utilize Bt for clot imaging differs significantly from previous studies aimed at demonstrating the utility of Tc99-Bitistatin to map blood clots in vivo.
- the present imaging strategy is based on the innate near infrared (NIR) fluorescence emitted upon excitation of the NDP-F, thereby eliminating high radioactivity exposure required by other imaging techniques. It is also envisioned that coupling Bt (or other polypeptides) to a nanoparticle will be beneficial for the extension of the lifetime of the Bt at the site of its biological target.
- NDP-F or FNDP Fluorescent nano-diamond particles
- —COOH carboxyl groups
- Size distribution analysis revealed the peak of the diameter of the NDP was 734.5 ( ⁇ 223.6, SD) nm.
- Optimization of fluorescence for the NDPs was performed by 2D screening of excitation vs. emission wavelengths ( FIG. 9 ). Two areas of optimal fluorescence were established for NDPs, which should be useful for application in medical imaging (circled on FIG. 9 ). Detailed screening revealed two optimal correlations of excitation vs. emission wavelengths: 480 nm vs. 520 nm, and 565 nm vs.
- the first correlation represents the typical green fluorescence, whereas the second is characterized by the long Stokes shift of fluorescence with near IR emission.
- the near IR emission is very useful for detection in vivo because it is in the optical therapeutic window of autofluorescence of factors present in human and non-human animal non-invasive imaging environments (e.g., water, hemoglobin, oxyhemoglobin, melanin).
- the NDP-Fs were found to be resistant to photobleaching. Exposure of the slides containing NDPs to intense fluorescence light resulted in no changes in the intensity of their fluorescence in the time points up to 5 hours (data not shown).
- Bitistatin is generally derived from snake venom and belongs to the disintegrin family of proteins. It has previously been investigated as a potential reagent for detection of deep venous thrombosis (DVT) using radioactive tags. This RGD-disintegrin showed desirable parameters for detection of DVT when compared with other snake venom disintegrins, such as kistrin and barbourin. Therefore, this fibrinogen receptor-binding ligand was selected for coupling to NDP-Fs for the purpose of detecting activated platelets (or their aggregates) in clots present in the venous circulation (vein thrombus).
- Bitistatin is generally an 83-amino acid polypeptide, which originally was isolated from venom of Bitis arietants. This naturally occurring polypeptide was purified from the same snake venom using methodology developed in the laboratory for purification of other snake venom disintegrins (Marcinkiewicz, Cezary, et al. “EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits ⁇ 4 and ⁇ 5 integrins in an RGD-independent manner.” Journal of Biological Chemistry 274.18 (1999): 12468-12473.; incorporated herein by reference).
- this method includes two steps of reverse phase HPLC with application of C 18 column and a linear gradient of acetonitrile as a protein elution agent. Purity of the obtained Bt was tested by SDS-PAGE and quantified by digitization of bands on standard protein gels by Coomassie blue staining. The content of Bt was estimated at over 98% in the final protein preparation. This preparation was suspended in PBS for coupling to NDPs.
- the active site of Bt was characterized and found to include an RGD motif, which is important for ligand binding to certain integrins, such as ⁇ IIb ⁇ 3, ⁇ v ⁇ 3, and ⁇ 5 ⁇ 1.
- Bt is quite selective in that it has been shown to bind only the PFR, ⁇ IIb ⁇ 3 integrin, which is exclusively expressed on circulating platelets.
- the aspartic acid in the RGD sequence was recognized by site-directed mutagenesis of recombinant proteins and short peptide synthesis as the most essential amino acid for disintegrin binding to the fibrinogen receptor.
- NDPs functionalized by a carboxyl group were selected to attach the Bt on NDPs surfaces.
- Sample A contained 1 mg Bt per 1 mg NDPs.
- Sample B contained 1 mg BSA per 1 mg NDPs, and served as a control.
- the activated NDPs were transferred to 1.5 ml centrifuge tubes and centrifuged at 10,000 ⁇ g for 5 minutes at room temperature.
- the NDP pellets were washed twice with 1 ml PBS and suspended in coupling buffer (PBS).
- PBS coupling buffer
- One milligram of either Bt or BSA in 1 ml of PBS was added to each sample tube.
- the tubes were incubated for two hours at room temperature with gentle rotating.
- Ten ⁇ l of 1M Hydroxylamine-HCl 350 mg in 5 ml PBS
- was added to each tube for quenching final concentration of Hydroxylamine-HCl should be about 10 mM).
- the sample tubes were centrifuged at 10,000 ⁇ g for 5 minutes at room temperature. The supernatants were saved for protein concentration determination to check coupling efficiency.
- the NDP-F-Bt particles were washed three times with 1 ml PBS each time. The washed particles were suspended in a volume of PBS to achieve a concentration of 1 mg/ml.
- Coupling efficiency was evaluated using immune detection of Bt on the surface of NDPs (NDP-Bt).
- NDP-Bt NDPs
- the detection method is called semi-ELISA.
- polyclonal antibody against Bt was developed commercially in rabbits (Chemicon/Millipore Inc.) using purified native polypeptide as the antigen.
- the saturated concentration of Bt was estimated at 1 mg per 1 mg NDPs.
- a representative plot from three independent experiments is presented in FIG. 10 .
- NDP-F-Bt or NDP-F-BSA solution (1 mg/ml NDP in PBS) was each applied to a separate well. The plate was centrifuged for 10 minutes at 1,000 ⁇ g. The supernatant was removed and the plate gently shaken by vortexing to disperse and re-suspend the pellet of NDP-F.
- NDP-Bt The activity of NDP-Bt was tested using PFR purified from platelets, ⁇ IIb ⁇ 3 integrin (Millipore Inc.). Two types of assays were applied to confirm the presence of disintegrin on NDP-Bt, including binding of soluble PFR to NDP-F-Bt and adhesion of NDP-F-Bt to fibrinogen receptor immobilized on the surface (plastic or glass). Binding of soluble PFR was determined on the basis of the functional “sandwich” ELISA, which is referred to herein as a functional semi-ELISA. In this case, immune-detection of ⁇ IIb ⁇ 3 integrin bound to the NDP-Bt was performed using a polyclonal antibody against the ⁇ II ⁇ integrin subunit (purchased from Santa Cruz Inc.).
- NDP-F-Bt or NDP-F-BSA suspension (1 mg/ml NDP in PBS) was each applied to a separate well. The plate was centrifuged for 10 minutes at 1,000 ⁇ g. The supernatant was removed and the plate gently shaken by vortexing to disperse the pellet of NDP-F. 200 ⁇ l of 3% BSA PBST (PBS+0.05% Tween-20) was added and the composition was mixed a few times by intensive aspiration and releasing from a pipet tip. The mixture was incubated for one hour at 37° C.
- the blocking step may be performed in a tube before application on the 96-well plate.
- the mixture was centrifuged as above and washed three times with 200 ⁇ l of PBST. After each centrifugation, the pellet was dispersed by vortexing.
- Fibrinogen receptor was then added at the desired concentrations (i.e., the amounts required to generate a dose-response); see FIG. 11 (in 200 ⁇ l of HBSS containing physiological concentrations of Ca 2+ and Mg 2+ and incubated for one hour at 37° C. The plate was then washed three times with PBST as above. Next, 100 ⁇ l of anti-fibrinogen receptor (2 ⁇ g/ml from Santa Cruz Inc.) polyclonal antibody in PBST was added to the wells and incubated for one hour at room temperature. The plate was washed three times with PBST as above.
- AP substrate pNPP from Sigma
- the reaction was blocked by adding 100 ⁇ l of 3 M NaOH (this step is optional).
- the plate was centrifuged and 100 ⁇ l of supernatant was transferred to the well of a 96-well plate (flat bottom). The absorbance of the supernatant was measured at 405 nm using an ELISA plate reader.
- Adhesion of NDP-Bt to immobilized fibrinogen receptor was performed in two formats based on the estimation of the fluorescence of attached NDPs.
- integrin was immobilized on a 96-well plate and adhered NDPs were detected using a fluorescence plate reader. The results obtained showed linear progression of the adhesion of NDP-Bt to increased concentration of immobilized purified receptor ( FIG. 12 ).
- Adhesion of NDP-Bt was also monitored under fluorescence microscopy. The number of adhered NDPs was quantified using computer software ( FIG. 13 ). Representative images of adhered NDP-Bt are presented in FIG. 14 .
- FIGS. 15A-D show imaging of fluorescence that was performed on an IVIS scanner designed for whole animal imaging using a 580-610 nm excitation and a 695-770 nm emission passband with a 2 second exposure. Auto-fluorescence was subtracted based on excitation at 445-490 nm.
- FIG. 15A shows an in situ carotid bifurcation region image, indicating fluorescence of carotid arterial clot after treatment visible via IVIS imaging after exposure of the carotid bifurcation zone.
- FIGS. 15B and 15C are high magnification images of fluorescence emanating from the carotid bifurcation in vivo, suggesting accumulation of FNDP in the clot.
- FIG. 15D is an ex vivo photograph of fluorescence of carotid artery bifurcation denoting one branch showing fluorescence corresponding to the clot location within the carotid bifurcation.
- FIGS. 15E and 15F are confocal images taken on an Olympus IX83 of FNDP in which fluorescence is detected at an excitation of 543 nm and an emission of 655-755 nm.
- FIG. 15E shows ex vivo fluorescence of the carotid artery at 4 ⁇ magnification.
- FIG. 15F shows FNDP treated carotid arteries after they were flushed with RIPA lysis buffer and replicates were combined together to form a lysate. Lysate was then deposited onto a cover-glass and imaged at 20 ⁇ magnification. Large numbers of FNDP at various aggregate sizes around platelets are visible.
- FIG. 16 shows fluorescent images taken by IVIS and confocal microscopy of carotid artery clots after intravenous treatment with FNDP.
- treatment with saline control or FNDP by intravenous infusion via tail vein or femoral vein was performed in three rats.
- FNDP were infused (over 10 min) as a suspension in PBS at 1 ml solution containing 1 mg/ml FNDP.
- Carotid arteries were removed from the animal for imaging and placed in 70% denatured ethanol for preservation until imaging. FNDP were conspicuously identified at the site of clot formation.
- FIGS. 16A and 16B show imaging of fluorescence as performed on an IVIS scanner designed for whole animal imaging using a 580-610 nm excitation and a 695-770 nm emission passband with a 2 second exposure. Autofluorescence was subtracted based on excitation at 445-490 nm.
- FIG. 8A shows an ex vivo fluorescent image of a carotid artery from saline-treated control. Auto-fluorescence could not be entirely eliminated, but was evenly distributed across control specimen.
- FIGS. 16B shows an ex vivo fluorescent image of a carotid artery from an IV FNDP-treated animal, showing fluorescence localized to the branch with a clot.
- FIGS. 16C-16F show confocal images taken on an Olympus IX83. The figures show that FNDP fluorescence was detected at an excitation of 543 nm and an emission of 655-755 nm. Background fluorescence was collected from the same excitation, with emissions of 555-625 nm and was subtracted from the foreground to reduce auto-fluorescence.
- FIGS. 16C and 16D show ex vivo fluorescence of carotid artery at 4 ⁇ magnification of saline treated and FNDP treated animals, respectively.
- FIG. 16E shows that the saline-treated control showed no detectable fluorescence.
- FIG. 16F shows that FNDP appear as frequent fluorescent spots in the treated samples.
- FIG. 16G presents a graph showing the number of FNDPs present in carotid clot lysates from animals treated locally via the external carotid artery or intravenously as compared with saline treated controls. FNDPs were counted in replicate images after thresholding in ImageJ.
- FIG. 17 depicts images of rat blood plasma clots following treatment with F-NDP-Bt and F-NDP-BSA.
- Rat blood was collected by heart puncture and centrifuged at 100 ⁇ g for 20 minutes at room temperature to obtain platelet rich plasma (PRP).
- PRP platelet rich plasma
- a thrombus was generated by adding thrombin (1 U/ml) and incubating for 15 minutes at 37° C.
- the clot that was formed was washed 3 ⁇ by decanting with HBSS containing calcium and magnesium, and then sliced.
- FIG. 17A Images of plasma clots obtained from fluorescence microscope Olympus IX81 analysis, under 100 ⁇ magnification, are shown in FIG. 17A . Images of plasma clots obtained using an IVIS 50 imaging system are shown in FIG. 17B . Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). Exposure time: 1 minute. Arrows in FIG. 17B point the localization of the clot.
- FIG. 17 shows the specificity of interaction of F-NDP-Bt with a clot generated from rat blood plasma by thrombin (1 U/ml).
- Analysis of the clot under a fluorescence microscope revealed that F-NDP-Bt accumulated on the surface of the thrombus to a high extent, although this accumulation was not evenly distributed.
- Fluorescence microscopy imaging identified areas with high green fluorescence intensity (represented by bright spots in the black and white image), which may indicate zones of the condensation of activated platelets.
- Fluorescence live imaging system (IVIS 50) also exhibited binding of F-NDP-Bt to the plasma clot ( FIG. 17B ).
- NIR near infrared
- FIG. 18 The skin areas of observation fields were prepared for implantation by hair shaving. The incision was made by scalpel and vessels were inserted under the skin of dead rats. The dead rats were placed in IVIS 50 Imaging System, and measurement of fluorescence under NIR spectrum was performed. Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm).
- FIG. 18A A representative image of the implanted glass capillaries filled with F-NDP-Bt (4 mg/ml) or PBS (control) are shown in FIG. 18A . Exposure time was 5 seconds.
- FIG. 10B shows an image of a rat aorta filled with F-NDP-Bt. The rat aorta was dissected from a euthanized female rat, washed with PBS to remove residues of coagulated blood, and filled with 300 ⁇ l of F-NDP-Bt suspension (2 mg/ml) in PBS. The aorta was secured from both ends by knots of surgical sutures. Exposure time was 1 minute.
- FIG. 10B shows an image of a rat aorta filled with F-NDP-Bt. The rat aorta was dissected from a euthanized female rat, washed with PBS to remove residues of coagulated blood, and filled with 300 ⁇ l of F-ND
- FIG. 18A demonstrates NIR imaging of F-NDP-Bt, experimentally implanted under rat skin. Suspensions of F-NDP-Bt were infused into glass capillaries and into dissected rat aorta ( FIG. 18B ), before subcutaneous implantation. Clear images showed precise localization of both artificial (capillary) and natural (aorta) vessels in the rats.
- FIGS. 18C-18D the specificity of the interaction of F-NDP-Bit with the fibrinogen receptor present on activated platelets in a preformed PRP clot.
- clots were incubated with F-NDP-Bit for 15 or 60 minutes, respectively.
- a clot was generated from rat PRP by thrombin (1 U/mL) and incubated with F-NDP-Bit (250 ⁇ g/mL) in the presence or absence of Lt (4.67 ⁇ mol/mL).
- FIG. 18C IVIS imaging was performed using GFP filters (excitation 445-490 nm, emission 515-575 nm).
- the clot was incubated with F-NDP-Bit for 15 minutes (upper panel) or 60 minutes (lower panel). Intensity of fluorescence was evaluated using IVIS Living Image 4.3.1 software. Insets above the bars represent respective images of clots from IVIS. (FIG. 18D) Phase-contrast and fluorescence microscope images of clots (100 ⁇ ). Areas of accumulation of F-NDP-Bit are framed in yellow. Irrespective of the duration of incubation, binding of F-NDP-bit was always 4-5 fold higher than that of the nonspecific control particles (F-NDP-BSA). Furthermore, preincubation of the clots with lotrafiban (lt) reduced F-NDP-Bit binding to the level of the control F-NDP-BSA.
- lotrafiban lotrafiban
- Bitistatin was purified from the venom of Bitis arientans (Latoxan Serpentarium, Valence, France) using two steps of reverse-phase HPLC.
- F-NDP chemically surface-functionalized with carboxyl groups (—COOH), were purchased from Adamas Nanotechnologies (Raleigh. N.C., USA).
- F-NDP(NVN) green fluorescent F-NDP based on N-V-N color centers
- F-NDP(NV) red fluorescent based on N-V (F-NDP(NV)) color centers at 100 nm (5 ⁇ 10 11 particles/mg), 700 nm (2 ⁇ 10 8 particles/mg), and 10,000 nm (5 ⁇ 10 5 particles/mg).
- Isoflurane was purchased from Henry Schein (B34C16A Dublin, Ohio, USA).
- 70% Denatured Ethyl Alcohol and PE-10 tubing were purchased from Fisher Scientific (Pittsburgh, Pa., USA).
- Silk Suture was purchased from Roboz SUT-15-1, Roboz Surgical Instrument Co. (Gaithersburg, Md., USA).
- Parafilm and FeCl 3 was purchased from Sigma-Aldrich, (St. Louis, Mo., USA).
- Bitistatin was coupled to the F-NDP of all types using EDC (1-ethyl-3-[3dimethylaminopropyl] carbodiimide hydrochloride) as a hetero-bifunctional cross-linker. Coupling efficiency and preservation of Bitistatin activity on the various functionalized nanodiamond particles (F-NDP-Bit) were verified using a semi-ELISA methodology.
- the following example demonstrates the use of functionalized fluorescent nanodiamond particles (e.g., (F-NDP-Bt)) to bind to platelets and preferentially to activated platelets from humans.
- the data also shows that the particles do not substantially interfere with platelet aggregation.
- FIGS. 19A-19C show dose response curves for aggregation of platelets with and without probe (i.e., F-NDP-Bt), determined as a function of concentration of proteinase-activated receptor 4 (PAR4 AP), adenosine diphosphate (ADP), and arachidonic acid (AA).
- PAR4 AP proteinase-activated receptor 4
- ADP adenosine diphosphate
- AA arachidonic acid
- FIGS. 20A-20C show the ability of a F-NDP-Bt probe having an average particle diameter of 700 nm or 200 nm to bind to various platelet populations at different concentrations.
- FIGS. 21-222 shows the difference in binding of probes (700 nm or 200 nm in diameter) in stimulated versus unstimulated platelet populations.
- FIGS. 23A-23D and FIGS. 24A-24D Flow cytometry data of stimulated and unstimulated platelets are shown in FIGS. 23A-23D and FIGS. 24A-24D , using the F-NDP-Bt probes.
- the following example demonstrates an exemplary method for extracting, isolating, and/or quantifying F-NDP-(NV) in blood and/or biological tissues.
- F-NDP-BSA NV 700 nm were prepared using a coupling protocol as described herein, in sterile conditions (see e.g., Example 8). Final concentrations of 5 mg/ml were be prepared in PBS for animal administration.
- Blood containing F-NDP-BSA may be lyophilized using SpeedVac system (SC110A Plus, Thermo Savant) with 4,680 ⁇ g. Control animal may be used for preparation of standard curve. Standard curve may be prepared by mixing known amount of F-NDP-BSA with blood. 8 serial dilution will be prepared starting from the highest, 2 mg/ml particles density.
- Dry mass of particles containing blood collected in the course of the experiment of may be dissolved in 12 N HCl at same volume staring volume of blood (approx. 1 ml). Solubilization may be performed by overnight incubation at 60° C.
- Supernatant may be removed by centrifugation (17,000 ⁇ g for 5 min at room temperature) and pellet re-suspended in the same volume original volume (e.g., water 1 ml). Centrifugation will be repeated one time for washing. At this point, particles may be condensed using smaller amount of water, to improve sensitivity. For example, final volume of water may be twice lower than volume of blood used for lyophilization, e.g., such that sensitivity for detection of F-NDP would be twice increased.
- F-NDP-BSA of investigated samples and standard curve may be applied on 96-well plate (100 microliters per well) and plate may be read in Tecan using NIR wavelength (excitation 570 nm, emission 670 nm).
- NIR wavelength excitation 570 nm, emission 670 nm.
- number of particles per ml may be established by disposable hemocytometer (Incyto Inc., Cheonan-si, Korea), counting under fluorescence microscope, e.g., using an Olympus IX81 with TRICI wavelength and 400 ⁇ magnification. Amount of F-NDP-BSA in investigated samples may be deducted from the standard curve.
- the following example demonstrates an exemplary method for sterilization and/or lyophilization of F-NDPs.
- F-NDPs were suspended in 70% ethanol and incubate for 15 min at room temperature (23+/ ⁇ 2° C.), using gentle agitation on “Speci Mix Test Tube Rocker” (ThermoScientific Inc., Waltham, Mass. USA). Density of F-NDPs was approximately 0.5 mg/ml.
- the suspension of F-NDPs may be centrifuged (e.g., 17,000 ⁇ g for 5 min at room temperature). Supernatant (ethanol) may be removed by vacuum aspiration and pellet suspended in water or buffer (e.g., PBS or MES) and centrifuged once again under the same speed conditions for washing purposes.
- F-NDPs were suspended in water or working buffer (e.g., MES if coupling to protein will be performed) in desired density (e.g. 1 mg/ml).
- working buffer e.g., MES if coupling to protein will be performed
- desired density e.g. 1 mg/ml
- Lyophilization of F-NDPs may be performed using a SpeedVac system (SC110A Plus, Thermo Savant, and Holbrook, N.Y., USA).
- SC110A Plus SpeedVac
- Polypropylene tubes 5 ml Sarstedt Inc., Numbrecht, Germany
- 1.5 ml Fsher Inc. Waltham, Mass. USA
- This system generally operates with concentrator set up for working in ambient temperature giving low drying rates.
- application of high drying rates and work in a range of, for example, 43° C.-65° C. temperature may be harmful for some polypeptides and/or polynucleotides attached to the F-NDP.
- Concentrator may be used with 8,500 rpm maximal speed giving 4,680 ⁇ g maximal force.
- Vacuum pump (model VLP120, Thermo Savant), may be set up for gas-ballast control “closed” position giving ultimate total pressure 1.5 ⁇ 10-3 Torr.
- Refrigerated vapor trap (model RVT400, Thermo Savant) may be used with 4 liter chamber capacity giving, approximate operating temperature ⁇ 50° C.
- Lyophilization may be performed from water or buffer suspension dependent on required purposes (e.g. PBS may be used for in vivo application for diagnostic approaches such as thromboembolic events in vasculature).
- Reconstitution of F-NDP may be performed using sterile deionized water, to the desired volume. All procedures may be performed in sterile conditions including all materials such as tubes and tips.
- FIGS. 25A-25B show a high overlap of same F-NDPs for Particles Size Distribution (Malvern, PSD) assayed before and after sterilization.
- F-NDP fluorescent-NanoDiamond particles
- F-NDP-Bit bitistatin
- NIR near infrared
- Interavital imaging (IVIS) in vitro revealed that F-NDP(NV)—loaded glass capillaries could be detected across 6 mm of rat red-muscle barrier and 12 mm porcine skin, which to average vertical distance of a human carotid artery bifurcation from the surface of the adjacent skin (14 mm).
- IVIS Interavital imaging
- Bitistatin was purified from the venom of Bitis arientans (Latoxan Serpentarium, Valence, France) using two steps of reverse-phase HPLC, as described above.
- F-NDP chemically surface-functionalized with carboxyl groups (—COOH), were purchased from Adamas Nanotechnologies (Raleigh. N.C., USA).
- F-NDP(NVN) green fluorescent F-NDP based on N-V-N color centers
- F-NDP(NV) red fluorescent based on N-V (F-NDP(NV)) color centers at 100 nm (5 ⁇ 1011 particles/mg), 700 nm (2 ⁇ 108 particles/mg), and 10,000 nm (5 ⁇ 105 particles/mg).
- Isoflurane was purchased from Henry Schein (B34C16A Dublin, Ohio, USA).
- 70% Denatured Ethyl Alcohol and PE-10 tubing were purchased from Fisher Scientific (Pittsburgh, Pa., USA).
- 5-0 Silk Suture was purchased from Roboz SUT-15-1, Roboz Surgical Instrument Co. (Gaithersburg, Md., USA).
- Parafilm and FeCl 3 was purchased from Sigma-Aldrich, (St. Louis, Mo., USA).
- Bitistatin was coupled to the F-NDP of all types using EDC (1-ethyl-3-[3 dimethylaminopropyl] carbodiimide hydrochloride) as a hetero-bifunctional cross-linker. Coupling efficiency and preservation of Bitistatin activity on the various functionalized nanodiamond particles (F-NDP-Bit) were verified using a semi-ELISA methodology.
- NIR fluorescence profiles of F-NDP were characterized using a Tecan Infinite 200 PRO (Tecan AG, Gurnnedorf, CH). 100 ⁇ l of 3 mg/ml of 700 nm F-NDP(NV) or F-NDP(NVN) suspended in de-ionized (DI) water were loaded into 96-well polystyrene. Fluorescence was scanned for all wells with excitations from 230 nm-850 nm and emissions from 290 nm-850 nm ( FIG. 1A ) at 20 nm intervals. Data was processed in Matlab 2015b (Mathworks, Natick, Mass., USA). Background fluorescence was subtracted from empty wells without F-NDP and the resulting net fluorescence value was Log10 transformed for visualization.
- Glass capillaries 40 mm length, 1 mm internal diameter, (Thermo Fisher Scientific, Waltham, Mass., USA) were filled with equal volumes (30 microliters) of suspensions of F-NDP at concentrations from 0.06 and up to 4 mg/ml (1.8-120 ⁇ g total particle mass) and sealed at each end by plasticine (Hasbro, Pawtucket, R.I., USA).
- the NIR fluorescence intensity of the various suspensions in the capillaries were analyzed using an IVIS 50 Imaging System (PerkinElmer Inc., Akron Ohio) using an excitation filter set to ‘Cy5.5 BkG’ (580-610 nm) and an emission filter set to ‘Cy5.5’ (695-770 nm) as these filters matched the desired NIR emission profile detected as described above. Imaging was completed with ‘binning’ set to 4, and a 10 cm field of view, with exposure times between 2 and 40 seconds.
- the left carotid artery was dissected and exposed at the bifurcation region.
- a 5-0 surgical silk suture was wrapped below the common carotid (CCA), external carotid (ECA), and internal carotid (ICA) arteries.
- CCA common carotid
- ECA external carotid
- ICA internal carotid
- a PE-10 cannula was then inserted in the ECA for studies where F-NDP(NV)-Bit were injected locally.
- a PE-10 cannula was also inserted into the left femoral vein for studies where F-NDP(NV)-Bit was infused intravenously (IV).
- the ICA stem was wrapped in Parafilm soaked in 50% FeCl 3 and kept in place for 10 minutes.
- NIR fluorescence was detected using a 580-610 nm excitation and a 695-770 nm emission pass-band with 2 second exposure, ‘binning’ set to 4, and a 7 cm field of view as described above.
- Auto-fluorescence was subtracted based on excitation at 445-490 nm under otherwise similar imaging conditions.
- Carotid arteries were exposed before imaging to enable clear visualization for in situ images.
- carotid arterial bifurcations were removed from animals and placed on a glass plate for imaging ex vivo using identical imaging parameters to those used for in situ imaging.
- the mean fluorescence intensity of the images compensated for auto-fluorescence was calculated using ImageJ (NIH, Bethesda, Md., USA).
- F-NDP F-NDP were isolated from extracted carotid arteries by homogenization in RIPA lysis buffer (Teknova Inc. Hollister, Calif., USA) at 100 mg/ml. Aliquots (10 microliters) of the lysate suspension were applied on the microscope slides and analyzed under LSCM as above under 20 ⁇ objective.
- F-NDP(NV) were isolated from extracted carotid arteries by solubilizing the clot bearing vessel segment in 12 N hydrochloric acid (HCl) (Thermo Fisher Scientific, Waltham, Mass., USA) overnight at 60° C. at 100 mg/ml. The solution was centrifuged (14,000 ⁇ g at room temperature for 10 minutes) and the pellet was washed 1 ⁇ with distilled water. The pellet containing the insoluble F-NDP(NV)-Bit was re-suspended in DI-water while keeping the initial mass/volume ratio.
- HCl hydrochloric acid
- Fluorescent characteristics of F-NDP may vary with size of particle.
- the NIR emission of identical mass per mL of F-NDP(NV) was compared for particles of three different sizes ( FIGS. 27A-27D ).
- the lowest fluorescence intensity was observed for smallest (100 nm) particles, while the highest fluorescence emission was observed for 700 nm F-NDP. Fluorescence scaled linearly with exposure time revealing no bleaching at the higher exposure times tested. While fluorescence from the 700 nm F-NDP(NV) particles saturated the detector in less than 20 seconds, longer exposure times were required to clearly display fluorescence from the F-NDP(NVN) particles.
- FIG. 28B porcine axillary vein
- FIG. 28C porcine axillary vein
- FIG. 28D 2.5 mm of defatted porcine skin
- FIG. 28E NIR fluorescence was monitored through 2.5 mm of defatted porcine skin at concentrations from 1-4 mg/ml (30-120 micrograms total) ( FIG. 28E ) as the signal did not penetrate full-thickness tissue.
- Porcine axillary veins loaded with 1 mL of 2 mg/mL of F-NDP(NV) particles could be visualized through 8 mm of porcine skin ( FIG. 28F ).
- FIG. 29A , FIG. 29B Imaging of fluorescence in situ ( FIG. 29A , FIG. 29B ) in the vessel branches corresponding to the location of the clot in the exposed artery.
- a strong fluorescent signal is detected ( FIG. 29C , FIG. 29D vs FIG. 29E , FIG. 29F ) in the FeCl 3 -treated arteries.
- FIGS. 30A-30C After IV injection of the high dose of F-NDP(NV)-Bit, clot-associated fluorescence was demonstrated in situ in all treated animals ( FIGS. 30A-30C ). Arteries with FeCl 3 -generated lesions and the contralateral control were then dissected and imaged independently by IVIS and confocal microscopy. A strong fluorescence signal in the treated artery was observed by both IVIS ( FIGS. 30D-30F vs FIGS. 30G-30I ) and confocal imaging ( FIGS. 30J-30L vs FIGS. 30M-30O ). The difference in brightness to that of the control artery was statistically significant ( FIG. 30R , FIG. 30S ) with p ⁇ 0.05.
- Lysates collected by dissolving the carotid arteries also demonstrated a large number of fluorescent particles residing in the lesioned artery and a low, but consistent, number of particles in the contralateral control arteries ( FIG. 30P ). This difference was highly statistically significant ( FIG. 30Q ) with p ⁇ 0.01.
- the two main objectives of the example described above were 1) characterization of the two strains of the F-NDP (F-NDP(NV) and F-NDP(NVN)) in terms of their NIR emission parameters and 2) identification of the F-NDP strain, which emits sufficient energy that most likely penetrates biological tissues over a distance required for the translational application in human NIR vascular pathology imaging.
- F-NDP includes the stability/durability of the NIR emission.
- Nanoparticles in general tend to have reduced toxicity with increased diameter. Specifically, nanodiamonds display reduced toxicity (as compared to e.g.
- the first objective was to systematically investigate the emission attributes each of F-NDP across four independent variables: a) the fluorescence spectrum and brightness resulting from the atomic manipulations (N-V, N-V-N); b) particles total mass relationships to emission intensity; c) the relationship of particle diameter to emission intensity and d) speed and extent of NIR acquisition kinetics. These variables have been exercised ‘head to head’ between N-V and N-V-N strains using IVIS technology, which were considered all well suited for such comparison in due to its sensitivity and its non-invasive NIR light detection capability.
- the data presented in FIGS. 26A-27D point to the prospect of the F-NDP(NV) strain as useful for in vivo NIR fluorescent penetration through biological tissues.
- the 700 nm F-NDP(NV) exhibited 10-60 higher NIR emission intensity than the F-NDP(NVN).
- NIR emission from F-NDP(NV) was not directly correlated with particle size, and was maximized for 700 nm F-NDP(NV).
- the 700 nm particles were ⁇ 4 times brighter in IVIS images, and consistently and across all acquisition periods tested; NIR fluorescence emission from 10,000 nm particles was weaker than from e 700 nm particles ( FIG. 2 ). While 10,000 nm F-NDP(NV) may be not likely to be useable for IV injection, the 10,000 nm particles demonstrated that under equal mass conditions particle brightness was not correlated with diameter, but may be maximized for particles of a specific diameter range.
- FIGS. 28A-28H further support the potential of the F-NDP(NV) to support in vivo vascular clot imaging.
- FIG. 3 presents several conditions where tissues penetration of NIR fluorescence emitted from F-NDP(NV) was tested. The maximum distance detectable by NIR through porcine skin, used as a human skin analog, ( FIG. 28G ) was 12 mm.
- FIG. 28H presents an ultrasound recording of normal human carotid artery bifurcation annotated for the ICA, ECA and CCA. The linear dashed bar in FIG.
- NIR fluorescent imaging of a clot bin the carotid artery bifurcation is likely to be within an achievable diagnostic opportunity.
- NIR fluorescence recorded in FIG. 28H represents a source generated from ⁇ 670 ug of 700 nm F-NDP(NV) particles. The same amount of particles tagged onto human clot in this region could enable clot detection by NIR fluorescence imaging. Results in FIG.
- F-NDP(NV)-Bit covalently coupled with bitistatin.
- F-NDP(NV)-Bit were administered systemically to anesthetized rats subjected to an established carotid artery clot procedure at the site of the bifurcation.
- F-NDP(NV)-Bit were first administered via the ECA (‘high dose’, 15 mg/Kg) or via the femoral artery (‘low dose’, 3 mg/Kg).
- This experimental design was selected since pharmacokinetics and particles distribution dynamics are as yet unknown. Therefore, to avoid possible loss of significant amount of particles via ‘first path’ elimination or tissue distribution (potential ‘false negative’ outcome), injection via the
- ECA ascertains maximum exposure of the particles to the clot in the targeted region.
- three independent methods were deployed: a) IVIS total body imaging ( FIG. 29A , FIG. 29B ); b) LSCM of extracted vessels carrying clots ( FIG. 29C , FIG. 29D ) and c) direct count of particles extracted from clot-bearing vessels after solubilization of all organic material ( FIG. 29L ). Association of F-NDP(NV) by infusion of a high dose of F-NDP(NV)-Bit via the ECA is easily detected by all three methods.
- FIGS. 30A-30C all three animal tested displayed a strong fluorescence signal emanating from the carotid bifurcation zone (IVIS), as also clearly visible in the fluorescence of isolated vessels ( FIGS. 30D-30I ) and under inspection by LSCM ( FIGS. 30J-30O ). Particles were also present in large numbers in solubilized clot-bearing vessels ( FIG. 30P ).
- FIGS. 30Q-30S show the quantitative analysis of the robust deposition of particles in clot-bearing vessels vs. the control contralateral.
- the F-NDP(NV) deployed in this study can associate with clot in vivo, such as a thrombus formed in a rat carotid artery bifurcation model.
- the proof-of-concept here is based on three independent measures or the NIR fluorescence detected at the in situ clot formation, including direct counting of fluorescence particles isolated from the extracted clot.
- the data demonstrates the possibility to detect by NIR fluorescence imaging emitted from F-NDP(NV) over a distance corresponding to that present in vascular pathology (e.g. clot in the carotid artery bifurcation). If successfully translated to clinical practice, this minimally invasive procedure, conducted in ambulatory settings, could enhance preventative measures, such as earlier initiation of anti-thromboembolic medications.
- a reference to “A and/or B,” when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A without B (optionally including elements other than B); in another embodiment, to B without A (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- At least one of A and B can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
Abstract
Description
- This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/383,657, filed Sep. 6, 2016, and entitled “Engineering And Utility Of Fluorescent Nanodiamond Particles (F-NDP) For Diagnostics And Treatment Of Blood Clots In Human And Veterinary Medicine,” and to U.S. Provisional Application No. 62/522,036, filed Jun. 19, 2017, and entitled “Nanodiamond Particles And Related Devices And Methods,” each of which is incorporated herein by reference in its entirety for all purposes.
- Nanodiamond particles and related devices and methods, such as nanodiamond particles for the detection and/or quantification of analytes, are generally described. In addition, the present invention relates to the field of medical and veterinary diagnostics and treatment. More specifically, the invention relates to a diagnostic reagent, tool, and system that are specific for detection of platelets and blood clots. In addition, the invention relates to detection of internal body bleeding sites in a variety of diseases and trauma conditions.
- Cardiovascular diseases, such as stroke and heart attack, are the leading cause of mortality in developed countries. Deaths from strokes and heart attacks are predominantly the consequence of blood clots (thrombi) formed in the cerebral and cardiac vessels or thrombo-embolic events (TEE) associated with blood clots formed in remote vessels (e.g., peripheral venous system, cardiac atria appendixes). While several factors are well known to contribute to a fatal TEE (e.g., atherosclerosis vascular disease) there is a clear “diagnostic and prognostic gap” in the assessment of the specific and “total clot burden” in individuals that carry known risk factors (e.g., atherosclerotic vascular disease), let alone factors not yet fully vetted as predictive of TEE. Invariably, clinical presentation of consequences of blood flow occlusion by thrombi leading to stroke or heart attack command prompt medical investigations in search for the TEE culprits. Such investigations are mostly hospital-based imaging tests, such as angiography, CAT scans, MRI, and ultrasound. The current technologies are important for timely and successful management of strokes and heart attacks, yet several important limiting factors must be addressed. First, the general population, especially elderly people who carry cardiovascular risks, often have limited access to hospital-based technologies to assess blood clots in vessels. Second, even in hospitals, access to these imaging technologies has a certain time requirement associated with the tests and their evaluation by specialists. In the case of a stroke, where the treatment window is limited to three to four and a half hours after the onset of the event, much of the time is spent in establishing patient eligibility for thrombolysis treatment, often to the extent of missing the critical window for treatment.
- On the other extreme, once a diagnosis of cardiac arrhythmia, such as atrial fibrillation (chronic, relapsing) is made, the risk of TEE mandates lifelong treatment with anti-coagulants even though the presence of clots in the cardiac chambers (appendixes) is unknown. These few examples point to a major “diagnostic gap” of TEE risks, which due to lack of early diagnosis and preventative measures often results in fatal outcomes. Early assessment of whole body clot burden or TEE risk, in ambulatory settings, that allows easy and broad access and affordable cost, is needed.
- Furthermore, immunochromographic assays, such as lateral flow assays, are generally used to detect the presence or absence of an analyte such as an antigen in a sample. However, such assays generally lack automated processing, accurate quantification methods, and may, in some cases, require subjective interpretation, leading to false positives and/or false negatives.
- Accordingly, improved devices and methods are needed.
- Nanodiamond particles and related devices and methods, such as nanodiamond particles (e.g., fluorescent nanodiamond particles) for the detection and/or quantification of analytes, are generally described. The subject matter of the present invention involves, in some cases, interrelated products, alternative solutions to a particular problem, and/or a plurality of different uses of one or more systems and/or articles.
- In one aspect, diagnostic agents are provided. In some embodiments, the diagnostic agents comprise a fluorescent nanodiamond particle chemically bonded to a polypeptide and/or polynucleotide.
- In another aspect, fluidic devices are provided. In some embodiments, the fluidic device comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region, and a control region in fluidic communication with the detection region, the control region comprising a plurality of a third species bound to the control region.
- In yet another aspect, systems are provided. In some embodiments, the system comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region and a detector configured to quantify a fluorescent emission at the detection region.
- In some embodiments, the system comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region and a detector configured to quantify an infrared signal at the detection region.
- In yet another aspect, methods are provided. In some embodiments, the method comprises introducing, into a fluidic channel of a fluidic device, a sample suspected of containing an analyte, exposing the sample to a species bound to a plurality of fluorescent nanodiamond particles such that the analyte, if present, binds to at least a portion of the species bound to the plurality of fluorescent nanodiamond particles, removing any fluorescent nanodiamond particles and species not bound to the analyte, and quantifying a fluorescence emission of the plurality of fluorescent nanodiamond particles bound to the analyte.
- In some embodiments, the method comprises administering, to a subject (e.g., a human, a mammal) suspected of having a particular analyte, a plurality of fluorescent nanodiamond particles bound to a species such that the species may bind to the analyte, if present, and detecting a fluorescent emission of the plurality of fluorescent nanodiamond particles comprising the species bound to, if present, the analyte.
- Other advantages and novel features of the present invention will become apparent from the following detailed description of various non-limiting embodiments of the invention when considered in conjunction with the accompanying figures. In cases where the present specification and a document incorporated by reference include conflicting and/or inconsistent disclosure, the present specification shall control.
- Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying figures, which are schematic and are not intended to be drawn to scale. In the figures, each identical or nearly identical component illustrated is typically represented by a single numeral. For purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the invention shown where illustration is not necessary to allow those of ordinary skill in the art to understand the invention. In the figures:
-
FIG. 1A is a schematic illustration of a system including fluorescent nanodiamond particles, according to one set of embodiments; -
FIG. 1B is a schematic illustration of a system including fluorescent nanodiamond particles, according to one set of embodiments. -
FIG. 2A is a schematic illustration of a system including fluorescent nanodiamond particles for detection of an analyte, according to one set of embodiments. -
FIG. 2B is a schematic illustration of a system including fluorescent nanodiamond particles for detection of an analyte upon introduction of a sample suspected of containing the analyte, according to one set of embodiments. -
FIG. 2C is a schematic illustration of a system including fluorescent nanodiamond particles for detection of an analyte after introduction of a sample suspected of containing the analyte, according to one set of embodiments. -
FIG. 3 is a schematic illustration of an exemplary fluorescent nanodiamond particle functionalized with a species such as human IgG, according to one set of embodiments. -
FIG. 4 is a photograph of an exemplary system including a reservoir comprising a plurality of fluorescent nanodiamond particles, according to one set of embodiments. -
FIG. 5 is a plot of semi-ELISA for detection of human IgG bound to fluorescent nanodiamond particles at various concentrations versus control (bovine serum albumin (BSA)), according to one set of embodiments. -
FIG. 6 is a plot of the quantification of fluorescent nanodiamond particles functionalized with bitistatin in a carotid artery clot versus control vessels in rats, according to one set of embodiments. -
FIG. 7A shows scanning confocal microscopy images of carotid arteries from rats with generated clots with fluorescent nanodiamond particles introduced, according to one set of embodiments. -
FIG. 7B shows a scanning confocal microscopy image of a carotid artery from a rat with a generated clot with fluorescent nanodiamond particles introduced, according to one set of embodiments. -
FIG. 8 shows images of tissue suspensions of clots treated or not with fluorescent nanodiamond particles, injected systematically to the femoral vein close to a clot generated in carotid artery, according to one set of embodiments; -
FIG. 9 is a fluorescence scan result showing two dimensional screening of excitation vs. emission wavelengths to optimize fluorescence of NDP-Fs used in the exemplary embodiment. The figure shows optimization of the maximal fluorescence for NDP-Fs. The heat map represents the results of fluorescence screening in the entire spectrum of excitation vs. emission wavelengths. The experiment was performed using a Tecan plate reader. NDP-Fs were applied on a 96-well plate (0.3 mg/0.1 ml) as a suspension in PBS. The blank, or negative control, was established using PBS alone. -
FIG. 10 presents a line graph indicating detection of Bt on NDP-Fs in a “semi-ELISA” assay. NDPs were coupled to Bt or BSA, which were used in concentrations as indicated on the X-axis, per 1 mg of NDP-Fs. 0.2 mg of each NDP sample was used for semi-ELISA in three replicates. The experiment was performed on a 96-well plate (U-shape bottom) with gentle rotation during incubations. NDPs were blocked with 10% goat serum before primary antibody against Bt was added. NDP samples were incubated with anti-Bt antibody for one hour at 37° C., and the plate was washed three times with PBST by centrifugation (1,000×g) at room temperature. Goat anti-rabbit IgG AP conjugated (Sigma Inc.), diluted 1:2000, was added and incubated for one hour as above. Final washing was performed as above and substrate (pNPP) was added to AP. Color was developed for 30 minutes, and NDP samples were centrifuged. The supernatant was transferred to a 96-well plate and read using an ELISA plate reader under 405 nm wavelength. Error bars represent standard deviation (SD) from three independent samples applied for the semi-ELISA procedure. -
FIG. 11 is a line graph showing interaction of purified integrin with NDPs in semi-ELISA. The experiment was performed using a U-shape bottom 96-well plate. The plate was blocked overnight with 5% BSA, whereas NDPs were blocked with 3% BSA by incubation for 1 hour at 37° C. before application on the plate. Blocked NDPs were added to the wells (0.2 mg per well) and the plate was centrifuged (10,000×g) at room temperature. Platelet Fibrinogen Receptor (PFR) at the indicated concentrations was added in 0.1 ml of Hanks' Balanced Salt Solution (HBSS) containing Ca2+ (as CaCl2) and Mg2+ (as MgCl2) at physiological concentrations to each well and incubated for 1 hour at 37° C. NDPs were washed three times by centrifugation of the plate (1,000×g) at room temperature and primary polyclonal antibody against the fibrinogen receptor was added (2 μg/ml). Incubation was performed for one hour at 37° C., and samples were washed three times, as described above. Goat anti-rabbit IgG AP conjugated (Sigma Inc.), diluted 1:3000, was added and incubated for one hour as above. Final washing was performed as above and substrate (pNPP) was added to AP. Color was developed for 30 minutes, and NDP samples on the plate were centrifuged at 10,000×g at room temperature to collect the NDP as a pellet. Supernatant was transferred to flat bottom 96-well (0.1 ml) plates and read using an ELISA plate reader at 405 nm wavelength. -
FIG. 12 presents a line graph showing adhesion of NDP-F-Bt and NDP-BSA to immobilized PFR. PFR was immobilized on a 96-well plate by overnight incubation at 4° C. in PBS. The plate and NDPs were blocked with 3% BSA. NDPs coupled to 1 mg protein (Bt or BSA) were used in the experiment. NDPs (300 mg) were added to the wells. Incubation was performed for one hour at 37° C. in HBSS buffer containing calcium and magnesium at physiological concentrations. Unbound NDPs were intensively washed out six times using the same buffer with vacuum aspiration. Finally, HBSS (100 μl) was added to the wells and fluorescence was read using a fluorescence plate reader with 485 nm (excitation) and 530 (emission) wavelengths. -
FIG. 13 presents a line graph showing quantitation of adhesion of NDP-F-Bt and NDP-BSA to immobilized fibrinogen receptor. Fibrinogen receptor was immobilized on 8-well glass chamber slides by overnight incubation at 4° C. The wells were blocked with 3% BSA, and NDPs previously also blocked by 3% BSA were added (50 mg per well per 200 ml) in HBSS containing calcium and magnesium at physiological concentrations. The adhesion procedure was performed as perFIG. 12 . In the final step, the slide was prepared with mounting buffer (Vector Lab). Images were analyzed under fluorescence microscope (400×) using an oil objective. The numbers of NDPs were calculated using ImageJ software. Error bars represent SD for three independent pictures taken for each concentration of fibrinogen receptor. -
FIG. 14 depicts representative images of adhered NDP-F-Bt to immobilized PFR. PFR (concentrations indicated) was immobilized on an 8-well chamber slide, and the experiment was performed as described inFIG. 13 . In the legend, the bars represent 20 μm. -
FIG. 15 shows pictures of fluorescent images taken by IVIS and confocal microscopy of carotid artery clots after treatment with FNDP via an external carotid artery infusion.FIG. 15A shows an in situ carotid bifurcation region image indicating fluorescence of a carotid arterial clot after treatment visible via IVIS imaging after exposure of the carotid bifurcation zone.FIGS. 15B and 15C are high magnification images of fluorescence emanating from the carotid bifurcation in vivo suggesting accumulation of FNDP in the clot.FIG. 15D shows ex vivo fluorescence of carotid artery bifurcation denoting one branch that shows fluorescence corresponding to the clot location within the carotid bifurcation.FIGS. 15E and 15F show confocal images taken on an Olympus IX83, showing that FNDP fluorescence is detected at an excitation of 543 nm and an emission of 655-755 nm. -
FIG. 16 shows fluorescent images taken by IVIS and confocal microscopy of carotid artery clots after intravenous treatment with FNDP.FIG. 16A shows an ex vivo fluorescent image of a carotid artery from saline-treated control.FIG. 16B shows an ex vivo fluorescent image of a carotid artery from an IV FNDP-treated animal showing fluorescence localized to the branch with clot.FIGS. 16C-F show confocal images taken on an Olympus IX83.FIG. 16G is a graph showing the number of FNDPs present in carotid clot lysates from animals treated locally via the external carotid artery or intravenously as compared with saline treated controls. -
FIGS. 17A-17B show fluorescent microscopy of the specificity of the interaction of F-NDP-Bt for clot generation from rat blood plasma by thrombin (1 U/ml).FIG. 17A shows images of plasma clots obtained from fluorescence microscope Olympus IX81 analysis, under 100× magnification.FIG. 17B shows images of plasma clots obtained in anIVIS 50 imaging system. Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). Exposure time: 1 minute. Arrows point the localization of the clot. -
FIGS. 18A-18B show images of vessels filled with F-NDP-Bt implanted subcutaneously in a rat (post-mortem).FIG. 18A shows an image of the implanted glass capillaries filled with F-NDP-Bt (4 mg/ml) or PBS (control). Exposure time was 5 seconds.FIG. 18B shows an image of a rat aorta filled with F-NDP-Bt. The rat aorta was dissected from a euthanized female rat, washed with PBS to remove residues of coagulated blood, and filled with 300 μl of F-NDP-Bt suspension (2 mg/ml) in PBS. -
FIG. 18C shows plots of average fluorescence intensity for F-NDP-Bt, F-NDP-Bt+lotrafiban (lt), and F-NDP-BSA in thrombin-induced PRP clots. -
FIG. 18D shows representative images of the clots inFIG. 18C from IVIS. -
FIGS. 19A-19C show dose response curves with and without 700 nm diameter fluorescent nanodiamond particles functionalized with bitistatin (i.e. probe) for mean maximum platelet aggregation +/−standard deviation linear regression lines for proteinase-activated receptor 4 (PAR4 AP,FIG. 19A ), adenosine diphosphate (ADP,FIG. 19B ), and arachidonic acid (AA,FIG. 19C ). -
FIGS. 20A-20C show box plots of 700 nm and 200 nm diameter probes binding to platelet populations at various concentrations.FIG. 20A shows the percentage of all platelets,FIG. 20B shows the percentage of CD62+ve platelets, andFIG. 20C shows the percentage of GPIIb/IIIa+ve platelets bound to the 700 nm and 200 nm probes at various concentrations. Data shown are the mean (+), the line within the box represents the median, upper and lower edges of the box represents 75th and 25th percentiles, and upper and lower whiskers represent the 95th and 5th percentiles. -
FIG. 21 shows a plot of percentage of platelets bound to 700 nm diameter probes for stimulated versus unstimulated platelet populations. Data shown are mean percentage (+/−standard deviation) of all platelets bound to the probe in simulated versus unsimulated platelets at a concentration of 350 mcg/mL of probe. -
FIG. 22 shows a plot of percentage of platelets bound to 200 nm diameter probes for stimulated versus unstimulated platelet populations. Data shown are mean percentage (+/−standard deviation) of all platelets bound to the probe in simulated versus unsimulated platelets at a concentration of 350 mcg/mL of probe. -
FIGS. 23A-23D show flow cytometry dotplots for unsimulated and simulated populations of cells and platelets. -
FIGS. 24A-24D show flow cytometry dotplots for unsimulated and simulated populations of cells and platelets. -
FIGS. 25A-25B show plots of volume versus size (FIG. 25A ) and fluorescence intensity versus size (FIG. 25B ) for F-NDPs before and after sterilization. -
FIGS. 26A-26C show a comparison of NIR fluorescence intensity of F-NDP(NV) and F-NDP(NVN) in suspensions. (FIG. 26A ) F-NDP suspensions were scanned for fluorescence in a fluorescence plate reader for a range of excitation and emissions. The fluorescence is normalized by subtracting a blank well and log 10 processed. (FIG. 26B ) Capillaries were filled with indicated density of F-NDP in PBS and analyzed by IVIS imaging using 5 seconds exposure. Insert indicates representative images of capillaries. Average fluorescence is presented in the plot. (FIG. 26C ) Comparison of fluorescence intensity for different concentrations of F-NDP(NV) as function of exposure time. Error bars represent SD for three to five independent experiments. *Difference between F-NDP(NV) and F-NDP(NVN) (P<0.01) -
FIGS. 27A-27D show a comparison of intensity of fluorescence of different sizes of F-NDP(NV) under different exposure times in IVIS. Left panes shows representative images of F-NDP(NV), presented in concentrations as pointed on the plot. Sizes of particles are (from the top): 100, 700, and 10,000 nm, respectively. Error bars represent SD for three independent experiments. -
FIGS. 28A-28H show a comparison of the ability to detect F-NDP NIR fluorescence through different biological barriers using IVIS. (FIG. 28A ) Capillaries filled with F-NDP(NV) (4 mg/ml), F-NDP(NVN) (4 mg/ml), or PBS were positioned under abdominal skin patch of euthanized rat. Positions of capillaries are indicated by arrows. (FIG. 28B ) Capillary filled with F-NDP(NV) (4 mg/ml) covered by rat quadriceps muscles ranged from 2 mm (flanking) to 5.9 mm (in the center). (FIG. 28C ) Capillaries filled with F-NDP (4 mg/ml) or PBS were inserted into porcine axillary vein. (FIG. 28D ) Capillaries filled with F-NDP (4 mg/ml) or PBS were covered with porcine skin (2.5 mm) free of subdermis (FIG. 28E ) Intensity of fluorescence for different concentrations of F-NDP(NV) through 2.5 mm porcine skin free of subdermis. (FIG. 28F ) Porcine axillary veins filled with F-NDP(NV) (2 mg/ml) or PBS and covered with 8 mm porcine skin including dermis and subdermis. (FIG. 28G ) Capillaries filled with F-NDP(NV) (20 mg/ml), F-NDP(NVN) (20 mg/ml) and PBS (same volume) covered with porcine skin containing increased thickness of adipose tissue (presented on the insert). (FIG. 28H ) Representative ultrasound of human carotid artery showing the artery 11.89 mm below the surface. -
FIGS. 29A-29N show F-NDP(NV)-Bit infusion via external carotid artery. Carotid arteries clots are imaged in situ and removed from the animal for further direct imaging and analysis. (FIGS. 29A-29F ) Images of fluorescence recorded by an IVIS scanner designed for whole animal imaging using a 580-610 nm excitation and a 695-770 nm emission passband with 2 second exposure. Auto-fluorescence was subtracted based on excitation at 445-490 nm (FIG. 29A ,FIG. 29B ) In situ fluorescence imaging of carotid arterial clot after treatment in duplicate animals by IVIS (separation of neck particle by dissection) Scale bar=1 cm. (FIGS. 29C-29F ) Ex-vivo fluorescence of isolated carotid artery after F-NDP(NV)-Bit treatment (FIG. 29C ,FIG. 29D ) or with vehicle control of saline (FIG. 29E ,FIG. 29F ). Scale bar=1 mm. (FIGS. 29G-29J ) Confocal image stacks were taken onOlympus FV 1000. F-NDP(NV)-Bit fluorescence was detected at an excitation of 543 nm and an emission of 655-755 nm. Background fluorescence was collected from the same excitation, with emissions of 555-625 nm and was subtracted from the foreground. Scale bar=1 mm. Fluorescence of carotid artery after F-NDP(NV)-Bit treatment (FIG. 29G ,FIG. 29H ) or with saline treatment (FIG. 29I ,FIG. 29J ). (FIG. 29K ) In situ images of a FeCl3-generated clot carotid artery compared with untreated contralateral artery. (FIGS. 29L-29N ) Clots dissolved with RIPA lysis buffer and replicates are combined together to form a lysate. Aliquots of the lysate was then deposited onto a cover glass (10 μL) and imaged with 20 objective. Scale bar=100□ m. (FIG. 29K ) Large numbers of F-NDP(NV)-Bit are visible. (FIG. 29L ) After IV treatment at low dose (1 mg), F-NDP(NV)-Bit are found in the lysate at the site of clot formation. (FIG. 29N ) Almost no fluorescent particles are detected in saline control. -
FIGS. 30A-30S shows F-NDP(NV)-Bit intravenous infusion. (FIGS. 30A-30J ) images of fluorescence are performed on an IVIS scanner designed whole animal imaging using a 580-610 nm excitation and a 695-770 nm emission passband with 2 second exposure. Autofluorsesence was subtracted based on excitation at 445-490 nm. (FIGS. 30A-30C ) Gross image indicating fluorescence of carotid arterial clot after treatment in triplicate animals is visible via IVIS imaging after exposure of artery. Scale bar=1 cm. (FIGS. 30D-30I ) Ex-vivo fluorescence of carotid artery after F-NDP(NV)-Bit treatment (FIGS. 30D-30F ) or with saline treatment (FIGS. 30G-30I ) Scale bar=1 mm. (FIGS. 30J-30O ) Confocal image stacks taken onOlympus FV 1000. F-NDP(NV)-Bit fluorescence is detected at an excitation of 543 nm and an emission of 655-755 nm. Scale bar=1 mm. Fluorescence of carotid artery after F-NDP(NV)-Bit treatment (FIGS. 30J-30L ) or with saline treatment (FIGS. 30M-30O ). (FIG. 30P ) Lysates from solubilized carotid arteries are imaged and F-NDP(NV)-Bit are counted by hemocytometer. Contralateral untreated control is presented in insert. Scale bar=100 μm (FIG. 30Q ) Total number of F-NDP(NV)-Bit detected per carotid bifurcation in the clotted side compared with the contralateral control as counted by hemocytometer. (FIG. 30R ,FIG. 30S ) Brightness after subtraction of background via IVIS (FIGS. 30D-30I ) and LSCM (FIGS. 30J-30O ) imaging of treated and contralateral untreated carotid bifurcations. Error bars represent standard deviation. *=p<0.05, **=p<0.01 vs control by t-test. - Nanodiamond particles and related devices and methods, such as nanodiamond particles for the detection and/or quantification of analytes, are generally described. In some embodiments, the present invention provides diagnostic agents and methods for risk assessment of subjects, including both humans and non-human animals at risk of thrombo-embolic events (TEE), which are the main cause of cardiovascular death from strokes and heart attacks. The diagnostic agents and methods of the invention enable assessment of the total body burden of intravascular clots and detection of nascent thrombi at common predilection sites for clot formation using non-radiation (e.g., X-ray), non-MRI, and non-ultrasound techniques. The technology generally comprises a non-invasive, telemetry-based fluorescent recording system suitable for use in a fast and affordable ambulatory setting. The invention includes multiple innovative scientific and engineering breakthroughs.
- The invention is based, at least in part, on the recognition that fluorescent nano-diamond particles (NDP-F) functionalized with a species (e.g., a polypeptide such as the disintegrin Bitistatin (Bt), immunoglobulins such as IgG, and/or bovine serum albumin (BSA)) may have the innate ability to bind e.g., avidly to activated platelet fibrinogen receptors (PFR). For example, data presented herein demonstrate successful coupling of Bt to NDP-F and retention of Bt bioactivity. The methods, reagents, and de novo protocols used to accomplish the invention are not known to the inventors as having been reported by others before.
- In some embodiments, the device comprises a plurality of nanodiamond particles and a species (e.g., a polypeptide, a polynucleotide) bound to the nanodiamond particles. In certain embodiments, the plurality of nanodiamond particles may be exposed to a sample suspected of containing an analyte. In some cases, the analyte may bind to the species such that the presence of the analyte in the sample may be detected. In some embodiments, the devices, systems, and methods described herein are useful for the detection of an analyte in a sample obtained from a subject for, for example, diagnostic purposes. In some cases, the systems, devices, and methods described herein may be useful for diagnosing, prevent, treating, and/or managing a disease or bodily condition. In an exemplary embodiment, such systems, devices, and methods described herein may be useful for detecting and/or quantifying the presence of a virus (e.g., ebola) in a subject and/or a sample obtained from the subject.
- Advantageously, as compared to traditional systems for quantifying analytes (e.g., viruses, bacteria, toxins, environmental pollutants, etc.) in a sample from a subject, the systems and methods described herein may comprise quantification of the amount of analyte present in the sample.
- The present invention may also enable broad scale survey of TEE risks that may be applicable in many medical emergency and life-threatening conditions beyond strokes and heart attacks. The technology not only can be used for individuals suspected to be at risk for TEE but also can be periodically deployed as part of primary health care office assessments, no different than annual mammography, lipids tests, or physical examinations. For example, in some embodiments, the present invention monitors fluorescent light emittance and is expected to be highly affordable, minimally invasive (requiring only a single injection of a safe dose of nanoparticles), and can be conducted and interpreted in an ambulatory setting by a trained emergency medical technician or a primary care physician, similar to ECG monitoring.
- One general aspect of the invention is an imaging agent for detection of a thrombus in a subject. The agent is composed, in an exemplary embodiment, of three elements, as follows: i) a fluorescent nano-diamond particle (NDP-F); ii) a ligand that functionalizes the NDP-F, such as a —COOH, —OH, —NH2, or —C═O moiety; and iii) a protein attached to the ligand. The three can be bonded together in any order and by any type of chemical bonds, but are typically covalently bonded in the order described. The objective of the imaging agent is to specifically bind the agent to a discrete biological target in a human or non-human animal body.
- Yet another aspect of the invention is a diagnostic method for detection of activated platelets. In some cases, the diagnostic method is based in large part on the ability of a species such as a polypeptide (e.g., bitistatin, BSA, human IgG) to bind to a specific antigen (e.g., PFR) with high affinity and/or avidity. In some embodiments, the polypeptide (e.g., bitistatin) is configured to target the NDP-F to e.g., activated platelets, and thus sites of thrombus formation. In some embodiments, the fluorescence of the NDP-F allows non-invasive and relatively harmless imaging of the location and size of the thrombus, or multiple thrombi. In certain embodiments, the diagnostic method is qualitative, and in other embodiments it is semi-quantitative or quantitative. In some embodiments, the method comprises: i) administering to a subject suspected of having, or potentially having, one or more sites of thrombus, a detectable amount of the diagnostic agent of the invention, ii) allowing sufficient time for the diagnostic agent to localize to the site(s) of thrombus, and iii) detecting the diagnostic agent by detecting fluorescence emission after excitation with a suitable electromagnetic stimulus (e.g., excitation light, such as emission from a hand held device). It is to be understood that, in some embodiments, in step iii) the act of excitation can be omitted if the fluorescent tag is intrinsically fluorescent in the subject's body. The step of administering can be any action that results in introduction of the imaging agent into the systemic blood stream of the subject. It thus may be, for example and without limitation, via intravenous injection or infusion.
- Yet further, and in accordance with the method described immediately above, the invention includes a method of detecting clots or clot formation in subjects. As with the method described above, this method can be considered a method of detecting or imaging clots, clot formation, platelet activation, or pathological zones that form a risk for clot formation, such as an atherosclerotic vascular plaque or inflammation. The method steps are those described above. For example, in some embodiments, a clot in a subject may be detected by administering a plurality of nanodiamond particles functionalized with a species (e.g., a polypeptide such as bitistatin) which may bind to at least a portion of a clot.
- As those of skill in the art will immediately recognize, the diagnostic and imaging methods of the present invention, by virtue of introduction of a non-natural bio-active substance into a subject's body, do not relate solely to collection of data regarding a biological event, but instead relate to physical and physiological changes to the subject's body. For example, introduction of the non-naturally occurring imaging agent into the blood stream of a subject physically alters the make-up of the blood stream. In addition, binding of the imaging agent to activated platelets alters the body's natural ability to interact with the activated platelets, and thus the clotting cascade. Other physical and physiological changes upon administration of the imaging agent of the invention will be apparent to the skilled artisan.
- The present invention also encompasses kits for practicing the methods of the invention. Broadly speaking, a kit according to the invention includes the imaging agent of the invention in packaged form suitable for distribution, delivery, and/or storage for use in a method of the invention. In customary fashion, the package is made of a suitable material, such as, but not limited to, a cardboard or plastic box and the like, a metal container and the like, or a foil pouch or the like. In some embodiments, the kit includes sufficient imaging agent in a container for a single administration, whereas in other embodiments, the kit includes sufficient imaging agent for two or more administrations. In embodiments where the kit includes sufficient imaging agent for two or more administrations, the imaging agent can be supplied in a single container for multiple uses or in two or more containers, each containing sufficient imaging agent for a single use. In some cases, a combination of single-use and multiple-use containers can be included in a kit. In certain embodiments, the kit (regardless of how many containers of imaging agent are provided in the kit) can be provided in packaged combination with one or more reagents or devices for administration of the imaging agent to a subject. As such, and without limitation, a kit of the invention can include, in packaged combination, the imaging agent with an antiseptic (e.g., ethanol swabs or pads or iodine swabs or pads), one or more syringes, one or more needles adapted to connect with a syringe, and/or one or more pieces of gauze and/or adhesive to facilitate closure and healing of the site of administration.
- In some embodiments, a plurality of nanodiamond particles (e.g., NDP-F) bound to a species such as a polypeptide or polynucleotide may be introduced into a sample suspected of containing an analyte. In certain embodiments, the polypeptide and/or polynucleotide may be selected such that, if present, the polypeptide and/or polynucleotide binds to the analyte.
- In some embodiment, if an analyte is present in the sample, the analyte, the species, and/or the nanodiamond particle may bind such that the presence of the analyte may be detected. In some cases, the detection of the analyte comprises quantification of an emission (e.g., a fluorescent emission, a near infrared emission) by the nanodiamond particle. In some embodiments, quantification of the emission comprises quantification of a relative intensity and/or quantification of a wavelength of the emission. Without wishing to be bound by theory, in some cases, the intensity of the emission may be proportional (e.g., directly proportional, exponentially proportional, logarithmically proportional) to the amount of analyte present in the sample.
- In some embodiments, the plurality of (fluorescent) nanodiamond particles are administered to a subject. In certain embodiments, the plurality of nanodiamond particles may be administered orally, rectally, vaginally, nasally, or uretherally to the subject. In some cases, the plurality of nanodiamond particles are administered surgically (e.g., implanted) and/or injected (e.g., into the systemic circulation, intraoccularly, into the spinal system, e.g., via syringe).
- In another exemplary embodiment, the plurality of nanodiamond particles (e.g., the plurality of nanodiamond particles comprising a species bound to the nanodiamond particles) may be administered to a subject (e.g., for the detection of an analyte suspected of being present in the subject). For example, in some cases, the plurality of nanodiamond particles comprising the species may be administered to the subject and, upon detection of an emission (e.g., fluorescent emission, near infrared emission) of the nanodiamond particles, demonstrate the presence of an analyte in the subject. In some cases, the analyte may be at least a portion of a (blood) clot capable of binding to the nanodiamond particles. In some embodiments, a detection device configured to measure and/or detect a fluorescent emission and/or a near infrared emission may be applied to the subject (e.g., on or near the skin, at a location internal of the subject) such that, if the analyte is present, the emission is detected and/or quantified.
- As described above, the methods, devices, and systems described herein may be useful for determining and/or quantifying the amount of analyte present in a sample. In some embodiments, the sample is a fluid. In certain embodiments, the sample is whole blood. In certain embodiments, the sample is obtained from a subject such as whole blood, plasma, urine, sputum, sweat, and/or other biological fluids. Methods for collecting such samples are known in the art. In some embodiments, the sample is introduced into a fluidic device (e.g., a fluidic device comprising a reservoir comprising a plurality of nanodiamond particles).
- In certain embodiments, the sample may be diluted (e.g., prior to determining and/or quantifying the amount of analyte present in the sample). For example, in certain embodiments, a buffer solution may be added to the fluidic device comprising the plurality of nanodiamond particles before, during, and/or after introducing the sample to the fluidic device such that the sample is diluted. In some embodiments, the buffer solution is contained within a reservoir in fluidic communication with one or more components of the fluidic device. The sample may be diluted in a buffer solution prior to, or during, the introduction of the plurality of nanodiamond particles to the sample. In some embodiments, an analyte in a sample is readily determinable without any subsequent process steps. In some cases, the analyte is present in a subject and the nanodiamond particles may be administered to the subject, as described above.
- The term ‘nanodiamond particle’ generally refers to a diamond particle having an average cross-sectional dimension of less than 1 micrometer (e.g., less than or equal to 900 nanometers, less than or equal to 800 nanometers, less than or equal to 700 nanometers, less than or equal to 600 nanometers, less than or equal to 500 nanometers, less than or equal to 400 nanometers, less than or equal to 300 nanometers, less than or equal to 200 nanometers, less than or equal to 100 nanometers, less than or equal to 90 nanometers, less than or equal to 80 nanometers, less than or equal to 70 nanometers, less than or equal to 60 nanometers, less than or equal to 50 nanometers, less than or equal to 40 nanometers, less than or equal to 30 nanometers, less than or equal to 20 nanometers, or less than or equal to 10 nanometers). In some cases, the nanodiamond particle may have an average cross-sectional dimension of greater than or equal to 5 nanometers, greater than or equal to 10 nanometers, greater than or equal to 20 nanometers, greater than or equal to 30 nanometers, greater than or equal to 40 nanometers, greater than or equal to 50 nanometers, greater than or equal to 60 nanometers, greater than or equal to 70 nanometers, greater than or equal to 80 nanometers, greater than or equal to 90 nanometers, greater than or equal to 100 nanometers, greater than or equal to 200 nanometers, greater than or equal to 300 nanometers, greater than or equal to 400 nanometers, greater than or equal to 500 nanometers, greater than or equal to 600 nanometers, greater than or equal to 700 nanometers, greater than or equal to 800 nanometers, or greater than or equal to 900 nanometers. Combinations of the above-referenced ranges are also possible (e.g., less than 1 micrometer and greater than or equal to 5 nanometers, less than or equal to 700 nanometers and greater than or equal to 100 nanometers). Other ranges are also possible. Those of ordinary skill in the art would be capable of selecting suitable methods for determining the average cross-sectional dimension of a nanodiamond based upon the teachings of this specification.
- Without wishing to be bound by theory, in some cases, the nanodiamond particles described herein may be auto-fluorescent (e.g., the nanodiamond particles emit fluorescent light e.g., after absorption of electromagnetic radiation). In some cases, the nanodiamond particles may comprise one or more atomistic-type defects (e.g., a point defect such as a nitrogen-vacancy (NV) center, a point defect such as a nitrogen-vacancy-nitrogen (NVN) defect, combinations thereof) which result in near-infrared fluorescence and/or photoluminescence that may be detected and/or quantified. Other defects are also possible (e.g., Si-vacancy defects). In certain embodiments, the nanodiamond particles fluoresce in response to an applied electromagnetic radiation.
- For example, in some embodiments, the nanodiamond particle may be excited (e.g., by applying electromagnetic radiation having a first wavelength) such that the nanodiamond particle emits a detectable emission (e.g., an electromagnetic radiation having a second wavelength, different than the first wavelength). In a particular set of embodiments, if an analyte is present in a sample, the analyte binds to the nanodiamond particle (e.g., binds to a species bound to the nanodiamond particle) such that an emission from the nanodiamond particle may be detected and/or quantified. In some cases, detection of an emission of nanodiamond particles in a subject may indicate that the nanodiamond particles are bound to the suspected analyte. In some such cases, the emission may be quantified (e.g., to determine the relative amount of analyte present in the subject).
- In another set of embodiments, the sample suspected of containing the analyte may be added to a fluidic device such that, if present, the analyte binds to the nanodiamond particles (e.g., to the species bound to the nanodiamond particles) and to a detection region in the fluidic device. In some such embodiments, the presence of an emission indicates the presence of the analyte in the sample. In some cases, the intensity and/or wavelength of the emission may be quantified.
- As described herein, in some embodiments, the systems, devices, and methods comprise a plurality of nanodiamond particles and a species bound to the plurality of nanodiamond particles. Advantageously, the devices and methods described herein may, in some embodiments, permit the analysis of analytes from whole blood without additional filtering or separation steps and/or have relatively high sensitivity as compared to certain existing analyte quantification methods.
- As illustrated in
FIG. 1A , in some embodiments,device 100 comprises a plurality ofnanodiamond particles 110 associated with a species 120 (e.g., a species which may bind to an analyte, if present). In some embodiments, the nanodiamond particles are associated with (e.g., bound to) the species via functionalization of the nanodiamond particle. For example, in some embodiments, a nanodiamond particle is associated with a species via formation of a bond, such as an ionic bond, a covalent bond, a hydrogen bond, Van der Waals interactions, and the like. The covalent bond may be, for example, a carbon-carbon, carbon-oxygen, oxygen-silicon, sulfur-sulfur, phosphorus-nitrogen, carbon-nitrogen, metal-oxygen, or other covalent bond. The hydrogen bond may be, for example, between hydroxyl, amine, carboxyl, thiol, and/or similar functional groups. For example, the species may include a functional group, such as a thiol, aldehyde, ester, carboxylic acid, hydroxyl, and the like, wherein the functional group forms a bond with the nanodiamond particle. In some cases, the species may be an electron-rich or electron-poor moiety wherein interaction between the nanodiamond particle and the species comprises an electrostatic interaction. - For example, the species may be associated with a functionalized nanodiamond particle comprising a —COOH, —OH, —NH2, —SH, or —C═O functional group by reacting the functionalized nanodiamond particle and the species in the presence of a cross-linking agent. Non-limiting examples of suitable cross-linking agents include carbodiimides such as 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC); amine-reactive compounds such as N-Hydroxysuccinimide ester, imidoester, and hydromethylphosphine; sulfhydryl-reactive compounds such as maleimide, pyridyl disulfides, and iodoacetyl; aldehyde-reactive compounds such as hydrazide and alkoxyamine; and photoreactive cross-linking agents such as aryl azides and diazirine. Other cross-linking agents are also possible. Those of ordinary skill in the art would be capable of selecting suitable cross-linking agents based upon the type of species selected and the teachings of this specification.
- In some embodiments, the species may bind with a target analyte. In some cases, the species may comprise a biological or a non-biological (chemical) group capable of binding another biological or chemical molecule in a sample (e.g., a biological or chemical molecule present on an analyte). For example, the species may include a functional group, such as a thiol, aldehyde, ester, carboxylic acid, hydroxyl, amine, polyethelene glycol and the like, wherein the functional group forms a bond with the analyte. In some cases, the species may be an electron-rich or electron-poor moiety wherein interaction between the analyte and the species comprises an electrostatic interaction.
- In some embodiments, the species and analyte interact via a binding event between pairs of biological molecules including proteins, nucleic acids, glycoproteins, carbohydrates, hormones, and the like. Specific examples include an antibody/peptide pair, an antibody/antigen pair, an antibody fragment/antigen pair, an antibody/antigen fragment pair, an antibody fragment/antigen fragment pair, an antibody/hapten pair, an enzyme/substrate pair, an enzyme/inhibitor pair, an enzyme/cofactor pair, a protein/substrate pair, a nucleic acid/nucleic acid pair, a protein/nucleic acid pair, a peptide/peptide pair, a protein/protein pair, a protein/receptor pair, a small molecule/protein pair, a glutathione/GST pair, an anti-GFP/GFP fusion protein pair, a Myc/Max pair, a maltose/maltose binding protein pair, a carbohydrate/protein pair, a carbohydrate derivative/protein pair, a metal binding tag/metal/chelate, a peptide tag/metal ion-metal chelate pair, a peptide/NTA pair, a lectin/carbohydrate pair, a receptor/hormone pair, a receptor/effector pair, a complementary nucleic acid/nucleic acid pair, a ligand/cell surface receptor pair, a virus/ligand pair, a Protein A/antibody pair, a Protein G/antibody pair, a Protein L/antibody pair, an Fc receptor/antibody pair, a biotin/avidin pair, a biotin/streptavidin pair, a drug/target pair, a zinc finger/nucleic acid pair, a small molecule/peptide pair, a small molecule/protein pair, a small molecule/target pair, a carbohydrate/protein pair such as maltose/MBP (maltose binding protein), a small molecule/target pair, and a metal ion/chelating agent pair. Specific non-limiting examples of species include peptides, proteins, DNA, RNA, and PNA. Other species and binding pairs are also possible. In an exemplary embodiment, the species is an antibody (e.g., an antibody to a target analyte).
- In an exemplary embodiment, the species and analyte interact via an antibody/antigen pair binding event.
- In another exemplary embodiments, the species and analyte interact via a protein/receptor pair binding event. For example, the species may comprise a protein such as disintegrin (e.g., Bitistatin) and the analyte may comprise a receptor molecule such as a fibrinogen receptor.
- In some embodiments, the species and the analyte interact via a binding event between pairs of biological molecules including proteins, nucleic acids, glycoproteins, carbohydrates, hormones, or the like.
- In some embodiments, the species is selected from the group consisting of (poly)peptides, (poly)nucleotides, and ligands. In an exemplary embodiment, the species is a polypeptide, such as a protein, an antibody, and/or an antigen. For example, in some embodiments, the antibody is an immunoglobulin such as IgA, IgG, IgM, IgE, or the like, In another exemplary embodiment, the species is a (poly)nucleotide (e.g., an oligonucleotide), such as DNA or RNA. In yet another exemplary embodiment, the species is a disintegrin such as albolabrin, applagin, barbourin, batroxostatin, bitistatin, obtustatin, schistatin, echistatin, elegantin, eristicophin, flavoridin, halysin, kistrin, mojastin, rubistatin, tergeminin, salmosin or triflavin. In some embodiments, the species may comprise a protein such as serum albumin (e.g., bovine serum albumin).
- Examples of suitable nanodiamond particles functionalized with a species(e.g., Bitistatin) are discussed in more detail in U.S. Provisional Patent Application No. 62/383,657, filed Sep. 6, 2016, entitled “Engineering and Utility of Fluorescent Nanodiamond Particles (NDP-F) for Diagnostics and Treatment of Blood Clots in Human and Veterinary Medicine,” which is incorporated herein by reference in its entirety. Other functionalization methods are also possible.
- Non-limiting examples of analytes that may be detected and/or quantified include a biological compound, a drug, a macromolecule, a salt, an electrolyte, an enzyme, a nucleic acid (e.g., a (poly)nucleotide), a carbohydrate, a (poly)peptide, a protein, a lipid, a phosphate, a sulfonate, a virus, a pathogen, a bacterium, a fungus, an oxidant, a reductant, a toxin, a surfactant, and combinations thereof.
- In an exemplary set of embodiments, the analyte is a virus (e.g., ebola, Marburg, Bundibugyo, sudan, junin, lassa, MERS, small pox, Zika, pertussis, rubella, rubeola). In some embodiments, the analyte is a bacterial toxin (e.g., anthrax). In some embodiments the analyte is a biological entity associated with a particular parasite and/or fungus. Advantageously, the systems and methods described herein may be useful for the detection and/or quantification of viruses such as ebola.
- In yet another exemplary set of embodiments, the analyte is a receptor molecule (e.g., a fibrinogen receptor). Advantageously, the systems and methods described herein may be useful for the detection of blood clots.
- In some cases, the analyte may comprise a marker/antigen for a particular disease or condition. For example, in some cases, the analyte may be a marker/antigen associated with blood clots, traumatic brain injury, bone diseases (e.g., osteroporosis, osteoarthrosis), inflammation and/or (auto)immune diseases (e.g., Crohn, psoriasis) ulcers, cardiac ischemia and stroke, atherosclerosis, muscle diseases, Alzheimer's/Parkinson's, tumors and tumor metastasis, or others. For example, the systems and methods described herein may be useful for the detection and/or diagnosis in a subject of blood clots, traumatic brain injury, inflammation and/or (auto)immune diseases (e.g., Crohn's, psoriasis), ulcers, cardiac ischemia and stroke, atherosclerosis, muscle diseases, Alzheimer's/Parkinson's, tumors and tumor metastasis, or others.
- In some embodiments, the plurality of nanodiamond particles and the species associated with the nanodiamond particles are present (e.g., in a reservoir) and/or introduced into a fluidic device. For example, as illustrated in
FIG. 1B ,fluidic device 102 comprises asample inlet 130 and areservoir 140 in fluidic communication withsample inlet 130. In certain embodiments,reservoir 140 comprises a plurality of (fluorescent) nanodiamond particles 110 (andspecies 120 associated with nanodiamond particle 110). - In certain embodiments, a sample may be introduced to the sample inlet such that the sample flows into the reservoir and the sample interacts with the plurality of nanodiamond particles and species. In some embodiments, an analyte, if present in the sample, binds to the species.
- In some cases,
detection region 150 may be positioned downstream of, and/or in fluidic communication with,reservoir 140. In certain embodiments, adetector 160 may be positionedproximate detection region 150. The detector, in some cases, may be configured to quantify an emission (e.g., an intensity of the emission, a wavelength of the emission) at the detection region. In some cases, the emission may be fluorescent and/or near-infrared. For example, the analyte, if present, may bind to the species. In some such cases, the analyte may bind to a second species (e.g., an antibody) associated with (e.g., bound to) the detection region. In some embodiments, the analyte bound to the second species and the first species (associated with the nanodiamond particles) may be detected and/or quantified by measuring (e.g., via the detector) the emission of the nanodiamond particles. - In some embodiments, a detector may be positioned proximate a region of a subject suspected of containing an analyte and/or a clot. For example, the plurality of (fluorescent) nanodiamond particles functionalized with a species may be administered to a subject, and the detector may be positioned proximate the subject such that any nanodiamond particles bound to the analyte and/or clot may be detected (e.g., via an emission of the nanodiamond particles).
- Any suitable detector may be used with the devices and methods described herein. For example, in some embodiments, the detector may be an optical detector (e.g., fluorescence detectors, visible light and/or UV detectors, near infrared detectors, microscopes).
- In some embodiments, the emission is a fluorescent emission. In certain embodiments, the wavelength of the emission is greater than or equal to 250 nm, greater than or equal to 300 nm, greater than or equal to 350 nm, greater than or equal to 400 nm, greater than or equal to 450 nm, greater than or equal to 500 nm, greater than or equal to 550 nm, greater than or equal to 600 nm, or greater than or equal to 650 nm. In certain embodiments, the wavelength of the emission is less than or equal to 700 nm, less than or equal to 650 nm, less than or equal to 600 nm, less than or equal to 550 nm, less than or equal to 500 nm, less than or equal to 450 nm, less than or equal to 400 nm, less than or equal to 350 nm, or less than or equal to 300 nm. Combinations of the above-referenced ranges are also possible (e.g., greater than or equal to 250 nm and less than or equal to 700 nm). Other ranges are also possible.
- In certain embodiments, the emission is a near infrared emission. In some embodiments, the wavelength of the emission is greater than 700 nm, greater than or equal to 750 nm, greater than or equal to 800nm, greater than or equal to 850 nm, greater than or equal to 900 nm, or greater than or equal to 950 nm. In certain embodiments, the wavelength of the emission is less than or equal to 1000 nm, less than or equal to 950 nm, less than or equal to 900 nm, less than or equal to 850 nm, less than or equal to 800 nm, or less than or equal to 750 nm. Combinations of the above-referenced ranges are also possible (e.g., greater than 700 nm and less than or equal to 1000 nm). Other ranges are also possible.
- In some embodiments, the nanodiamond particle may emit a fluorescent and/or near infrared emission upon excitation by electromagnetic radiation having a particular wavelength. For example, in some embodiments, the nanodiamond particle may be exposed to electromagnetic radiation having a wavelength of greater than or equal to 250 nm, greater than or equal to 300 nm, greater than or equal to 350 nm, greater than or equal to 400 nm, greater than or equal to 450nm, greater than or equal to 500 nm, greater than or equal to 550 nm, greater than or equal to 600 nm, greater than or equal to 650 nm, greater than or equal to 700 nm, greater than or equal to 750 nm, greater than or equal to 800 nm, greater than or equal to 850 nm, greater than or equal to 900 nm, or greater than or equal to 950 nm (e.g., such that the nanodiamond particle emits a fluorescent emission and/or near infrared emission in one of the above-referenced ranges). In certain embodiments, the nanodiamond particle may be exposed to electromagnetic radiation having a wavelength of less than or equal to 1000 nm, less than or equal to 950 nm, less than or equal to 900 nm, less than or equal to 850 nm, less than or equal to 800 nm, or less than or equal to 750 nm, less than or equal to 700 nm, less than or equal to 650 nm, less than or equal to 600 nm, less than or equal to 550 nm, less than or equal to 500 nm, less than or equal to 450 nm, less than or equal to 400 nm, less than or equal to 350 nm, or less than or equal to 300 nm. Combinations of the above-referenced ranges are also possible (e.g., greater than or equal to 250nm and less than or equal to 1000 nm, greater than or equal to 550 nm and less than or equal to 650 nm). Other ranges are also possible.
- While much of the description herein is in the context of (fluorescent) nanodiamond particles, those of ordinary skill in the art would understand, based upon the teachings of this specification, that other particles are also possible. For example, in some embodiments, the device may comprise a particle such as a nanoparticle (e.g., a silica nanoparticle, a sapphire nanoparticle, a garnet nanoparticle, a ruby nanoparticle) having an emission in one of the above referenced ranges associated with a species (e.g., a species capable of binding to one or more target analytes). In some cases, the particle may be autofluorescent. In other cases, the particle may be functionalized with (e.g., associated with) a fluorescent molecule.
- In some embodiments, the fluidic device (e.g., comprising a sample inlet and a reservoir comprising a plurality of nanodiamond particles and a species associated with the nanodiamond particles) comprises a lateral flow assay configuration (e.g., in a lateral flow device). Those of ordinary skill in the art would understand, based upon the teachings of this specification, how to incorporate a plurality of nanodiamond particles and a species associated (e.g., bound) to the nanodiamond particles into a lateral flow assay device. For example, as illustrated schematically in
FIG. 2A , in an exemplary embodiment,system 200 comprises a lateral flow assay format. In certain embodiments,system 200 comprisesreservoir 210 comprising a plurality offluorescent nanodiamond particles 220 bound to a first species. Downstream ofreservoir 210, in certain embodiments, is asecond reservoir 230 comprising a second species (e.g., a first antibody to a target analyte) and athird reservoir 240 comprising a third species (e.g., a second antibody capable of binding to the antibody to the target analyte). In certain embodiments, the first species and the second species are the same. - Now referring to
FIG. 2B , a sample suspected of containing ananalyte 250 may be introduced into system 200 (e.g., such that the sample flows and interacts with reservoir 210). In some embodiments, at least a portion ofanalyte 250 binds to the species on plurality offluorescent nanodiamond particles 220. As illustrated inFIG. 2C , as the sample suspected of containinganalyte 250 flows along the system, at least a portion of the analytes 250 (e.g., now bound to the species and/or plurality of fluorescent nanodiamond particles 220) bind to the second species inreservoir 230. In some cases, at least a portion of plurality offluorescent nanodiamond particles 220 not bound to the analyte may be captured in reservoir 240 (e.g., where the third species is capable of binding to the first species). - In some cases, the devices and systems herein may be multiplexed. That is to say, in some embodiments, the devices may comprise two or more, three or more, four or more, or five or more fluidic components and/or reservoirs comprising a plurality of nanodiamond particles. In some such embodiments, more than one analyte may be detected, if present in the sample, in a single device. In certain embodiments, one or more analytes may be detected in a device comprising a plurality of fluidic components and/or reservoirs comprising a plurality of nanodiamond particles.
- In an exemplary embodiment, a sample suspected of containing an analyte may be introduced into a fluidic channel of a fluidic device, exposing the sample to a species bound to a plurality of fluorescent nanodiamond particles such that the analyte, if present, binds to at least a portion of the species bound to the plurality of fluorescent nanodiamond particles. In some embodiments, any fluorescent nanodiamond particles and species not bound to the analyte may be removed and a fluorescence emission of the plurality of fluorescent nanodiamond particles bound to the analyte may be quantified. As described herein, in some cases, the amount of analyte present in the sample may be correlated with the intensity of the fluorescence emission.
- In another exemplary embodiment, a system comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, and a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region. In some cases, the detector may be configured to quantify a fluorescent emission at the detection region and/or configured to quantify an infrared signal at the detection region.
- In yet another exemplary embodiment, a fluidic device comprises a sample inlet, a reservoir in fluidic communication with the sample inlet, the reservoir comprising a plurality of fluorescent nanodiamond particles, a plurality of a first species bound to the plurality of fluorescent nanodiamond particles, and a detection region in fluidic communication with the reservoir, the detection region comprising a plurality of a second species bound to the detection region. In some embodiments, the fluidic device may further comprise a control region in fluidic communication with the detection region, the control region comprising a plurality of a third species bound to the control region. In some such embodiments, the third species may be the same or different as the first species and/or the second species. For example, the first species bound to the plurality of fluorescent nanodiamond particles may be a first antibody (e.g., capable of binding selectively to the target analyte), the second species may be the first antibody or may be a second antibody different than the first antibody (e.g., capable of binding selectively to the target analyte), and the third species may be an anti-antibody to the first antibody. The control region may provide an indication, if an emission is present, that the system is working properly (e.g., the plurality of nanodiamond particles were properly featured and introduced into the sample).
- In some embodiments, the fluidic device comprises an absorbent material. In some embodiments, an absorbent region comprising the absorbent material is positioned downstream of, and in fluidic communication with, the detection region and/or the control region. In some cases, the absorbent material is associated with one or more components (e.g., the reservoir, the detection region) of the fluidic device. In some cases, the absorbent material may at least partially drive the flow of the sample in the fluidic device (e.g., wicking). In other embodiments, capillary action may at least partially drive the flow of the sample in the fluidic device.
- Non-limiting examples of suitable absorbent materials include solid materials, porous materials, particles, powders, and gels. In some embodiments, the absorbent material may comprise fabric, cellulose, cotton, and/or a polymer. Those of ordinary skill in the art would be capable of selecting suitable absorbent materials based upon the teachings of this specification.
- In another exemplary embodiment, the methods described herein comprise administering, to a subject suspected of having a particular analyte (e.g., present in the bloodstream), a plurality of fluorescent nanodiamond particles bound to a species such that the species may bind to the analyte, if present, and detecting a fluorescent and/or near infrared emission of the plurality of fluorescent nanodiamond particles comprising the species bound to, if present, the analyte. In some cases, detecting a fluorescent emission indicates the presence of a blood clot in the subject. In certain embodiments, detecting a fluorescent emission indicates the presence of a virus (e.g., ebola, Marburg, Bundibugyo, sudan, junin, lassa, MERS, etc.) in the subject.
- As should be evident, in some embodiments, the present invention also provides a diagnostic agent for detection or imaging of thrombotic events in a human or non-human animal, where the agent comprises a fluorescent nanodiamond particle chemically bonded to disintegrin Bitistatin (Bt). In certain embodiments, the fluorescent nanodiamond particle and the Bt are covalently bonded. The diagnostic agent may be fluorescent as a result of an intrinsic property of the nanodiamond particle. In some embodiments, the diagnostic agent emits a detectable electromagnetic signal when excited by an electromagnetic source.
- Additional exemplary embodiments relate to a method for diagnosis or prognosis of a thrombo-embolic event. In these embodiments, the method comprises: administering to a subject suspected of having suffered from or suspected of being at risk of, a thrombo-embolic event, a diagnostically effective amount of the diagnostic agent of the invention; allowing sufficient time for the diagnostic agent to localize to the site(s) of thrombus; and detecting the diagnostic agent by detecting fluorescence emission of the diagnostic agent. The method can be practiced as a method of detection of activated platelets and/or a method of detecting clots or clot formation in subjects.
- Another exemplary embodiment of the invention relates to a kit. The kit may include the diagnostic agent of the invention in packaged form suitable for distribution, delivery, and/or storage for use in a diagnostic method (e.g., a diagnostic method for detection of a thrombus). The packaged form may include a suitable material for distribution, delivery, and/or storage of the diagnostic agent. In certain embodiments, the kit further comprises, in packaged combination, one or more reagents or devices for administration of the diagnostic agent of the invention to a subject. The kit can also include a device that emits excitation energy for the diagnostic agent, and preferably further includes a detector for detection of emission response from the diagnostic agent. In a particular exemplary embodiment, the device (e.g., a device that emits excitation energy, a detector for detection of emission response) is a hand-held device.
- It will be apparent to those skilled in the art that various modifications and variations can be made in the practice of the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
- A “subject” or a “patient” refers to any mammal (e.g., a human), for example, a mammal that may be susceptible to a disease or bodily condition. Examples of subjects or patients include a human, a non-human primate, a cow, a horse, a pig, a sheep, a goat, a dog, a cat or a rodent such as a mouse, a rat, a hamster, or a guinea pig. Generally, the invention is directed toward use with humans. A patient may be a subject diagnosed with a certain disease or bodily condition or otherwise known to have a disease or bodily condition. In some embodiments, a patient may be diagnosed as, or known to be, at risk of developing a disease or bodily condition. In other embodiments, a patient may be suspected of having or developing a disease or bodily condition, e.g., based on various clinical factors and/or other data. In some cases, the patient may be diagnosed with having or developing a particular disease or bodily condition after the detection and/or quantification of an analyte (e.g., a virus, an antigen, an antibody) in a sample obtained from the patient. In some embodiments, a subject may demonstrate health benefits, e.g., upon administration of the fluorescent nanodiamond particles.
- As used herein, a “fluid” is given its ordinary meaning, i.e., a liquid or a gas. A fluid cannot maintain a defined shape and will flow during an observable time frame to fill the container in which it is put. Thus, the fluid may have any suitable viscosity that permits flow. If two or more fluids are present, each fluid may be independently selected among essentially any fluids (liquids, gases, and the like) by those of ordinary skill in the art.
- The following examples are intended to illustrate certain embodiments of the present invention, but do not exemplify the full scope of the invention.
- The following example demonstrates an exemplary functionalized fluorescent nanodiamond particle with a species (e.g., for binding to anti-human IgG-AP).
-
FIG. 3 illustrates the conjugation of a fluorescent nanodiamond particle (F-NDP), functionalized with a carboxylic acid group, and bound to a species (e.g., Bitistatin). Such functionalized F-NDPs can be used, for example, to image and detect the presence of blood clots using external scanners (e.g., detectors for UV and/or NIR emissions). - The following example demonstrates the incorporation of fluorescent nanodiamond particles into an exemplary system such as a lateral flow assay format.
-
FIG. 4 shows the loading of three exemplary systems (system 400,system 410, and system 420), each with a reservoir of fluorescent nanodiamond particles (shown as the dot in each system) placed on a nitrocellulose substrate. Upon introduction of water tosystem 400, water with 1% Tween 20 tosystem % Tween 20 tosystem 420, flow of the fluorescent nanodiamond particles along the substrate of each device was observed (system 402,system 412, andsystem 422 respectively). - The following example demonstrates the use of fluorescent nanodiamond particles (F-NDP) conjugated with a species (e.g., human IgG) for the detection of an analyte (e.g., anti-human IgG).
-
FIG. 5 shows a plot of semi-ELISA for detection of human IgG coupled to the F-NDP NV (700 nm). F-NDP were coupled to human IgG, or BSA (control), which were used in concentrations as indicated, per 1 mg of F-NDP. 0.2 mg of each F-NDP-IgG or F-NDP-BSA sample were used for semi-ELISA, which was performed on a U-shape bottom 96-well plate. The plate was blocked overnight with 3% BSA in PBST. F-NDP-IgG were blocked with 3% BSA in PBST by incubation for 1 hour at 37° C. Blocking agent was removed by centrifugation (1,000 g) at room temperature and washed 2× with PBST. Goat anti-human IgG AP-conjugated (Sigma Inc.), diluted 1:5000, was added and incubated for 1 hr. as above. Final washing was performed as above, and p-nitrophenyl phosphate substrate (pNPP) to alkaline phosphatase (AP) was added. Color was developed for 30 min, and NDP samples on plate were centrifuged. Supernatant was transferred to a flat bottom 96-well plate and read using an ELISA plate reader under 405 nm wave length. Error bars represent four repeats in semi-ELISA from the same samples. - The following example demonstrates the use of F-NDPs functionalized with a species (e.g., Bitistatin (Bt)) for the detection of blood clots.
FIG. 6 shows the accumulation number of F-NDP-Bt in carotid arteries in rats with generated clots. Carotid arteries with generated clots or not (control) were dissected from rats at the end of the experiments. Vessels were solubilized with 12 N HCl by overnight incubation at 60° C. in a ratio of 100 mg per ml. The resulting solution was diluted 10× with water and centrifuged using 14,000 rpm at room temperature and re-suspended in the same volume of water. F-NDP-Bt were counted using a hemocytometer with fluorescence microscope (40× objective, TRITC wavelengths). Presented numbers show total accumulated particles. Error bars represent standard deviation from three rats (clot value=2.8±0.38 ×107; control value=6.6±4.7×105) -
FIG. 7A is a scanning confocal microscope (SCM) image of carotid arteries from rats with a generated clot. Generation of a clot was performed using ferric chloride. F-NDP-Bt suspension was injected locally, close to the clot. Rats were euthanized, and carotid arteries with clots were dissected. Imaging was performed using SCM. Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). NIR detection of F-NDP-Bit is indicated by the white arrows. -
FIG. 7B shows a scanning confocal microscope image of carotid arteries from rats with generated clot. Generation of a clot was performed using ferric chloride. F-NDP-Bt suspension was systemically injected to the animal tail. The rat was euthanized, and the carotid artery with clots was dissected. Imaging was performed using SCM. Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). NIR detection is indicated by white arrows. -
FIG. 8 shows images of tissue suspensions of clots treated or not with F-NDP-Bt, injected systematically to the femoral vein close (locally) to the clot generated in carotid artery. Tissues of the clot were manually homogenized in the presence of RIPA buffer (Triton X-100 based) in ratio one vein for 100 ml. Suspension of the lysate was applied on glass slide and immediately analyzed under the microscope.Magnification 100×. - The following example demonstrates the functionalization of F-NDP (i.e., NDP-F) with a polypeptide (e.g., Bitistatin (Bt)) and the detection of one or more analytes and/or blood clots.
- The methodology of coupling proteins/peptides to carboxyl-functionalized NDP-F is described herein. Preservation of the active domains responsible for the biological action of the coupled proteins/peptides remains challenging, and is generally considered to be a trial and error endeavor. A major innovation of the present invention is the demonstration of a concentration-dependent association of the engineered NDP-F-Bt agent to purified PFR. The selection of Bt was based on the high selectivity/specificity of Bt to the PFR, concomitant with negligible interactions with other RGD-dependent integrins, such as receptors for vitronectin (avb3) and fibronectin (a5b1). The present strategy to utilize Bt for clot imaging differs significantly from previous studies aimed at demonstrating the utility of Tc99-Bitistatin to map blood clots in vivo. The present imaging strategy is based on the innate near infrared (NIR) fluorescence emitted upon excitation of the NDP-F, thereby eliminating high radioactivity exposure required by other imaging techniques. It is also envisioned that coupling Bt (or other polypeptides) to a nanoparticle will be beneficial for the extension of the lifetime of the Bt at the site of its biological target.
- Fluorescent nano-diamond particles (NDP-F or FNDP) functionalized by carboxyl groups (—COOH) were purchased from Adamas Nanotechnologies, Inc. (Raleigh, N.C.). Size distribution analysis revealed the peak of the diameter of the NDP was 734.5 (±223.6, SD) nm. Optimization of fluorescence for the NDPs was performed by 2D screening of excitation vs. emission wavelengths (
FIG. 9 ). Two areas of optimal fluorescence were established for NDPs, which should be useful for application in medical imaging (circled onFIG. 9 ). Detailed screening revealed two optimal correlations of excitation vs. emission wavelengths: 480 nm vs. 520 nm, and 565 nm vs. 700 nm. The first correlation represents the typical green fluorescence, whereas the second is characterized by the long Stokes shift of fluorescence with near IR emission. The near IR emission is very useful for detection in vivo because it is in the optical therapeutic window of autofluorescence of factors present in human and non-human animal non-invasive imaging environments (e.g., water, hemoglobin, oxyhemoglobin, melanin). - The NDP-Fs were found to be resistant to photobleaching. Exposure of the slides containing NDPs to intense fluorescence light resulted in no changes in the intensity of their fluorescence in the time points up to 5 hours (data not shown).
- Bitistatin is generally derived from snake venom and belongs to the disintegrin family of proteins. It has previously been investigated as a potential reagent for detection of deep venous thrombosis (DVT) using radioactive tags. This RGD-disintegrin showed desirable parameters for detection of DVT when compared with other snake venom disintegrins, such as kistrin and barbourin. Therefore, this fibrinogen receptor-binding ligand was selected for coupling to NDP-Fs for the purpose of detecting activated platelets (or their aggregates) in clots present in the venous circulation (vein thrombus).
- Bitistatin is generally an 83-amino acid polypeptide, which originally was isolated from venom of Bitis arietants. This naturally occurring polypeptide was purified from the same snake venom using methodology developed in the laboratory for purification of other snake venom disintegrins (Marcinkiewicz, Cezary, et al. “EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner.” Journal of Biological Chemistry 274.18 (1999): 12468-12473.; incorporated herein by reference). Briefly, this method includes two steps of reverse phase HPLC with application of C18 column and a linear gradient of acetonitrile as a protein elution agent. Purity of the obtained Bt was tested by SDS-PAGE and quantified by digitization of bands on standard protein gels by Coomassie blue staining. The content of Bt was estimated at over 98% in the final protein preparation. This preparation was suspended in PBS for coupling to NDPs.
- The active site of Bt was characterized and found to include an RGD motif, which is important for ligand binding to certain integrins, such as αIIbβ3, αvβ3, and α5β1. Bt is quite selective in that it has been shown to bind only the PFR, αIIbβ3 integrin, which is exclusively expressed on circulating platelets. The aspartic acid in the RGD sequence was recognized by site-directed mutagenesis of recombinant proteins and short peptide synthesis as the most essential amino acid for disintegrin binding to the fibrinogen receptor. It was hypothesized by the inventors that coupling of Bt to NDPs that were functionalized by an attached amine group could affect the activity of disintegrin by engagement with carboxyl groups present in the side chain of the aspartic acid. Therefore, NDPs functionalized by a carboxyl group were selected to attach the Bt on NDPs surfaces.
- Coupling of carboxyl (—COOH) groups present on NDPs to NH2 groups present on Bt was performed using a standard protocol developed previously (Grabarek and Gergely, 1990). This method was based on the application of the cross-linker 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), which activates carboxyl groups to bind amine groups by forming an O-acylisourea intermediate that quickly reacts with an amino group to form an amide bond. O-acylisourea generally undergoes quick hydrolysis. Therefore, to increase the efficiency of coupling, sulfo-N-hydroxysuccinimide (sulfo-NHS) was added to the reaction mixture to generate an amine-reactive sulfo-NHS ester.
- BSA was coupled in parallel to the control NDPs.
- A detailed description of an exemplary suitable coupling procedure follows:
- Two samples of NDP, each containing 2 mg in 1.8 ml of 0.1M MES, 0.5M NaCl, pH 6.0, were prepared. Sample A contained 1 mg Bt per 1 mg NDPs. Sample B contained 1 mg BSA per 1 mg NDPs, and served as a control.
- To each sample, 0.72 mg EDC was added and the mixture incubated at room temperature (about 21° C. to 25° C.). with gentle rotating for 15 minutes. After incubation, 2.5 μl of 2-mercaptoethanol (to give a final concentration of 20 mM) was added to quench the EDC and stop the carboxyl group activation.
- The activated NDPs were transferred to 1.5 ml centrifuge tubes and centrifuged at 10,000×g for 5 minutes at room temperature. The NDP pellets were washed twice with 1 ml PBS and suspended in coupling buffer (PBS). One milligram of either Bt or BSA in 1 ml of PBS was added to each sample tube. The tubes were incubated for two hours at room temperature with gentle rotating. Ten μl of 1M Hydroxylamine-HCl (350 mg in 5 ml PBS) was added to each tube for quenching (final concentration of Hydroxylamine-HCl should be about 10 mM).
- The sample tubes were centrifuged at 10,000×g for 5 minutes at room temperature. The supernatants were saved for protein concentration determination to check coupling efficiency. The NDP-F-Bt particles were washed three times with 1 ml PBS each time. The washed particles were suspended in a volume of PBS to achieve a concentration of 1 mg/ml.
- Coupling efficiency was evaluated using immune detection of Bt on the surface of NDPs (NDP-Bt). For ease of reference in this document, the detection method is called semi-ELISA. Broadly speaking, polyclonal antibody against Bt was developed commercially in rabbits (Chemicon/Millipore Inc.) using purified native polypeptide as the antigen. The saturated concentration of Bt was estimated at 1 mg per 1 mg NDPs. A representative plot from three independent experiments is presented in
FIG. 10 . - An exemplary suitable assay for determining coupling efficiency follows:
- Using a 96-well plate having a U-shaped bottom and that has previously been blocked by incubation overnight at 4° C. with 5% BSA in PBS, 200 μl of an NDP-F-Bt or NDP-F-BSA solution (1 mg/ml NDP in PBS) was each applied to a separate well. The plate was centrifuged for 10 minutes at 1,000×g. The supernatant was removed and the plate gently shaken by vortexing to disperse and re-suspend the pellet of NDP-F.
- 200 μl of 10% goat serum in PBST (PBS+0.05% Tween-20) was added and mixed a few times by intensive aspiration and releasing from a pipet tip. The mixture was incubated for one hour at 37° C. with slow agitation. The mixture was centrifuged as above and washed three times with 200 μl of PBST. After each centrifugation, the pellet was dispersed by vortexing. After the final wash, 100 μl of anti-bitistatin (5 μg/ml in PBST) was added to the wells and incubated for one hour at room temperature. The plate was then washed three times with PBST as described above. To each pellet, 100 μl of a 1:2000 dilution of goat anti-rabbit IgG AP conjugate (from Sigma) in PBST was added to the wells and the mixture incubated for one hour at 37° C. The mixture was centrifuged at 1,000×g for 10 minutes, and the pellet was washed three times with PBST as above.
- 150 μl of the AP substrate pNPP (from Sigma) was added and color was developed for approximately 30 minutes (until the intensity of the yellow color was visible) at room temperature with gentle agitation. The reaction was blocked by adding 100 μl of 3 M NaOH (this step is optional). The plate was then centrifuged and 100 μl of the supernatant was transferred to a 96-well plate (flat bottom). The absorbance of the supernatant was measured at 405 nm using an ELISA plate reader.
- The activity of NDP-Bt was tested using PFR purified from platelets, αIIbβ3 integrin (Millipore Inc.). Two types of assays were applied to confirm the presence of disintegrin on NDP-Bt, including binding of soluble PFR to NDP-F-Bt and adhesion of NDP-F-Bt to fibrinogen receptor immobilized on the surface (plastic or glass). Binding of soluble PFR was determined on the basis of the functional “sandwich” ELISA, which is referred to herein as a functional semi-ELISA. In this case, immune-detection of αIIbβ3 integrin bound to the NDP-Bt was performed using a polyclonal antibody against the αIIβ integrin subunit (purchased from Santa Cruz Inc.).
- An exemplary suitable protocol for a functional semi-ELISA for detecting binding of fibrinogen receptor to NDP-F-Bt follows:
- Using a 96-well plate having a U-shaped bottom and that has previously been blocked by incubation overnight at 4° C. with 5% BSA in PBS, 200 μl of an NDP-F-Bt or NDP-F-BSA suspension (1 mg/ml NDP in PBS) was each applied to a separate well. The plate was centrifuged for 10 minutes at 1,000×g. The supernatant was removed and the plate gently shaken by vortexing to disperse the pellet of NDP-F. 200 μl of 3% BSA PBST (PBS+0.05% Tween-20) was added and the composition was mixed a few times by intensive aspiration and releasing from a pipet tip. The mixture was incubated for one hour at 37° C. with slow agitation. Alternatively, the blocking step may be performed in a tube before application on the 96-well plate. The mixture was centrifuged as above and washed three times with 200 μl of PBST. After each centrifugation, the pellet was dispersed by vortexing.
- Fibrinogen receptor was then added at the desired concentrations (i.e., the amounts required to generate a dose-response); see
FIG. 11 (in 200 μl of HBSS containing physiological concentrations of Ca2+ and Mg2+ and incubated for one hour at 37° C. The plate was then washed three times with PBST as above. Next, 100 μl of anti-fibrinogen receptor (2 μg/ml from Santa Cruz Inc.) polyclonal antibody in PBST was added to the wells and incubated for one hour at room temperature. The plate was washed three times with PBST as above. To the pellets, 100 μl of a 1:3000 dilution of goat anti-rabbit IgG AP conjugate (from Sigma) in PBST was added to the wells and incubated for one hour at 37° C. The mixture was centrifuged at 1,000×g for 10 minutes, and the pellets washed three times with PBST as above. - 150 μl of the AP substrate pNPP (from Sigma) was added and color was developed for approximately 30 minutes at room temperature with gentle agitation. The reaction was blocked by adding 100 μl of 3 M NaOH (this step is optional). The plate was centrifuged and 100 μl of supernatant was transferred to the well of a 96-well plate (flat bottom). The absorbance of the supernatant was measured at 405 nm using an ELISA plate reader.
- As can be seen from
FIG. 11 , the PFR bound to the NDP-Bt in a dose-dependent manner, whereas the control NDP-BSA were not active in this assay. - Adhesion of NDP-Bt to immobilized fibrinogen receptor was performed in two formats based on the estimation of the fluorescence of attached NDPs. First, integrin was immobilized on a 96-well plate and adhered NDPs were detected using a fluorescence plate reader. The results obtained showed linear progression of the adhesion of NDP-Bt to increased concentration of immobilized purified receptor (
FIG. 12 ). Adhesion of NDP-Bt was also monitored under fluorescence microscopy. The number of adhered NDPs was quantified using computer software (FIG. 13 ). Representative images of adhered NDP-Bt are presented inFIG. 14 . - To further characterize the effects of the FNDP, fluorescent images were taken by IVIS and confocal microscopy of carotid artery clots after treatment with FNDP via external carotid artery infusion. The results are shown in
FIG. 15 . In two independent experiments, infusion of FNDP via the external carotid artery commenced 3-5 minutes after FeCl3 application and continued over 15 minutes (5 minutes beyond the end of FeCl3 infusion). The FNDP solution consisted of 1.5 ml of PBS where 5 mg/ml of FNDP was suspended (after vortexing of the solution). This route of infusion was selected so as to avoid possible “first pass” elimination of the particles by peripheral organs. Following completion of FNDP infusion, the rat was euthanized and subjected to imaging by IVIS and/or fluorescent microscopy.FIGS. 15A-D show imaging of fluorescence that was performed on an IVIS scanner designed for whole animal imaging using a 580-610 nm excitation and a 695-770 nm emission passband with a 2 second exposure. Auto-fluorescence was subtracted based on excitation at 445-490 nm.FIG. 15A shows an in situ carotid bifurcation region image, indicating fluorescence of carotid arterial clot after treatment visible via IVIS imaging after exposure of the carotid bifurcation zone.FIGS. 15B and 15C are high magnification images of fluorescence emanating from the carotid bifurcation in vivo, suggesting accumulation of FNDP in the clot.FIG. 15D is an ex vivo photograph of fluorescence of carotid artery bifurcation denoting one branch showing fluorescence corresponding to the clot location within the carotid bifurcation.FIGS. 15E and 15F are confocal images taken on an Olympus IX83 of FNDP in which fluorescence is detected at an excitation of 543 nm and an emission of 655-755 nm. Background fluorescence was collected from the same excitation, with emissions of 555-625 nm, and was subtracted from the foreground to reduce auto-fluorescence.FIG. 15E shows ex vivo fluorescence of the carotid artery at 4× magnification.FIG. 15F shows FNDP treated carotid arteries after they were flushed with RIPA lysis buffer and replicates were combined together to form a lysate. Lysate was then deposited onto a cover-glass and imaged at 20× magnification. Large numbers of FNDP at various aggregate sizes around platelets are visible. -
FIG. 16 shows fluorescent images taken by IVIS and confocal microscopy of carotid artery clots after intravenous treatment with FNDP. After clot formation by ferric chloride, treatment with saline control or FNDP by intravenous infusion via tail vein or femoral vein was performed in three rats. FNDP were infused (over 10 min) as a suspension in PBS at 1 ml solution containing 1 mg/ml FNDP. Carotid arteries were removed from the animal for imaging and placed in 70% denatured ethanol for preservation until imaging. FNDP were conspicuously identified at the site of clot formation. FNDP were identified in each of the three specimens obtained following intravenous infusion, yet the three specimens were treated together as one for lysate inspection.FIGS. 16A and 16B show imaging of fluorescence as performed on an IVIS scanner designed for whole animal imaging using a 580-610 nm excitation and a 695-770 nm emission passband with a 2 second exposure. Autofluorescence was subtracted based on excitation at 445-490 nm.FIG. 8A shows an ex vivo fluorescent image of a carotid artery from saline-treated control. Auto-fluorescence could not be entirely eliminated, but was evenly distributed across control specimen.FIG. 16B shows an ex vivo fluorescent image of a carotid artery from an IV FNDP-treated animal, showing fluorescence localized to the branch with a clot.FIGS. 16C-16F show confocal images taken on an Olympus IX83. The figures show that FNDP fluorescence was detected at an excitation of 543 nm and an emission of 655-755 nm. Background fluorescence was collected from the same excitation, with emissions of 555-625 nm and was subtracted from the foreground to reduce auto-fluorescence.FIGS. 16C and 16D show ex vivo fluorescence of carotid artery at 4× magnification of saline treated and FNDP treated animals, respectively. Auto-fluorescence could not be entirely eliminated, but was evenly distributed across control specimens, while fluorescence was localized to the branch with clot in the IV treated animal. (See panels 16E and 16F.) Treated carotid arteries were flushed with RIPA lysis buffer and replicates were combined together to form a lysate. Lysate was then deposited onto a cover-glass and imaged at 20× magnification. In order to increase contrast for visual inspection, images were processed with an un-sharp mask in ImageJ. -
FIG. 16E shows that the saline-treated control showed no detectable fluorescence.FIG. 16F shows that FNDP appear as frequent fluorescent spots in the treated samples.FIG. 16G presents a graph showing the number of FNDPs present in carotid clot lysates from animals treated locally via the external carotid artery or intravenously as compared with saline treated controls. FNDPs were counted in replicate images after thresholding in ImageJ. -
FIG. 17 depicts images of rat blood plasma clots following treatment with F-NDP-Bt and F-NDP-BSA. Rat blood was collected by heart puncture and centrifuged at 100×g for 20 minutes at room temperature to obtain platelet rich plasma (PRP). A thrombus was generated by adding thrombin (1 U/ml) and incubating for 15 minutes at 37° C. The clot that was formed was washed 3× by decanting with HBSS containing calcium and magnesium, and then sliced. Pieces of the clot were incubated with a suspension of F-NDP-Bt and F-NDP-BSA (50 μg/ml in HBSS containing calcium and magnesium for 60 minutes at 37° C., and washed 3× with the same buffer as above, then applied on the glass slide for imaging. Images of plasma clots obtained from fluorescence microscope Olympus IX81 analysis, under 100× magnification, are shown inFIG. 17A . Images of plasma clots obtained using anIVIS 50 imaging system are shown inFIG. 17B . Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). Exposure time: 1 minute. Arrows inFIG. 17B point the localization of the clot. -
FIG. 17 shows the specificity of interaction of F-NDP-Bt with a clot generated from rat blood plasma by thrombin (1 U/ml). Analysis of the clot under a fluorescence microscope (FIG. 17A ) revealed that F-NDP-Bt accumulated on the surface of the thrombus to a high extent, although this accumulation was not evenly distributed. Fluorescence microscopy imaging identified areas with high green fluorescence intensity (represented by bright spots in the black and white image), which may indicate zones of the condensation of activated platelets. Fluorescence live imaging system (IVIS 50) also exhibited binding of F-NDP-Bt to the plasma clot (FIG. 17B ). However, in this system the near infrared (NIR) detection was set up based on the optimization performed as presented inFIG. 9 . Control nanoparticles, containing coupled BSA to the surface (F-NDP-BSA), interacted with the clot to a negligible level in both imaging assays. Detection of F-NDP-Bt by NIR suggested a usefulness of functionally active F-NDP-Bt for imaging in living organisms because the emission wavelength was localized within an “optical therapeutic window” (600-1300 nm). - Therefore, detection of F-NDP-Bt was performed in a rat model for verification of that hypothesis. The results are shown in
FIG. 18 . The skin areas of observation fields were prepared for implantation by hair shaving. The incision was made by scalpel and vessels were inserted under the skin of dead rats. The dead rats were placed inIVIS 50 Imaging System, and measurement of fluorescence under NIR spectrum was performed. Wavelengths used for measurement: excitation Cy5.5 BkG (580-610 nm), emission Cy5.5 (695-770 nm). For background subtraction: excitation GFP (445-490 nm), emission Cy5.5 (695-770 nm). - A representative image of the implanted glass capillaries filled with F-NDP-Bt (4 mg/ml) or PBS (control) are shown in
FIG. 18A . Exposure time was 5 seconds.FIG. 10B shows an image of a rat aorta filled with F-NDP-Bt. The rat aorta was dissected from a euthanized female rat, washed with PBS to remove residues of coagulated blood, and filled with 300 μl of F-NDP-Bt suspension (2 mg/ml) in PBS. The aorta was secured from both ends by knots of surgical sutures. Exposure time was 1 minute.FIG. 18A demonstrates NIR imaging of F-NDP-Bt, experimentally implanted under rat skin. Suspensions of F-NDP-Bt were infused into glass capillaries and into dissected rat aorta (FIG. 18B ), before subcutaneous implantation. Clear images showed precise localization of both artificial (capillary) and natural (aorta) vessels in the rats. - Finally, the specificity of the interaction of F-NDP-Bit with the fibrinogen receptor present on activated platelets in a preformed PRP clot (
FIGS. 18C-18D ) was investigated. In two separate experiments, clots were incubated with F-NDP-Bit for 15 or 60 minutes, respectively. A clot was generated from rat PRP by thrombin (1 U/mL) and incubated with F-NDP-Bit (250 μg/mL) in the presence or absence of Lt (4.67 μmol/mL). (FIG. 18C ) IVIS imaging was performed using GFP filters (excitation 445-490 nm, emission 515-575 nm). The clot was incubated with F-NDP-Bit for 15 minutes (upper panel) or 60 minutes (lower panel). Intensity of fluorescence was evaluated using IVIS Living Image 4.3.1 software. Insets above the bars represent respective images of clots from IVIS. (FIG. 18D) Phase-contrast and fluorescence microscope images of clots (100×). Areas of accumulation of F-NDP-Bit are framed in yellow. Irrespective of the duration of incubation, binding of F-NDP-bit was always 4-5 fold higher than that of the nonspecific control particles (F-NDP-BSA). Furthermore, preincubation of the clots with lotrafiban (lt) reduced F-NDP-Bit binding to the level of the control F-NDP-BSA. - Bitistatin was purified from the venom of Bitis arientans (Latoxan Serpentarium, Valence, France) using two steps of reverse-phase HPLC. F-NDP, chemically surface-functionalized with carboxyl groups (—COOH), were purchased from Adamas Nanotechnologies (Raleigh. N.C., USA). Two strains of F-NDP were used: green fluorescent F-NDP based on N-V-N color centers (F-NDP(NVN)) at 700 nm (2×108 particles/mg) and red fluorescent based on N-V (F-NDP(NV)) color centers at 100 nm (5×1011 particles/mg), 700 nm (2×108 particles/mg), and 10,000 nm (5×105 particles/mg). Isoflurane was purchased from Henry Schein (B34C16A Dublin, Ohio, USA). 70% Denatured Ethyl Alcohol and PE-10 tubing were purchased from Fisher Scientific (Pittsburgh, Pa., USA). Silk Suture was purchased from Roboz SUT-15-1, Roboz Surgical Instrument Co. (Gaithersburg, Md., USA). Parafilm and FeCl3 was purchased from Sigma-Aldrich, (St. Louis, Mo., USA).
- Bitistatin was coupled to the F-NDP of all types using EDC (1-ethyl-3-[3dimethylaminopropyl] carbodiimide hydrochloride) as a hetero-bifunctional cross-linker. Coupling efficiency and preservation of Bitistatin activity on the various functionalized nanodiamond particles (F-NDP-Bit) were verified using a semi-ELISA methodology.
- The following example demonstrates the use of functionalized fluorescent nanodiamond particles (e.g., (F-NDP-Bt)) to bind to platelets and preferentially to activated platelets from humans. The data also shows that the particles do not substantially interfere with platelet aggregation.
- For example,
FIGS. 19A-19C show dose response curves for aggregation of platelets with and without probe (i.e., F-NDP-Bt), determined as a function of concentration of proteinase-activated receptor 4 (PAR4 AP), adenosine diphosphate (ADP), and arachidonic acid (AA). -
FIGS. 20A-20C show the ability of a F-NDP-Bt probe having an average particle diameter of 700 nm or 200 nm to bind to various platelet populations at different concentrations.FIGS. 21-222 shows the difference in binding of probes (700 nm or 200 nm in diameter) in stimulated versus unstimulated platelet populations. - Flow cytometry data of stimulated and unstimulated platelets are shown in
FIGS. 23A-23D andFIGS. 24A-24D , using the F-NDP-Bt probes. - The following example demonstrates an exemplary method for extracting, isolating, and/or quantifying F-NDP-(NV) in blood and/or biological tissues.
- 1. F-NDP-
BSA NV 700 nm were prepared using a coupling protocol as described herein, in sterile conditions (see e.g., Example 8). Final concentrations of 5 mg/ml were be prepared in PBS for animal administration. - 2. 4 doses of 1 ml (5 mg/ml in PBS) of F-NDP-BSA were injected per one subject (e.g., an animal). Blood (TBD) may be collected into 3.8% sodium citrate (in ratio 1:9) at different time intervals. Control group may be infused with equal volume of normal saline. Blood from PBS-injected animal may be collected in the same way treated samples were processed. At the conclusion of the protocol approximately 10 mL of blood may be collected.
- 3. Blood containing F-NDP-BSA may be lyophilized using SpeedVac system (SC110A Plus, Thermo Savant) with 4,680×g. Control animal may be used for preparation of standard curve. Standard curve may be prepared by mixing known amount of F-NDP-BSA with blood. 8 serial dilution will be prepared starting from the highest, 2 mg/ml particles density.
- 4. Dry mass of particles containing blood collected in the course of the experiment of may be dissolved in 12 N HCl at same volume staring volume of blood (approx. 1 ml). Solubilization may be performed by overnight incubation at 60° C.
- 5. Supernatant may be removed by centrifugation (17,000×g for 5 min at room temperature) and pellet re-suspended in the same volume original volume (e.g.,
water 1 ml). Centrifugation will be repeated one time for washing. At this point, particles may be condensed using smaller amount of water, to improve sensitivity. For example, final volume of water may be twice lower than volume of blood used for lyophilization, e.g., such that sensitivity for detection of F-NDP would be twice increased. - 6. Suspension of F-NDP-BSA of investigated samples and standard curve may be applied on 96-well plate (100 microliters per well) and plate may be read in Tecan using NIR wavelength (excitation 570 nm, emission 670 nm). In parallel, number of particles per ml may be established by disposable hemocytometer (Incyto Inc., Cheonan-si, Korea), counting under fluorescence microscope, e.g., using an Olympus IX81 with TRICI wavelength and 400× magnification. Amount of F-NDP-BSA in investigated samples may be deducted from the standard curve.
- The following example demonstrates an exemplary method for sterilization and/or lyophilization of F-NDPs.
- 1. F-NDPs were suspended in 70% ethanol and incubate for 15 min at room temperature (23+/−2° C.), using gentle agitation on “Speci Mix Test Tube Rocker” (ThermoScientific Inc., Waltham, Mass. USA). Density of F-NDPs was approximately 0.5 mg/ml.
- 2. The suspension of F-NDPs may be centrifuged (e.g., 17,000×g for 5 min at room temperature). Supernatant (ethanol) may be removed by vacuum aspiration and pellet suspended in water or buffer (e.g., PBS or MES) and centrifuged once again under the same speed conditions for washing purposes.
- 3. F-NDPs were suspended in water or working buffer (e.g., MES if coupling to protein will be performed) in desired density (e.g. 1 mg/ml).
- 4. Lyophilization of F-NDPs may be performed using a SpeedVac system (SC110A Plus, Thermo Savant, and Holbrook, N.Y., USA). For example,
polypropylene tubes 5 ml (Sarstedt Inc., Numbrecht, Germany) or 1.5 ml (Fisher Inc. Waltham, Mass. USA) were used for lyophilization. This system generally operates with concentrator set up for working in ambient temperature giving low drying rates. For example, application of high drying rates and work in a range of, for example, 43° C.-65° C. temperature may be harmful for some polypeptides and/or polynucleotides attached to the F-NDP. Concentrator may be used with 8,500 rpm maximal speed giving 4,680×g maximal force. Vacuum pump (model VLP120, Thermo Savant), may be set up for gas-ballast control “closed” position giving ultimate total pressure 1.5×10-3 Torr. Refrigerated vapor trap (model RVT400, Thermo Savant) may be used with 4 liter chamber capacity giving, approximate operating temperature −50° C. - Lyophilization may be performed from water or buffer suspension dependent on required purposes (e.g. PBS may be used for in vivo application for diagnostic approaches such as thromboembolic events in vasculature). Reconstitution of F-NDP may be performed using sterile deionized water, to the desired volume. All procedures may be performed in sterile conditions including all materials such as tubes and tips.
- 4. Measuring the effect of ethanol sterilization and lyophilization on size distribution may be performed using Zetasizer Nano ZS (Malvern Instruments Ltd., Westborough, Mass., USA). Working density of F-NDPs was estimated as 10 mg/ml.
FIGS. 25A-25B show a high overlap of same F-NDPs for Particles Size Distribution (Malvern, PSD) assayed before and after sterilization. - The following example demonstrates the ability of fluorescent-NanoDiamond particles (F-NDP) covalently conjugated with bitistatin (F-NDP-Bit) to detect vascular blood clots in vivo using extracorporeal near infrared (NIR) imaging. Specifically, NIR fluorescence properties of F-NDP were compared with color centers (NV vs. NVN) and sizes (100-10,000 nm). Optimal NIR fluorescence and tissue penetration across biological tissues (rat skin, porcine axillary veins and skin) was obtained for F-NDP(NV) with a mean diameter of 700 nm. Interavital imaging (IVIS) in vitro revealed that F-NDP(NV)—loaded glass capillaries could be detected across 6 mm of rat red-muscle barrier and 12 mm porcine skin, which to average vertical distance of a human carotid artery bifurcation from the surface of the adjacent skin (14 mm). In vivo, feasibility was demonstrated a rat model of FeCl3-generated occlusive blood clots I carotid artery bifurcation. Following systemic infusions of F-NDP(NV)-Bit (3 or 15 mg/Kg) via the external carotid artery (ECA) or femoral vein (N=3), presence of the particles in the thrombi was confirmed both in situ via IVIS, and ex vivo, via confocal imaging. F-NDP(NV) presence in the vascular clots was further confirmed by direct counting of fluorescence particles extracted from clots following tissue solubilization. The data suggests that F-NDP(NV)-Bit associate with vascular blood clots, presumably by F-NDP(NV)-Bit binding to activated platelets within the blood clot. It is posited that F-NDP(NV)-Bit could serve as non-invasive platform technology for identification of vascular thrombi using NIR energy monitored by an extra-corporeal device.
- Bitistatin was purified from the venom of Bitis arientans (Latoxan Serpentarium, Valence, France) using two steps of reverse-phase HPLC, as described above. F-NDP, chemically surface-functionalized with carboxyl groups (—COOH), were purchased from Adamas Nanotechnologies (Raleigh. N.C., USA). Two strains of F-NDP were used: green fluorescent F-NDP based on N-V-N color centers (F-NDP(NVN)) at 700 nm (2×108 particles/mg) and red fluorescent based on N-V (F-NDP(NV)) color centers at 100 nm (5×1011 particles/mg), 700 nm (2×108 particles/mg), and 10,000 nm (5×105 particles/mg). Isoflurane was purchased from Henry Schein (B34C16A Dublin, Ohio, USA). 70% Denatured Ethyl Alcohol and PE-10 tubing were purchased from Fisher Scientific (Pittsburgh, Pa., USA). 5-0 Silk Suture was purchased from Roboz SUT-15-1, Roboz Surgical Instrument Co. (Gaithersburg, Md., USA). Parafilm and FeCl3 was purchased from Sigma-Aldrich, (St. Louis, Mo., USA).
- Bitistatin was coupled to the F-NDP of all types using EDC (1-ethyl-3-[3 dimethylaminopropyl] carbodiimide hydrochloride) as a hetero-bifunctional cross-linker. Coupling efficiency and preservation of Bitistatin activity on the various functionalized nanodiamond particles (F-NDP-Bit) were verified using a semi-ELISA methodology.
- NIR fluorescence profiles of F-NDP were characterized using a
Tecan Infinite 200 PRO (Tecan AG, Männedorf, CH). 100 μl of 3 mg/ml of 700 nm F-NDP(NV) or F-NDP(NVN) suspended in de-ionized (DI) water were loaded into 96-well polystyrene. Fluorescence was scanned for all wells with excitations from 230 nm-850 nm and emissions from 290 nm-850 nm (FIG. 1A ) at 20 nm intervals. Data was processed in Matlab 2015b (Mathworks, Natick, Mass., USA). Background fluorescence was subtracted from empty wells without F-NDP and the resulting net fluorescence value was Log10 transformed for visualization. - Glass capillaries (40 mm length, 1 mm internal diameter, (Thermo Fisher Scientific, Waltham, Mass., USA) were filled with equal volumes (30 microliters) of suspensions of F-NDP at concentrations from 0.06 and up to 4 mg/ml (1.8-120 μg total particle mass) and sealed at each end by plasticine (Hasbro, Pawtucket, R.I., USA). The NIR fluorescence intensity of the various suspensions in the capillaries were analyzed using an
IVIS 50 Imaging System (PerkinElmer Inc., Akron Ohio) using an excitation filter set to ‘Cy5.5 BkG’ (580-610 nm) and an emission filter set to ‘Cy5.5’ (695-770 nm) as these filters matched the desired NIR emission profile detected as described above. Imaging was completed with ‘binning’ set to 4, and a 10 cm field of view, with exposure times between 2 and 40 seconds. For imaging through biological barriers (rat and porcine skins and rat muscles) auto-fluorescence was imaged with the blue-shifted excitation ‘GFP’ (445-490 nm) and the same emission filter ‘Cy5.5’ (695-770 nm) with similar imaging settings as above and subtracted from the foreground as modified fromIVIS 50 protocol to compensate for the large stokes shift of the F-NDP(NV).12 This correction was used for a simplified spectral un-mixing: A ratio of auto-fluorescence between the channel of interest and blue-shifted excitation channel is defined in control tissue. The same ratio was then used to subtract auto-fluorescence from the channel of interest based on the blue-shifted excitation channel in the test specimen. This operates under the assumption that the fluorophore being detected may have minimal excitation at the blue-shifted wavelength. To assess tissue penetration of NIR florescence emission from F-NDP, capillaries were placed under shaved abdominal rat skin (obtained from euthanized rats), covered with dissected rat quadriceps muscle (2-5.9 mm thick), or covered with porcine skin (isolated from shoulder of pig obtained from a local butcher shop) - Technical procedures of the FeCl3-induced vascular thrombosis model are generally known in the art. Specific modifications used in this particular work are briefly summarized below. All animal procedures were performed according to the guidelines of the US Animal Welfare Act and approved by the Institutional Animal Care & Use Committee at SUNY Downstate Medical Center. In brief: adult male Sprague-Dawley rats (Charles River, 350 Gm +/−10% body weight), were anesthetized using 4% isoflurane (IF, induction, in chamber) followed by 1-2% IF (maintenance) adjusted throughout the procedure. Rats were held in the supine position and subjected to surgery using clean instruments and aided by binoculars. The left carotid artery was dissected and exposed at the bifurcation region. A 5-0 surgical silk suture was wrapped below the common carotid (CCA), external carotid (ECA), and internal carotid (ICA) arteries. A PE-10 cannula was then inserted in the ECA for studies where F-NDP(NV)-Bit were injected locally. A PE-10 cannula was also inserted into the left femoral vein for studies where F-NDP(NV)-Bit was infused intravenously (IV). The ICA stem was wrapped in Parafilm soaked in 50% FeCl3 and kept in place for 10 minutes. Two to three minutes after placing the Parafilm onto the ICA, infusion of F-NDP(NV)-Bit suspension in PBS commenced either via the ECA (N=2, 15 mg/Kg in 1 mL), or via the femoral vein (N=6) at low dose (N=3, 3 mg/Kg in 1 mL PBS), or at high dose (N=3, 45 mg/Kg in 3 mL PBS). All infusions were completed over 10 minutes. Control rats were infused with vehicle at comparable volumes and duration.
- Following the completion of particles infusion, anesthesia was augmented to produce deep hypnosis using 5% IF. The lower aorta was quickly isolated and cut to allow blood drainage. Tissue was fixed and residual blood removed by perfusion with 10 mL of 70% denatured ethanol. Dissection of both bilateral carotid artery bifurcation regions was completed after whole body imaging (IVIS). Vessels were suspended 70% denatured ethanol for further ex vivo NIR fluorescence evaluation.
- Briefly, NIR fluorescence was detected using a 580-610 nm excitation and a 695-770 nm emission pass-band with 2 second exposure, ‘binning’ set to 4, and a 7 cm field of view as described above. Auto-fluorescence was subtracted based on excitation at 445-490 nm under otherwise similar imaging conditions. Carotid arteries were exposed before imaging to enable clear visualization for in situ images. Following in situ imaging, carotid arterial bifurcations were removed from animals and placed on a glass plate for imaging ex vivo using identical imaging parameters to those used for in situ imaging. For each artery, the mean fluorescence intensity of the images compensated for auto-fluorescence was calculated using ImageJ (NIH, Bethesda, Md., USA).
- Gross images of the entire carotid bifurcation region extracted from clot bearing or contralateral vessels were evaluated on a Fluoview FV1000 (Olympus, Tokyo, Japan) laser scanning confocal microscope (LSCM) using a 4× objective. NIR fluorescence emitted from F-NDP(NV) was detected at an excitation of 543 nm and an emission of 655-755 nm. Confocal stacks were combined using a maximum intensity projection so that the entire vessel is brought into focus. The mean fluorescence intensity of F-NDP in each artery was calculated after subtraction of the local background using ImageJ.
- F-NDP were isolated from extracted carotid arteries by homogenization in RIPA lysis buffer (Teknova Inc. Hollister, Calif., USA) at 100 mg/ml. Aliquots (10 microliters) of the lysate suspension were applied on the microscope slides and analyzed under LSCM as above under 20× objective.
- In animals treated with F-NDP(NV) via the femoral artery at high dose, F-NDP(NV) were isolated from extracted carotid arteries by solubilizing the clot bearing vessel segment in 12 N hydrochloric acid (HCl) (Thermo Fisher Scientific, Waltham, Mass., USA) overnight at 60° C. at 100 mg/ml. The solution was centrifuged (14,000×g at room temperature for 10 minutes) and the pellet was washed 1× with distilled water. The pellet containing the insoluble F-NDP(NV)-Bit was re-suspended in DI-water while keeping the initial mass/volume ratio. An aliquot of the suspension was applied to a hemocytometer (Incyto Inc., Cheonan-si, Korea), which was standardized for particles counting in an inverted fluorescence microscope (Olympus IX81) with 40× objective. Images of F-NDP(NV)-Bit were taken from each observation field for counting using TRITC filter cube. Numbers of particles were calculated for the entire solubilized tissue.
- Unless stated otherwise, each experiment in this example was performed independently three times in triplicate. No outlying data was excluded. Data are represented as mean±SD. Statistical analyses were done by the Student's t test using (
SigmaPlot® 12 SPSS, Systat Software Inc., San Jose, Calif., USA). P<0.05 was considered significant. - Comparison of NIR fluorescence intensity of F-NDP(NVN) and F-NDP(NV) fluorescence profile measurements revealed NIR fluorescence in both N-V and N-V-N particles. However, fluorescence in the NIR region was 20 times greater in the N-V particles (
FIG. 26A ). This experiment also revealed the peak excitation of F-NDP(NV) at 570 nm and peak emission at 670 nm. Using this peak excitation and emission profile, NIR emission of the F-NDPs was compared in the IVIS in a dose response manner (FIG. 26B ,FIG. 26C ). Capillary studies revealed that under the same excitation conditions, NIR emission of the F-NDP(NV) was more effective than that of F-NDP(NVN) by approximately an order of magnitude (FIG. 26B ). - Fluorescent characteristics of F-NDP may vary with size of particle. The NIR emission of identical mass per mL of F-NDP(NV) was compared for particles of three different sizes (
FIGS. 27A-27D ). The lowest fluorescence intensity was observed for smallest (100 nm) particles, while the highest fluorescence emission was observed for 700 nm F-NDP. Fluorescence scaled linearly with exposure time revealing no bleaching at the higher exposure times tested. While fluorescence from the 700 nm F-NDP(NV) particles saturated the detector in less than 20 seconds, longer exposure times were required to clearly display fluorescence from the F-NDP(NVN) particles. It is noteworthy that for the same acquisition time the NIR emission of 700 nm and 10,000 nm was not augmented. In fact, at 0.5 mg/ml and 1 mg/ml, the emission of the 10,000 nm particles, was significantly lower than that of the 700 nm particles (p<0.01,FIG. 27A ). We then tested the ability of NIR fluorescence emitted from equivalent sized (700 nm) F-NDP particles of the N-V and N-V-N strains of F-NDP to penetrate biological barriers as imaged in the IVIS (FIGS. 28A-28H ). Capillaries filled with 4 mg/ml F-NDP(NV) particles could be imaged through rat skin (FIG. 28A ) or quadriceps muscle (FIG. 28B ) as well as porcine axillary vein (FIG. 28C ) and 2.5 mm of defatted porcine skin (FIG. 28D ), while capillaries filled with F-NDP(NVN) particles could not be visualized with similar imaging parameters in any of these circumstances. NIR fluorescence was monitored through 2.5 mm of defatted porcine skin at concentrations from 1-4 mg/ml (30-120 micrograms total) (FIG. 28E ) as the signal did not penetrate full-thickness tissue. Porcine axillary veins loaded with 1 mL of 2 mg/mL of F-NDP(NV) particles could be visualized through 8 mm of porcine skin (FIG. 28F ). As a final test of penetration capacity, an angled piece of full thickness porcine skin varying from 9 to 14 mm in thickness was laid on top of capillaries containing 20 mg/mL (600 total) of F-NDP(NV). A detectable signal from the F-NDP(NV) was recorded through the porcine skin up 12 mm in thickness. In contrast, no light emission was detected at equal conditions of F-NDP(NVN) (FIG. 28G ). Noteworthy is data obtained by ultrasound imaging of human carotid arteries, where the carotid artery bifurcation distance from the skin surface was assessed at 14 mm below the skin surface. These findings suggest a translational prospect of F-NDP(NV) to detect blood clot in this area if comparable particle mass can be safely deposited on a blood clot in this region (FIG. 28H ). - The results depicted in
FIGS. 26A-28H suggest that F-NDP(NV) (700 nm) are the brightest of the particles tested and may be a useful F-NDP strain for imaging in vivo. Therefore, all subsequent in vivo studies were carried out with F-NDP(NV) coupled with Bit for detection of thrombi generated in the carotid artery bifurcation of rats. After clot formation and treatment with F-NDP(NV)-Bit via the ECA, carotid arteries were imaged in situ and removed from the animal for imaging and analysis. Injection of F-NDP via the ECA optimizes the exposure of the particles to the lesion site thus avoiding potentially confounding variables of distribution, uptake, and elimination. Imaging of fluorescence in the IVIS scanner demonstrated strong fluorescence in situ (FIG. 29A ,FIG. 29B ) in the vessel branches corresponding to the location of the clot in the exposed artery. After removing the carotid arterial bifurcations from treated and untreated animals, a strong fluorescent signal is detected (FIG. 29C ,FIG. 29D vsFIG. 29E ,FIG. 29F ) in the FeCl3-treated arteries. This was further validated by confocal imaging confirming co-location of clot and deposited particles (FIG. 29G ,FIG. 29H vsFIG. 291 ,FIG. 29J ). As a final validation method, particles were imaged in pooled lysates (2 lesions), showing large numbers of fluorescence particles in F-NDP(NV)-treated animals as compared to their absence in animals treated with vehicle (FIG. 29K ). Following in the initial proof of feasibility direct administration of the F-NDP(NV)-Bit via ECA, a low (3 mg/Kg) and high (15 mg/kg) dose of F-NDP(NV)-Bit were infused systemically into animals via the femoral vein. The results from animals treated with the low dose were inconclusive, as the signal was not consistently above the fluorescence level detected from carotid bifurcation isolated from control animals treated with vehicle only. Despite this, pooled lysates (3 lesions) showed that F-NDP particles had been logged in the clots, while no particle associated fluorescence was detectable from vehicle treated animals (FIG. 29L ). - After IV injection of the high dose of F-NDP(NV)-Bit, clot-associated fluorescence was demonstrated in situ in all treated animals (
FIGS. 30A-30C ). Arteries with FeCl3-generated lesions and the contralateral control were then dissected and imaged independently by IVIS and confocal microscopy. A strong fluorescence signal in the treated artery was observed by both IVIS (FIGS. 30D-30F vsFIGS. 30G-30I ) and confocal imaging (FIGS. 30J-30L vsFIGS. 30M-30O ). The difference in brightness to that of the control artery was statistically significant (FIG. 30R ,FIG. 30S ) with p<0.05. Lysates collected by dissolving the carotid arteries also demonstrated a large number of fluorescent particles residing in the lesioned artery and a low, but consistent, number of particles in the contralateral control arteries (FIG. 30P ). This difference was highly statistically significant (FIG. 30Q ) with p<0.01. - The two main objectives of the example described above were 1) characterization of the two strains of the F-NDP (F-NDP(NV) and F-NDP(NVN)) in terms of their NIR emission parameters and 2) identification of the F-NDP strain, which emits sufficient energy that most likely penetrates biological tissues over a distance required for the translational application in human NIR vascular pathology imaging. Given the prospect of longer (minutes) scale of imaging procedures in humans an important consideration in selection F-NDP includes the stability/durability of the NIR emission. Nanoparticles in general tend to have reduced toxicity with increased diameter. Specifically, nanodiamonds display reduced toxicity (as compared to e.g. nanotubes) with increasing diameter (tested up to 100 nm), suggesting that the 700 nm F-NDP(NV) used in this study may be safe. Preliminary studies suggest no mortality or morbidity in rats injected via venous port, with 700 nm F-NDP(NV) at 45 mg/kg while evaluated for weight and neurobehavioral tests for up to 5 days.
- The first objective was to systematically investigate the emission attributes each of F-NDP across four independent variables: a) the fluorescence spectrum and brightness resulting from the atomic manipulations (N-V, N-V-N); b) particles total mass relationships to emission intensity; c) the relationship of particle diameter to emission intensity and d) speed and extent of NIR acquisition kinetics. These variables have been exercised ‘head to head’ between N-V and N-V-N strains using IVIS technology, which were considered all well suited for such comparison in due to its sensitivity and its non-invasive NIR light detection capability. The data presented in
FIGS. 26A-27D point to the prospect of the F-NDP(NV) strain as useful for in vivo NIR fluorescent penetration through biological tissues. For example, in this example the 700 nm F-NDP(NV) exhibited 10-60 higher NIR emission intensity than the F-NDP(NVN). Of note, NIR emission from F-NDP(NV) was not directly correlated with particle size, and was maximized for 700 nm F-NDP(NV). At constant particle mass loading, the 700 nm particles were ˜4 times brighter in IVIS images, and consistently and across all acquisition periods tested; NIR fluorescence emission from 10,000 nm particles was weaker than frome 700 nm particles (FIG. 2 ). While 10,000 nm F-NDP(NV) may be not likely to be useable for IV injection, the 10,000 nm particles demonstrated that under equal mass conditions particle brightness was not correlated with diameter, but may be maximized for particles of a specific diameter range. - Commensurate with the physical properties delineated for the F-NDP(NV) (
FIGS. 26A-27D ) the data inFIGS. 28A-28H further support the potential of the F-NDP(NV) to support in vivo vascular clot imaging.FIG. 3 presents several conditions where tissues penetration of NIR fluorescence emitted from F-NDP(NV) was tested. The maximum distance detectable by NIR through porcine skin, used as a human skin analog, (FIG. 28G ) was 12 mm.FIG. 28H presents an ultrasound recording of normal human carotid artery bifurcation annotated for the ICA, ECA and CCA. The linear dashed bar inFIG. 28H indicates 11.89 mm depth of the human carotid artery bifurcation from the vertical distance from the neck surface. Considering the dense epidermis of porcine shoulder skin as compared to human neck and the distance of the IVIS camera from the target to be monitored versus the use of a similar hand-held device placed directly on the skin, it is posited that NIR fluorescent imaging of a clot bin the carotid artery bifurcation is likely to be within an achievable diagnostic opportunity. Furthermore, NIR fluorescence recorded inFIG. 28H represents a source generated from ˜670 ug of 700 nm F-NDP(NV) particles. The same amount of particles tagged onto human clot in this region could enable clot detection by NIR fluorescence imaging. Results inFIG. 30Q indicates a minimum of 0.7% of injected dose was captured in the lesion of interest (2×108 particles/mg in dose), which would imply a required dose of approximately 100 mg (1.4 mg/kg) to reach a similar emission profile in human. In preliminary studies in rat, doses as high as 45 mg/kg were well tolerated for 5 days without any adverse events recorded (data not shown). - In vivo studies were performed with an F-NDP(NV)-Bit covalently coupled with bitistatin. The procedure used EDC-mediated covalent heterobifunctional coupling, yielding a stable amide bond, which is resilient in biological systems. These F-NDP(NV)-Bit, were administered systemically to anesthetized rats subjected to an established carotid artery clot procedure at the site of the bifurcation. In the pilot translational study F-NDP(NV)-Bit were first administered via the ECA (‘high dose’, 15 mg/Kg) or via the femoral artery (‘low dose’, 3 mg/Kg). This experimental design was selected since pharmacokinetics and particles distribution dynamics are as yet unknown. Therefore, to avoid possible loss of significant amount of particles via ‘first path’ elimination or tissue distribution (potential ‘false negative’ outcome), injection via the
- ECA ascertains maximum exposure of the particles to the clot in the targeted region. To assess and confirm specific co-localization of F-NDP(NV)-Bit in the blood three independent methods were deployed: a) IVIS total body imaging (
FIG. 29A ,FIG. 29B ); b) LSCM of extracted vessels carrying clots (FIG. 29C ,FIG. 29D ) and c) direct count of particles extracted from clot-bearing vessels after solubilization of all organic material (FIG. 29L ). Association of F-NDP(NV) by infusion of a high dose of F-NDP(NV)-Bit via the ECA is easily detected by all three methods. However, infusion of a low dose (3 mg/Kg) of F-NDP(NV)-Bit via the femoral vein failed to detect emission by either IVIS or by LSCM (FIG. 4E-F ). A low amount of particles was counted in the clot extract (FIG. 29M ), yet it is not clear whether this very small number is specifically clot associated, loaded into the vessel wall via “vasa-vasorum” or both. It is clear however that the low dose of F-NDP(NV)-Bit did not produce a credible emission signal that could be detected by IVIS or LSCM, even if particles were in fact target to the clot. Next, F-NDP(NV)-Bit was intravenously administered at a higher dose (15 mg/Kg, N=3). As illustrated inFIGS. 30A-30C , all three animal tested displayed a strong fluorescence signal emanating from the carotid bifurcation zone (IVIS), as also clearly visible in the fluorescence of isolated vessels (FIGS. 30D-30I ) and under inspection by LSCM (FIGS. 30J-30O ). Particles were also present in large numbers in solubilized clot-bearing vessels (FIG. 30P ).FIGS. 30Q-30S show the quantitative analysis of the robust deposition of particles in clot-bearing vessels vs. the control contralateral. - In summary in this example evidence was demonstrated that the F-NDP(NV) deployed in this study can associate with clot in vivo, such as a thrombus formed in a rat carotid artery bifurcation model. The proof-of-concept here is based on three independent measures or the NIR fluorescence detected at the in situ clot formation, including direct counting of fluorescence particles isolated from the extracted clot. The data demonstrates the possibility to detect by NIR fluorescence imaging emitted from F-NDP(NV) over a distance corresponding to that present in vascular pathology (e.g. clot in the carotid artery bifurcation). If successfully translated to clinical practice, this minimally invasive procedure, conducted in ambulatory settings, could enhance preventative measures, such as earlier initiation of anti-thromboembolic medications.
- While several embodiments of the present invention have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the functions and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the present invention. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present invention is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, the invention may be practiced otherwise than as specifically described and claimed. The present invention is directed to each individual feature, system, article, material, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, and/or methods, if such features, systems, articles, materials, and/or methods are not mutually inconsistent, is included within the scope of the present invention. The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”
- The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified unless clearly indicated to the contrary. Thus, as a non-limiting example, a reference to “A and/or B,” when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A without B (optionally including elements other than B); in another embodiment, to B without A (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
- As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
- In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/987,351 US20210123909A1 (en) | 2016-09-06 | 2020-08-06 | Nanodiamond particles and related devices and methods |
US17/316,665 US20210270820A1 (en) | 2016-09-06 | 2021-05-10 | Nanodiamond particles and related devices and methods |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662383657P | 2016-09-06 | 2016-09-06 | |
US201762522036P | 2017-06-19 | 2017-06-19 | |
PCT/US2017/050257 WO2018048887A1 (en) | 2016-09-06 | 2017-09-06 | Nanodiamond particles and related devices and methods |
US201916330950A | 2019-03-06 | 2019-03-06 | |
US16/987,351 US20210123909A1 (en) | 2016-09-06 | 2020-08-06 | Nanodiamond particles and related devices and methods |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/330,950 Division US11085920B2 (en) | 2016-09-06 | 2017-09-06 | Nanodiamond particles and related devices and methods |
PCT/US2017/050257 Division WO2018048887A1 (en) | 2016-09-06 | 2017-09-06 | Nanodiamond particles and related devices and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/316,665 Continuation US20210270820A1 (en) | 2016-09-06 | 2021-05-10 | Nanodiamond particles and related devices and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210123909A1 true US20210123909A1 (en) | 2021-04-29 |
Family
ID=61561969
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/330,950 Active 2037-09-20 US11085920B2 (en) | 2016-09-06 | 2017-09-06 | Nanodiamond particles and related devices and methods |
US16/987,351 Abandoned US20210123909A1 (en) | 2016-09-06 | 2020-08-06 | Nanodiamond particles and related devices and methods |
US17/316,665 Pending US20210270820A1 (en) | 2016-09-06 | 2021-05-10 | Nanodiamond particles and related devices and methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/330,950 Active 2037-09-20 US11085920B2 (en) | 2016-09-06 | 2017-09-06 | Nanodiamond particles and related devices and methods |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/316,665 Pending US20210270820A1 (en) | 2016-09-06 | 2021-05-10 | Nanodiamond particles and related devices and methods |
Country Status (6)
Country | Link |
---|---|
US (3) | US11085920B2 (en) |
EP (1) | EP3510381A4 (en) |
JP (2) | JP2019533005A (en) |
AU (2) | AU2017324859A1 (en) |
CA (1) | CA3036051A1 (en) |
WO (1) | WO2018048887A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3510381A4 (en) * | 2016-09-06 | 2020-07-29 | Debina Diagnostics, Inc. | Nanodiamond particles and related devices and methods |
HK1257467A2 (en) * | 2018-06-22 | 2019-10-18 | Master Dynamic Ltd | Cancer cell detection and imaging system, process and product |
GB201814532D0 (en) * | 2018-09-06 | 2018-10-24 | Ucl Business Plc | in vitro dianostic assay methods |
US20220362399A1 (en) * | 2019-06-18 | 2022-11-17 | Debina Diagnostics, Inc. | Compositions and articles comprising (nano)diamond particles |
WO2020257466A1 (en) * | 2019-06-18 | 2020-12-24 | Debina Diagnostics, Inc. | Compositions and articles comprising (nano)diamond particles |
WO2021087055A1 (en) * | 2019-10-30 | 2021-05-06 | The Regents Of The University Of California | High contrast, dual-mode optical and 13c magnetic resonance imaging using diamond particles |
KR102496468B1 (en) * | 2021-05-27 | 2023-02-06 | (주)유아이엠디 | Image-based platelet counting method and count-information output method |
WO2023230135A1 (en) * | 2022-05-24 | 2023-11-30 | Debina Diagnostics, Inc. | Compositions and articles comprising (nano)diamond particles |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190212331A1 (en) * | 2016-09-06 | 2019-07-11 | Debina Diagnostics, Inc. | Nanodiamond particles and related devices and methods |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380646A (en) * | 1992-10-19 | 1995-01-10 | Temple University Of The Commonwealth System Of Higher Education | Thrombus detection using radiolabelled disintegrins |
CA2250212C (en) * | 1996-04-03 | 2010-02-09 | The Perkin-Elmer Corporation | Device and method for multiple analyte detection |
US7723123B1 (en) * | 2001-06-05 | 2010-05-25 | Caliper Life Sciences, Inc. | Western blot by incorporating an affinity purification zone |
US20080102036A1 (en) * | 2003-06-04 | 2008-05-01 | Poss Kirtland G | Biocompatible Fluorescent Silicon Nanoparticles |
WO2007092471A2 (en) | 2006-02-03 | 2007-08-16 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
US8168413B2 (en) * | 2006-11-22 | 2012-05-01 | Academia Sinica | Luminescent diamond particles |
US7943728B2 (en) | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
JP4783755B2 (en) * | 2007-05-24 | 2011-09-28 | 独立行政法人理化学研究所 | Substance detection method |
JP2009119561A (en) | 2007-11-15 | 2009-06-04 | National Institute Of Advanced Industrial & Technology | Microstructure composite and method for delivering molecule to be released into living organism by using the composite |
US7993216B2 (en) | 2008-11-17 | 2011-08-09 | Nike, Inc. | Golf club head or other ball striking device having multi-piece construction |
FR2963106A1 (en) | 2010-07-21 | 2012-01-27 | Ecole Polytechnique Dgar | METHOD AND DEVICE FOR ANALYZING MOLECULAR INTERACTIONS, AND USES THEREOF |
WO2012099721A2 (en) * | 2011-01-18 | 2012-07-26 | The Regents Of The University Of California | Real-time adaptive immune system and method |
JP2012206863A (en) | 2011-03-29 | 2012-10-25 | Shiga Univ Of Medical Science | Fluorescent nanodiamond |
WO2013071252A1 (en) | 2011-11-10 | 2013-05-16 | Francis Markland | Compositions and methods for inhibiting viral infection |
US9873119B2 (en) | 2011-12-28 | 2018-01-23 | Ibis Biosciences, Inc. | Multiple- analyte assay device and system |
EP2858630A4 (en) | 2012-06-07 | 2016-02-24 | Harvard College | Nanotherapeutics for drug targeting |
JP6352258B2 (en) * | 2012-07-16 | 2018-07-04 | センターズ フォー ディジーズ コントロール アンド プリベンション | Direct-reading detection kit for surface contamination with antitumor agents |
US9465035B2 (en) | 2012-10-12 | 2016-10-11 | Japan Science And Technology Agency | Nanodiamond particle and method of manufacturing the same, and fluorescent molecular probe and method of analyzing structure of protein |
JP2014095025A (en) * | 2012-11-08 | 2014-05-22 | Osaka Univ | Diamond composite particles |
WO2014121819A1 (en) | 2013-02-06 | 2014-08-14 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Folate functionalized nanodiamond particles, method for its preparation and their use |
WO2015038967A1 (en) | 2013-09-13 | 2015-03-19 | The Regents Of The University Of California | Universal bio diagnostic, drug delivery device and marker for correlated optical and electron microscopy |
WO2015087334A1 (en) | 2013-12-15 | 2015-06-18 | Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. | Viperistatin-derived peptides and uses thereof |
GB201403248D0 (en) * | 2014-02-25 | 2014-04-09 | Univ Singapore | Contrast agent and applications thereof |
WO2018048477A1 (en) | 2016-09-06 | 2018-03-15 | Debina Diagnostics, Inc. | Engineering and utility of fluorescent nanodiamond particles (ndp-f) for diagnostics and treatment of blood clots in human and veterinary medicine |
-
2017
- 2017-09-06 EP EP17849446.4A patent/EP3510381A4/en active Pending
- 2017-09-06 US US16/330,950 patent/US11085920B2/en active Active
- 2017-09-06 WO PCT/US2017/050257 patent/WO2018048887A1/en unknown
- 2017-09-06 AU AU2017324859A patent/AU2017324859A1/en not_active Abandoned
- 2017-09-06 CA CA3036051A patent/CA3036051A1/en active Pending
- 2017-09-06 JP JP2019533303A patent/JP2019533005A/en active Pending
-
2020
- 2020-08-06 US US16/987,351 patent/US20210123909A1/en not_active Abandoned
-
2021
- 2021-05-10 US US17/316,665 patent/US20210270820A1/en active Pending
-
2022
- 2022-02-04 JP JP2022016647A patent/JP2022070911A/en active Pending
-
2023
- 2023-01-19 AU AU2023200289A patent/AU2023200289A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190212331A1 (en) * | 2016-09-06 | 2019-07-11 | Debina Diagnostics, Inc. | Nanodiamond particles and related devices and methods |
Non-Patent Citations (5)
Title |
---|
Ashfold et al. "Nitrogen in Diamond", Chemical Reviews, 2020, vol. 120, pgs. 5745-5794. (Year: 2020) * |
Balasubramaniam et al. ("Nitrogen-Vacancy color center in diamond emerging nanoscale applications in bioimaging and biosensing," Current Opinion in Chemical Biology, vol. 20, pgs. 69-77, published 05/27/2014). (Year: 2014) * |
Chao et al. ("Nanometer-Sized Diamond Particle as a Probe for Biolabeling," Biophysical Journal, vol. 93, pgs. 2199-2208, September 2007). (Year: 2007) * |
Chung et al. ("The particle size-dependent photoluminescence of nanodiamonds," Surface Science vol. 601, pgs. 3866-3870, published 04/24/2007). (Year: 2007) * |
Mecedo et al. ("Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy," Current Protein and Peptide Science, vol. 16, pgs. 532-548, published 2015). (Year: 2015) * |
Also Published As
Publication number | Publication date |
---|---|
EP3510381A4 (en) | 2020-07-29 |
AU2017324859A1 (en) | 2019-03-21 |
JP2019533005A (en) | 2019-11-14 |
AU2023200289A1 (en) | 2023-03-02 |
JP2022070911A (en) | 2022-05-13 |
WO2018048887A1 (en) | 2018-03-15 |
EP3510381A1 (en) | 2019-07-17 |
US20190212331A1 (en) | 2019-07-11 |
US11085920B2 (en) | 2021-08-10 |
CA3036051A1 (en) | 2018-03-15 |
US20210270820A1 (en) | 2021-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210270820A1 (en) | Nanodiamond particles and related devices and methods | |
Kim et al. | Direct imaging of cerebral thromboemboli using computed tomography and fibrin-targeted gold nanoparticles | |
US20240138701A1 (en) | Detection of high-risk unstable atherosclerotic plaque | |
US20080025918A1 (en) | Invisible light fluorescent platelets for intraoperative detection of vascular thrombosis | |
EP2693939A2 (en) | In vivo immunomagnetic hyperthermia platform for any cell or virus having a target surface receptor | |
Belykh et al. | Intraoperative confocal laser endomicroscopy ex vivo examination of tissue microstructure during fluorescence-guided brain tumor surgery | |
Li et al. | Photostimulation of lymphatic clearance of red blood cells from the mouse brain after intraventricular hemorrhage | |
He et al. | Protein-enhanced NIR-IIb emission of indocyanine green for functional bioimaging | |
Xu et al. | Shortwave infrared fluorescence in vivo imaging of nerves for minimizing the risk of intraoperative nerve injury | |
Marcinkiewicz et al. | Bitistatin-functionalized fluorescent nanodiamond particles specifically bind to purified human platelet integrin receptor αIIbβ3 and activated platelets | |
WO2013082192A1 (en) | Methods for detection and characterization of ionizing radiation exposure in tissue | |
Kılıç et al. | A prospective randomized trial comparing homologous and autologous fibrin sealants for the control of alveolar air leak | |
Chen et al. | A Clot‐Homing Near‐Infrared Probe for In Vivo Imaging of Murine Thromboembolic Models | |
JP6220894B2 (en) | Composition for visualizing degenerated site of articular cartilage | |
CN111657861A (en) | Thrombolytic drug effect evaluation method based on two-photon microscope technology | |
WO2018048477A1 (en) | Engineering and utility of fluorescent nanodiamond particles (ndp-f) for diagnostics and treatment of blood clots in human and veterinary medicine | |
US20150093329A1 (en) | In vivo detection of apoptosis | |
Marone et al. | Human heart mast cells: Immunological characterization and | |
Li et al. | NIR-II fluorescence imaging of skin avulsion and necrosis | |
Li et al. | Noninvasive technology of photostimulation of lymphatic clearance of red blood cells from the mouse brain after intraventricular hemorrhage. | |
Wu et al. | A Nano-Based P1Cminimum Probe to Monitor Thrombosis in Grafts and Improve Cardiac Function After Coronary Artery Bypass Grafting Surgery | |
US20210268127A1 (en) | Enhanced surgical visualization of viable tissue and peptides therefor | |
Tan et al. | 99mTc‐labeled Duramycin for detecting and monitoring cardiomyocyte death and assessing atorvastatin cardioprotection in acute myocardial infarction | |
Ježková et al. | Immunological response to the revascularisation of experimental myocardial infarction | |
Liu et al. | Intracalvariosseous bone marrow injection detours the blood-brain barrier as a novel drug delivery approach for pre-clinic and clinic trials in stroke. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: DEBINA DIAGNOSTICS, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FEUERSTEIN, GIORA Z.;STERNBERG, MARK E.;REEL/FRAME:055015/0001 Effective date: 20190627 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |